Ireland Trials Monitor · Preview
Clinical trials with sites in Ireland
Trials that list an Irish site and are recruiting, about to open, or was updated in the last 90 days, across all therapy areas, from both ClinicalTrials.gov and the EU CTIS registry. For pharma and biotech teams, CROs, clinical research facilities, universities, medtech and femtech companies, and patient organisations in Ireland.
499trials open or about to open at Irish sites (309 US registry, 190 EU CTIS)
29newly registered in last 90 days
311updated in last 30 days
56%of open trials are industry-sponsored
81open trials flagged women's health
784records on this page (about 695 unique trials after cross-registry matches)
Open trials in Ireland at a glance
Charts cover the 499 trials open or about to open at an Irish site. Irish site and city counts come from ClinicalTrials.gov, because the EU CTIS search doesn't list site names.
By therapy area
By phase
Most active lead sponsors
Industry 278 · academic / other 221
Irish cities with open sites
Busiest Irish sites (open trials)
Women's health in Ireland
81 of 499 open trials are flagged women's health, covering female-only eligibility or conditions such as breast, ovarian, cervical or uterine cancer, pregnancy, fertility, endometriosis and menopause. By therapy area: oncology 66, women's health & maternal 11, other / unclassified 2, musculoskeletal, pain & surgery 1, metabolic & endocrine 1.
Trial table
Newest registry update first. "Ireland status" is the status at Irish sites, which can differ from the trial's overall status. Each ID links to the official record. Download the data: CSV.
| ID | Title / conditions | Therapy area | Lead sponsor | Phase | Ireland status | Irish cities | Enrolment | Start | Last update |
|---|---|---|---|---|---|---|---|---|---|
| NCT07472517 ClinicalTrials.gov · also 2025-520565-51-00 |
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy Small Cell Lung Cancer (SCLC); Extensive-stage Small Cell Lung Cancer (ES-SCLC) Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Boehringer Ingelheim Industry | Phase 3 | Not yet recruiting | Cork | 670 | 2026-04-13 | 2026-10-20 |
| NCT06907147 ClinicalTrials.gov |
SPYRAL GEMINI Pilot Study Hypertension; Vascular Diseases; Cardiovascular Diseases; Chronic Kidney Diseases Open in IrelandUpdated ≤30d | Cardiovascular | Medtronic Vascular Industry | N/A (non-drug) | Recruiting | Galway | 175 | 2025-05-01 | 2026-10-20 |
| NCT06136650 ClinicalTrials.gov · also 2023-504957-11-00 |
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Dublin | 1,314 | 2023-12-18 | 2026-10-20 |
| NCT01524276 ClinicalTrials.gov |
Product Surveillance Registry Cardiac Rhythm Disorders; Urological Disorders; Neurological Disorders; Cardiovascular Disorders Open in IrelandUpdated ≤30d | Cardiovascular | Medtronic Industry | Observational | Recruiting | Galway | 100,000 | 2012-01 | 2026-10-20 |
| NCT06865417 ClinicalTrials.gov |
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Ulcerative Colitis Open in IrelandUpdated ≤30d | Immunology, rheumatology & skin | Alfasigma S.p.A. Industry | Phase 3 | Not yet recruiting | Dublin | 80 | 2025-09-29 | 2026-10-20 |
| NCT07052903 ClinicalTrials.gov · also 2024-519917-72-00 |
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Transthyretin Amyloidosis With Cardiomyopathy Open in IrelandUpdated ≤30dAlso in CTIS | Cardiovascular | Alnylam Pharmaceuticals Industry | Phase 3 | Recruiting | Dublin | 1,750 | 2025-07-02 | 2026-10-20 |
| NCT06959524 ClinicalTrials.gov |
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions Coronary Arterial Disease (CAD); de Novo Lesions in Native Coronary Arteries Open in IrelandUpdated ≤30d | Cardiovascular | Boston Scientific Corporation Industry | N/A (non-drug) | Recruiting | Cork, Dublin, Galway | 1,616 | 2025-08-21 | 2026-10-20 |
| NCT07359846 ClinicalTrials.gov |
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) Severe Asthma Open in IrelandUpdated ≤30d | Respiratory | Generate Biomedicines Industry | Phase 3 | Recruiting | Drogheda | 786 | 2026-01-20 | 2026-10-20 |
| NCT07099898 ClinicalTrials.gov · also 2025-521627-78-00 |
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] Neoplasms, Lung Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | GlaxoSmithKline Industry | Phase 3 | Recruiting | Dublin | 420 | 2025-08-11 | 2026-10-20 |
| NCT07013929 ClinicalTrials.gov |
Spyral InSight Study Hypertension; Vascular Diseases; Cardiovascular Diseases Open in IrelandUpdated ≤30d | Cardiovascular | Medtronic Vascular Industry | N/A (non-drug) | Recruiting | Galway | 19 | 2025-06-09 | 2026-10-20 |
| NCT06430801 ClinicalTrials.gov |
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) Crohn's Disease Updated ≤30d | Immunology, rheumatology & skin | Merck Sharp & Dohme LLC Industry | Phase 3 | Completed | Dublin | 1,200 | 2024-06-05 | 2026-10-20 |
| NCT07335497 ClinicalTrials.gov · also 2025-523590-42-00 |
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors Locally Advanced / Metastatic Solid Tumors Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Crescent Biopharma, Inc. Industry | Phase 1/2 | Recruiting | Dublin | 540 | 2026-02-17 | 2026-10-20 |
| NCT05701358 ClinicalTrials.gov |
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Acute Myocardial Infarction; Coronary Artery Disease Updated ≤30d | Cardiovascular | Population Health Research Institute Academic / other | N/A (non-drug) | (not given) | Galway | 5,100 | 2023-06-22 | 2026-10-20 |
| NCT06586515 ClinicalTrials.gov |
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer Updated ≤30d | Oncology | Eli Lilly and Company Industry | Phase 1 | (not given) | Dublin | 630 | 2024-09-12 | 2026-10-20 |
| NCT06453330 ClinicalTrials.gov |
A Randomised Control Clinical Trial Investigating the Effect of H-PRF on Implant Stability and Marginal Bone Levels Osseointegration Failure of Dental Implant Updated ≤30d | Other / unclassified | University of Dublin, Trinity College Academic / other | N/A (non-drug) | (not given) | Dublin | 27 | 2024-05-17 | 2026-10-20 |
| NCT05152147 ClinicalTrials.gov · also 2023-510319-20-00 |
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma Updated ≤30dAlso in CTIS | Oncology | Jazz Pharmaceuticals Industry | Phase 3 | (not given) | Dublin | 920 | 2021-12-02 | 2026-10-20 |
| 2025-522227-99-00 EU CTIS |
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease Huntington’s Disease Open in IrelandUpdated ≤30d | Neurology | Novartis Pharma AG Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-07-28 | 2026-10-20 |
| 2025-523793-16-00 EU CTIS |
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study) Homeostatic iron regulator gene-related hereditary hemochromatosis Open in IrelandUpdated ≤30d | Eye & ear | CSL Behring LLC Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-07-15 | 2026-10-20 |
| 2025-522748-42-00 EU CTIS |
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2) Ovarian cancer Updated ≤30dWomen's health | Oncology | Incyte Corp. Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2026-07-10 | 2026-10-20 |
| 2024-517614-14-00 EU CTIS |
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Open in IrelandUpdated ≤30d | Neurology | Immunovant Sciences GmbH Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-12-04 | 2026-10-20 |
| 2025-520554-11-00 EU CTIS |
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a) Cardiovascular Disease Open in IrelandUpdated ≤30d | Cardiovascular | Amgen Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-20 |
| 2024-518589-29-00 EU CTIS |
A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY TM Study) Bronchiectasis Updated ≤30d | Respiratory | Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-08-21 | 2026-10-20 |
| 2024-519746-70-01 EU CTIS |
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose-Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease Sickle Cell Disease Updated ≤30d | Blood (non-cancer) | Agios Pharmaceuticals Inc. Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-09-15 | 2026-10-20 |
| 2024-511458-32-00 EU CTIS |
A multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of filgotinib, with single arm induction and maintenance, in pediatric subjects (8 to <18 years of age) with moderately to severely active ulcerative colitis Ulcerative colitis Open in IrelandUpdated ≤30d | Immunology, rheumatology & skin | Alfasigma S.p.A. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-06-15 | 2026-10-20 |
| 2024-512279-10-00 EU CTIS |
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy Triple Negative Breast Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | Gilead Sciences Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-11-25 | 2026-10-20 |
| 2023-508137-14-00 EU CTIS |
A Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema Alpha-1 Antitrypsin Deficiency (AATD) Emphysema Updated ≤30d | Respiratory | Sanofi AATD Inc. Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-03-11 | 2026-10-20 |
| 2023-507684-19-00 EU CTIS |
Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer Updated ≤30d | Oncology | Janssen Cilag International Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-07-24 | 2026-10-20 |
| 2023-504751-28-00 EU CTIS |
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-group, active-control, observer-masked, superiority, randomised controlled surgical trial. Exudative age-related macular degeneration Open in IrelandUpdated ≤30d | Musculoskeletal, pain & surgery | King's College London, King's College Hospital NHS Foundation Trust Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-09-24 | 2026-10-20 |
| NCT07213700 ClinicalTrials.gov |
InRAD Observational Study Alzheimer's Disease(AD); Mild Cognitive Impairment (MCI); Subjective Cognitive Decline (SCD); Non-Alzheimer Degenerative Dementia Open in IrelandUpdated ≤30d | Neurology | Stichting International Registry for Alzheimer's Disease and other Dementias Foundation Academic / other | Observational | Recruiting | Dublin | 50,000 | 2026-03-30 | 2026-10-19 |
| NCT07422480 ClinicalTrials.gov · also 2025-523544-12-00 |
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions Myelodysplastic Syndrome; Anemia Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Takeda Industry | Phase 3 | Not yet recruiting, Recruiting | Cork, Dublin, Galway | 300 | 2026-05-21 | 2026-10-19 |
| NCT02991469 ClinicalTrials.gov |
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) Juvenile Idiopathic Arthritis Open in IrelandUpdated ≤30d | Immunology, rheumatology & skin | Sanofi Industry | Phase 2 | Recruiting | Crumlin | 51 | 2018-08-09 | 2026-10-19 |
| NCT05327894 ClinicalTrials.gov |
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia Open in IrelandUpdated ≤30d | Oncology | Princess Maxima Center for Pediatric Oncology Academic / other | Phase 3 | Recruiting | Dublin | 160 | 2022-12-15 | 2026-10-19 |
| NCT04316117 ClinicalTrials.gov |
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 Updated ≤30dWomen's health | Oncology | ECOG-ACRIN Cancer Research Group Academic / other | Phase 2 | (not given) | Cork | 138 | 2020-09-15 | 2026-10-19 |
| NCT04812925 ClinicalTrials.gov |
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Primary Immune Thrombocytopenia Updated ≤30d | Cardiovascular | argenx Industry | Phase 3 | (not given) | Dublin | 173 | 2021-11-17 | 2026-10-19 |
| NCT07880431 ClinicalTrials.gov |
Intelligent Physiological Monitoring to Predict Preterm Brain Injury Cerebral Palsy (CP); Intraventricular Hemorrhage Neonatal; Periventricular Leukomalacia; Neurodevelopmental Delay NewUpdated ≤30d | Neurology | University College Cork Academic / other | Observational | (not given) | Cork | 413 | 2026-04-13 | 2026-10-19 |
| NCT05566795 ClinicalTrials.gov |
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Low-grade Glioma; Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma; Pediatric Low-grade Glioma Updated ≤30d | Oncology | Day One Biopharmaceuticals, Inc. Industry | Phase 3 | (not given) | Crumlin | 418 | 2023-02-27 | 2026-10-19 |
| 2025-522731-34-00 EU CTIS |
A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer Ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | AstraZeneca AB Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-01-23 | 2026-10-19 |
| 2024-512998-27-00 EU CTIS |
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) Non-Small Cell Lung Cancer Updated ≤30d | Oncology | Genmab A/S Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-02-21 | 2026-10-19 |
| 2024-513547-82-00 EU CTIS |
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) Transthyretin Amyloidosis Open in IrelandUpdated ≤30d | Eye & ear | Eidos Therapeutics Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-03-11 | 2026-10-19 |
| 2023-506327-29-00 EU CTIS |
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) Non-Small Cell Lung Cancer Open in IrelandUpdated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-05-14 | 2026-10-19 |
| 2023-508852-21-00 EU CTIS |
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2) Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer Open in IrelandUpdated ≤30d | Oncology | AstraZeneca AB Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2022-06-10 | 2026-10-19 |
| 2023-507902-15-00 EU CTIS |
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer Updated ≤30d | Oncology | AbbVie Deutschland GmbH & Co. KG Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2019-03-26 | 2026-10-19 |
| 2022-502548-12-00 EU CTIS |
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma marginal zone lymphoma, follicular lymphoma Updated ≤30d | Oncology | BeOne Medicines AG Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2023-09-28 | 2026-10-19 |
| 2022-502669-14-00 EU CTIS |
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) Small cell lung cancer (SCLC) Updated ≤30d | Oncology | Amgen Inc. Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2023-12-18 | 2026-10-19 |
| NCT05347238 ClinicalTrials.gov |
Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis Late-Onset Neonatal Sepsis; Extreme Prematurity; Neonatal Hypotension Open in IrelandUpdated ≤30d | Infectious disease & vaccines | Mount Sinai Hospital, Canada Academic / other | Observational | Recruiting | Cork | 550 | 2023-02-06 | 2026-10-16 |
| NCT07115953 ClinicalTrials.gov |
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension Hypertension; Vascular Diseases; Cardiovascular Diseases; Chronic Kidney Diseases Updated ≤30d | Cardiovascular | Medtronic Vascular Industry | N/A (non-drug) | Terminated | Dublin | 130 | 2025-09-22 | 2026-10-16 |
| NCT06793397 ClinicalTrials.gov |
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder; Depression Disorders Open in IrelandUpdated ≤30d | Mental health | Cybin IRL Limited Industry | Phase 3 | Recruiting | Dublin, Galway | 330 | 2025-12-10 | 2026-10-16 |
| NCT07777614 ClinicalTrials.gov |
OPTIMISE Lung SABR Non Small Cell Lung Cancer Open in IrelandNewUpdated ≤30d | Oncology | Cancer Trials Ireland Academic / other | Phase 2 | Recruiting | Dublin | 208 | 2026-10-01 | 2026-10-16 |
| NCT03486873 ClinicalTrials.gov · also 2022-501254-10-00 |
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Solid Tumors; Hematologic Malignancies Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Dublin | 3,500 | 2018-08-21 | 2026-10-16 |
| NCT06623422 ClinicalTrials.gov · also 2023-506327-29-00 |
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Carcinoma, Non-Small-Cell Lung Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin | 680 | 2024-10-21 | 2026-10-16 |
| NCT06760637 ClinicalTrials.gov · also 2024-512925-95-00 |
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease Breast Cancer Updated ≤30dWomen's healthAlso in CTIS | Oncology | Pfizer Industry | Phase 3 | (not given) | Dublin | 1,035 | 2025-01-06 | 2026-10-16 |
| NCT03069352 ClinicalTrials.gov |
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy Acute Myeloid Leukemia (AML) Updated ≤30d | Oncology | AbbVie Industry | Phase 3 | (not given) | Dublin, Galway, Limerick | 211 | 2017-05-29 | 2026-10-16 |
| NCT06750289 ClinicalTrials.gov |
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment Eosinophilic Asthma Updated ≤30d | Respiratory | AstraZeneca Industry | Phase 3 | (not given) | Cork, Dublin, Moneymore | 130 | 2025-03-28 | 2026-10-16 |
| NCT05198674 ClinicalTrials.gov |
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN Hypertension; Vascular Diseases; Cardiovascular Diseases; Chronic Kidney Diseases Updated ≤30d | Cardiovascular | Medtronic Vascular Industry | N/A (non-drug) | (not given) | Dublin | 1,899 | 2021-10-20 | 2026-10-16 |
| NCT05979441 ClinicalTrials.gov |
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Myositis; Active Idiopathic Inflammatory Myopathy; Dermatomyositis; Polymyositis Updated ≤30d | Immunology, rheumatology & skin | argenx Industry | Phase 3 | (not given) | Dublin | 240 | 2023-09-12 | 2026-10-16 |
| NCT04908202 ClinicalTrials.gov |
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs Psoriatic Arthritis Updated ≤30d | Immunology, rheumatology & skin | Bristol-Myers Squibb Industry | Phase 3 | (not given) | Dublin, Galway, Manorhamilton | 670 | 2021-07-13 | 2026-10-16 |
| 2025-523837-25-00 EU CTIS |
4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome Barth Syndrome Open in IrelandNewUpdated ≤30d | Rare & genetic | Stealth Biotherapeutics Inc. Industry | Phase 3/4 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-16 |
| 2025-521587-35-00 EU CTIS |
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3) Metastatic colorectal cancer Open in IrelandUpdated ≤30d | Oncology | Summit Therapeutics Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-06-03 | 2026-10-16 |
| 2024-518895-30-00 EU CTIS |
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation Open in IrelandUpdated ≤30d | Neonatal & paediatric | Relay Therapeutics Inc. Industry | Phase 2 | Authorised, recruiting | Ireland (site detail on registry) | — | 2025-11-21 | 2026-10-16 |
| 2024-517584-23-00 EU CTIS |
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44) Duchenne Muscular Dystrophy Open in IrelandUpdated ≤30d | Rare & genetic | Entrada Therapeutics Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-05-16 | 2026-10-16 |
| 2023-509434-19-00 EU CTIS |
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Open in IrelandUpdated ≤30dWomen's health | Women's health & maternal | Janssen Cilag International Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-02-10 | 2026-10-16 |
| 2023-510333-28-00 EU CTIS |
EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial) Uveal Melanoma Open in IrelandUpdated ≤30d | Oncology | European Organisation For Research And Treatment Of Cancer Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-08-20 | 2026-10-16 |
| 2023-504957-11-00 EU CTIS |
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004) Metastatic castration resistant prostate cancer Open in IrelandUpdated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-03-24 | 2026-10-16 |
| 2023-506919-18-00 EU CTIS |
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type Updated ≤30d | Neurology | Novo Nordisk A/S Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2021-05-17 | 2026-10-16 |
| 2022-501254-10-00 EU CTIS |
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab Advanced tumors Open in IrelandUpdated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2018-08-24 | 2026-10-16 |
| NCT06422143 ClinicalTrials.gov · also 2023-510128-66-00 |
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] Non-small Cell Lung Cancer; NSCLC Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Dublin | 851 | 2024-06-10 | 2026-10-15 |
| NCT06925737 ClinicalTrials.gov · also 2024-517423-40-00 |
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Prostate Cancer; Prostatic Neoplasms Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin | 1,440 | 2025-05-13 | 2026-10-15 |
| NCT04728893 ClinicalTrials.gov |
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukaemia Open in IrelandUpdated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | Active, not recruiting, Recruiting | Dublin, Limerick | 490 | 2021-04-05 | 2026-10-15 |
| NCT05492344 ClinicalTrials.gov |
Personalized Mechanical Ventilation Guided by UltraSound in Patients With Acute Respiratory Distress Syndrome ARDS, Human; Lung Ultrasound; Mechanical Ventilation Open in IrelandUpdated ≤30d | Respiratory | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other | N/A (non-drug) | Recruiting | Galway | 538 | 2022-08-09 | 2026-10-15 |
| NCT07214779 ClinicalTrials.gov · also 2025-522748-42-00 |
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Ovarian Cancer Updated ≤30dWomen's healthAlso in CTIS | Oncology | Incyte Corporation Industry | Phase 3 | Completed | Dublin, Galway, Waterford | 466 | 2025-12-09 | 2026-10-15 |
| NCT05512234 ClinicalTrials.gov |
Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic Colic, Infantile Updated ≤30d | Neonatal & paediatric | BioGaia AB Industry | N/A (non-drug) | (not given) | Cork | 102 | 2022-07-13 | 2026-10-15 |
| NCT05100862 ClinicalTrials.gov · also 2022-502548-12-00 |
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma Updated ≤30dAlso in CTIS | Oncology | BeOne Medicines Industry | Phase 3 | (not given) | Dublin, Waterford | 799 | 2022-03-10 | 2026-10-15 |
| NCT04961996 ClinicalTrials.gov |
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) Early Breast Cancer Updated ≤30dWomen's health | Oncology | Hoffmann-La Roche Industry | Phase 3 | (not given) | Cork, Dublin, Galway, Limerick, Waterford | 4,170 | 2021-08-27 | 2026-10-15 |
| NCT06967805 ClinicalTrials.gov |
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) Idiopathic Pulmonary Fibrosis Updated ≤30d | Respiratory | Mediar Therapeutics Industry | Phase 2 | (not given) | Abbotstown, Drogheda, Dublin, Letterkenny | 168 | 2025-05-05 | 2026-10-15 |
| 2023-504135-40-00 EU CTIS |
A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY) Classical Homocystinuria Open in IrelandUpdated ≤30d | Metabolic & endocrine | Travere Therapeutics Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-07-29 | 2026-10-15 |
| 2024-517136-21-00 EU CTIS |
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033) Renal Cell Carcinoma Open in IrelandUpdated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-12-05 | 2026-10-15 |
| 2024-516609-22-00 EU CTIS |
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease Primary Sjögren’s Disease Updated ≤30d | Immunology, rheumatology & skin | Argenx Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2025-04-15 | 2026-10-15 |
| 2022-501050-11-01 EU CTIS |
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) Acute Lymphoblastic Leukaemia Open in IrelandUpdated ≤30d | Oncology | Karolinska University Hospital Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2020-07-13 | 2026-10-15 |
| 2023-508522-95-00 EU CTIS |
EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA Related-Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK-P1) PIK3CA-Related Overgrowth Spectrum (PROS) Updated ≤30d | Rare & genetic | Novartis Pharma AG Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-01-27 | 2026-10-15 |
| NCT06872892 ClinicalTrials.gov · also 2024-518589-29-00 |
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis Bronchiectasis Updated ≤30dAlso in CTIS | Respiratory | Boehringer Ingelheim Industry | Phase 3 | Active, not recruiting, Completed | Cork, Dublin | 1,755 | 2025-06-09 | 2026-10-14 |
| NCT06931717 ClinicalTrials.gov |
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy Non-Small Cell Lung Cancer Open in IrelandUpdated ≤30d | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 3 | Not yet recruiting, Recruiting | Cork, Dublin | 390 | 2026-01-12 | 2026-10-14 |
| NCT07064473 ClinicalTrials.gov · also 2025-521188-11-00 |
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases Open in IrelandUpdated ≤30dAlso in CTIS | Cardiovascular | Boehringer Ingelheim Industry | Phase 3 | Recruiting | Ballinasloe, Dublin, Galway | 11,800 | 2025-07-22 | 2026-10-14 |
| NCT06943872 ClinicalTrials.gov · also 2024-517131-52-00 |
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | BeOne Medicines Industry | Phase 3 | Recruiting | Dublin, Galway, Limerick | 630 | 2025-06-11 | 2026-10-14 |
| NCT07140172 ClinicalTrials.gov |
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery Breast Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | University Hospital, Basel, Switzerland Academic / other | N/A (non-drug) | Not yet recruiting, Recruiting | Cork, Dublin, Galway | 1,060 | 2026-01-01 | 2026-10-14 |
| NCT07840534 ClinicalTrials.gov |
Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU) Breast Cancer; Breast Cancer Survivorship; Cancer Survivorship; Endocrine Therapy Open in IrelandNewUpdated ≤30dWomen's health | Oncology | University College Cork Academic / other | N/A (non-drug) | (not given) | Cork | 30 | 2026-10-01 (est.) | 2026-10-14 |
| NCT04980833 ClinicalTrials.gov · also 2023-508522-95-00 |
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) PIK3CA-related Overgrowth Spectrum (PROS) Updated ≤30dAlso in CTIS | Other / unclassified | Novartis Pharmaceuticals Industry | Phase 2 | (not given) | Dublin | 41 | 2022-01-27 | 2026-10-14 |
| NCT06238622 ClinicalTrials.gov · also 2023-507353-15-00 |
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis Updated ≤30dAlso in CTIS | Respiratory | Boehringer Ingelheim Industry | Phase 3 | (not given) | Dublin | 1,666 | 2024-09-26 | 2026-10-14 |
| NCT03330847 ClinicalTrials.gov |
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. Metastatic Triple Negative Breast Cancer Updated ≤30dWomen's health | Oncology | AstraZeneca Industry | Phase 2 | (not given) | Cork, Dublin | 273 | 2018-03-07 | 2026-10-14 |
| NCT03816163 ClinicalTrials.gov |
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma Updated ≤30d | Oncology | Astellas Pharma Global Development, Inc. Industry | Phase 2 | (not given) | Elm Park | 393 | 2019-03-15 | 2026-10-14 |
| NCT05979311 ClinicalTrials.gov · also 2023-504993-40-00 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy HIV; HIV Infections Updated ≤30dAlso in CTIS | Infectious disease & vaccines | ViiV Healthcare Industry | Phase 3 | (not given) | Dublin | 463 | 2024-02-21 | 2026-10-14 |
| 2023-506669-70-00 EU CTIS |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Updated ≤30d | Cardiovascular | Alexion Pharmaceuticals Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-04-30 | 2026-10-14 |
| 2022-501453-36-00 EU CTIS |
EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) Breast cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | European Organisation For Research And Treatment Of Cancer Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-02-23 | 2026-10-14 |
| NCT06393374 ClinicalTrials.gov · also 2023-504962-52-00 |
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Triple-Negative Breast Cancer Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin, Galway | 1,530 | 2024-06-24 | 2026-10-13 |
| NCT07318558 ClinicalTrials.gov · also 2023-508047-40-00 |
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Ovarian Neoplasms; Ovarian Cancer Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin | 900 | 2026-02-16 | 2026-10-13 |
| NCT07216703 ClinicalTrials.gov · also 2025-521514-26-00 |
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Cervical Cancer Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin | 1,023 | 2026-01-19 | 2026-10-13 |
| NCT07225504 ClinicalTrials.gov |
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis (SPMS) Open in IrelandUpdated ≤30d | Neurology | Novartis Pharmaceuticals Industry | Phase 3 | Recruiting | Dublin | 1,275 | 2025-11-11 | 2026-10-13 |
| NCT06875310 ClinicalTrials.gov |
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) Carcinoma, Non-Small-Cell Lung Open in IrelandUpdated ≤30d | Oncology | Mirati Therapeutics Inc. Industry | Phase 3 | Recruiting | Cork, Dublin | 630 | 2025-04-24 | 2026-10-13 |
| NCT04613596 ClinicalTrials.gov |
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer Open in IrelandUpdated ≤30d | Oncology | Mirati Therapeutics Inc. Industry | Phase 2/3 | Recruiting, Withdrawn | Cork, Dublin, Galway, Limerick, Waterford | 626 | 2020-12-02 | 2026-10-13 |
| NCT06824467 ClinicalTrials.gov · also 2023-508015-23-00 |
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Dublin | 770 | 2025-04-09 | 2026-10-13 |
| NCT05086692 ClinicalTrials.gov · also 2023-507536-21-00 |
A Beta-only IL-2 ImmunoTherapY Study Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Medicenna Therapeutics, Inc. Industry | Phase 1/2 | Recruiting | Dublin | 160 | 2021-08-27 | 2026-10-13 |
| NCT06274801 ClinicalTrials.gov |
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) Pulmonary Arterial Hypertension Open in IrelandUpdated ≤30d | Cardiovascular | Gossamer Bio USA, Inc. Industry | Phase 3 | Recruiting | Dublin | 330 | 2024-09-03 | 2026-10-13 |
| NCT06312176 ClinicalTrials.gov · also 2023-504918-29-00 |
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) Breast Neoplasms Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin | 1,200 | 2024-04-14 | 2026-10-13 |
| NCT06952504 ClinicalTrials.gov · also 2024-519331-42-00 |
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) Endometrial Cancer Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin | 1,123 | 2025-05-22 | 2026-10-13 |
| NCT05633654 ClinicalTrials.gov |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Triple Negative Breast Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | Gilead Sciences Industry | Phase 3 | Not yet recruiting, Recruiting | Dublin, Limerick, Wilton | 1,514 | 2022-12-12 | 2026-10-13 |
| NCT04822181 ClinicalTrials.gov |
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) Non-alcoholic Steatohepatitis Updated ≤30d | Mental health | Novo Nordisk A/S Industry | Phase 3 | (not given) | Dublin | 1,205 | 2021-04-01 | 2026-10-13 |
| NCT04905069 ClinicalTrials.gov |
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Prostate Cancer Updated ≤30d | Oncology | Boston Scientific Corporation Industry | N/A (non-drug) | (not given) | Cork | 500 | 2021-12-21 | 2026-10-13 |
| NCT05970172 ClinicalTrials.gov |
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease Chronic Kidney Disease; Renal Anemia Updated ≤30d | Kidney & urology | Astellas Pharma Global Development, Inc. Industry | Phase 3 | (not given) | Dublin | 98 | 2024-01-16 | 2026-10-13 |
| NCT06732895 ClinicalTrials.gov |
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. Achondroplasia Updated ≤30d | Other / unclassified | Ascendis Pharma A/S Industry | Phase 2 | (not given) | Dublin | 25 | 2024-12-10 | 2026-10-13 |
| 2025-524054-34-00 EU CTIS |
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam Spinal Muscular Atrophy Open in IrelandNewUpdated ≤30d | Neurology | Biogen Idec Research Limited Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-13 |
| 2025-524623-50-00 EU CTIS |
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors Solid Tumors Open in IrelandUpdated ≤30d | Oncology | Revolution Medicines Inc. Industry | Phase 2 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-08-10 | 2026-10-13 |
| 2023-506091-27-00 EU CTIS |
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 years of age) with Achondroplasia followed by an Open Label Extension (OLE) period. Achondroplasia in Children and Adolescents Open in IrelandUpdated ≤30d | Neonatal & paediatric | Ascendis Pharma Growth Disorders A/S Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-09-19 | 2026-10-13 |
| 2023-503711-15-00 EU CTIS |
A Trial of Lu AG13909 in Participants with Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia Updated ≤30d | Metabolic & endocrine | H. Lundbeck A/S Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-01-25 | 2026-10-13 |
| 2025-524067-20-00 EU CTIS |
A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC) Primary Biliary Cholangitis (PBC) Open in IrelandNewUpdated ≤30d | Digestive & liver | Zydus Therapeutics Inc. Industry | Phase 3/4 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-12 |
| 2025-522373-10-00 EU CTIS |
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis Open in IrelandUpdated ≤30d | Respiratory | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-12 |
| 2025-522400-24-00 EU CTIS |
IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment Metastatic urothelial cancer Open in IrelandUpdated ≤30d | Oncology | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-01-27 | 2026-10-12 |
| 2023-510390-33-00 EU CTIS |
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA HER2-negative breast cancer, HER2-negative breast cancer patients with high relapse risk after
standard neoadjuvant treatment Updated ≤30dWomen's health | Oncology | GBG Forschungs GmbH Academic / other | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2020-10-23 | 2026-10-12 |
| 2023-509133-39-00 EU CTIS |
EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor Hormone receptor positive, HER2-negative advanced breast cancer Updated ≤30dWomen's health | Oncology | Novartis Pharma AG Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-11-29 | 2026-10-12 |
| 2023-507963-20-00 EU CTIS |
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Metastatic Gastric Adenocarcinoma Updated ≤30d | Oncology | Daiichi Sankyo Inc. Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2021-08-19 | 2026-10-12 |
| 2022-502122-41-00 EU CTIS |
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Clear cell renal cancer Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2021-05-11 | 2026-10-12 |
| NCT06585774 ClinicalTrials.gov · also 2023-510292-65-00 |
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Chronic Graft-versus-host-disease Open in IrelandUpdated ≤30dAlso in CTIS | Respiratory | Incyte Corporation Industry | Phase 3 | Recruiting | Dublin | 240 | 2025-01-21 | 2026-10-09 |
| NCT06405087 ClinicalTrials.gov · also 2023-508804-39-00 |
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) Ulcerative Colitis; Crohn's Disease Open in IrelandUpdated ≤30dAlso in CTIS | Immunology, rheumatology & skin | Takeda Industry | Phase 3 | Not yet recruiting | Crumlin | 70 | 2025-10-27 | 2026-10-09 |
| NCT06442930 ClinicalTrials.gov |
EXtubation Related Complications - the EXTUBE Study (EXTUBE) Extubation Open in IrelandUpdated ≤30d | Other / unclassified | University Health Network, Toronto Academic / other | Observational | Completed, Not yet recruiting | Castlebar, Cork, Dublin, Galway, Waterford | 3,000 | 2025-04-14 | 2026-10-09 |
| NCT06863272 ClinicalTrials.gov |
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Castration-Resistant Prostatic Cancer; Metastasis Open in IrelandUpdated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 1/2 | Recruiting | Dublin | 360 | 2025-07-03 | 2026-10-09 |
| NCT07266428 ClinicalTrials.gov · also 2025-524111-37-00 |
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors Advanced Solid Tumors Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Ottimo Pharma Limited Industry | Phase 1/2 | Recruiting | Dublin | 170 | 2025-12-17 | 2026-10-09 |
| NCT05444257 ClinicalTrials.gov |
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Cystic Fibrosis Updated ≤30d | Respiratory | Vertex Pharmaceuticals Incorporated Industry | Phase 3 | (not given) | Cork, Dublin, Limerick | 822 | 2022-11-08 | 2026-10-09 |
| NCT06026345 ClinicalTrials.gov |
Affera Global Registry Atrial Fibrillation Updated ≤30d | Cardiovascular | Medtronic Cardiac Ablation Solutions Industry | Observational | (not given) | Dublin | 540 | 2023-12-22 | 2026-10-09 |
| NCT06910358 ClinicalTrials.gov |
Study of Bitopertin in Participants With EPP or XLP (APOLLO) Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) Updated ≤30d | Other / unclassified | Disc Medicine, Inc Industry | Phase 3 | (not given) | Dublin | 183 | 2025-04-04 | 2026-10-09 |
| NCT05883748 ClinicalTrials.gov |
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP Erythropoietic Protoporphyria Updated ≤30d | Other / unclassified | Disc Medicine, Inc Industry | Phase 2/3 | (not given) | Dublin | 230 | 2023-08-31 | 2026-10-09 |
| NCT03701334 ClinicalTrials.gov · also 2023-510357-42-00 |
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer Early Breast Cancer Updated ≤30dWomen's healthAlso in CTIS | Oncology | Novartis Pharmaceuticals Industry | Phase 3 | (not given) | County Limerick, Dublin, Waterford, Wilton | 5,101 | 2018-12-07 | 2026-10-09 |
| 2025-522544-40-00 EU CTIS |
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN) Hereditary transthyretin-mediated amyloidosis with polyneuropathy Open in IrelandUpdated ≤30d | Neurology | Alnylam Pharmaceuticals Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-03-27 | 2026-10-09 |
| 2024-519128-26-00 EU CTIS |
A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-101, 2%, ophthalmic solution in patients with non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration: eDREAM study Non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration Open in IrelandUpdated ≤30d | Cardiovascular | Galimedix Therapeutics Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-05-22 | 2026-10-09 |
| 2023-509391-42-00 EU CTIS |
A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn’s Disease Chron's Disease Open in IrelandUpdated ≤30d | Immunology, rheumatology & skin | Takeda Development Center Americas Inc. Industry | Phase 3/4 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-06-02 | 2026-10-09 |
| 2022-503081-74-00 EU CTIS |
A Phase 3, Open-label Study Evaluating the Long‑term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older Cystic Fibrosis Open in IrelandUpdated ≤30d | Respiratory | Vertex Pharmaceuticals Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2023-09-05 | 2026-10-09 |
| NCT06247085 ClinicalTrials.gov |
Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment Homocystinuria Open in IrelandUpdated ≤30d | Other / unclassified | Travere Therapeutics, Inc. Industry | Phase 3 | Not yet recruiting | Dublin | 70 | 2023-12-28 | 2026-10-08 |
| NCT07287098 ClinicalTrials.gov |
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer Breast Neoplasms Open in IrelandUpdated ≤30dWomen's health | Oncology | Eli Lilly and Company Industry | Phase 2 | Not yet recruiting | Dublin, Galway | 600 | 2026-05-13 | 2026-10-08 |
| NCT06499285 ClinicalTrials.gov · also 2024-516009-22-00 |
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions Myelodysplastic Syndromes Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Takeda Industry | Phase 3 | Not yet recruiting, Recruiting | Cork, Dublin, Limerick | 225 | 2025-05-06 | 2026-10-08 |
| NCT07223203 ClinicalTrials.gov · also 2025-522544-40-00 |
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN Open in IrelandUpdated ≤30dAlso in CTIS | Neurology | Alnylam Pharmaceuticals Industry | Phase 3 | Recruiting | Dublin | 125 | 2026-02-03 | 2026-10-08 |
| NCT07174336 ClinicalTrials.gov |
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Breast Neoplasms; Neoplasm Metastasis Open in IrelandUpdated ≤30dWomen's health | Oncology | Eli Lilly and Company Industry | Phase 3 | Not yet recruiting | Cork, Dublin, Galway | 800 | 2025-12-22 | 2026-10-08 |
| NCT07854899 ClinicalTrials.gov |
Natural History Study of Advanced RCD Rod Cone Dystrophy Open in IrelandNewUpdated ≤30d | Eye & ear | SparingVision Industry | N/A (non-drug) | Not yet recruiting | Dublin | 100 | 2026-09-11 | 2026-10-08 |
| NCT07213804 ClinicalTrials.gov · also 2025-522255-25-00 |
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Oncology | Eli Lilly and Company Industry | Phase 3 | Not yet recruiting | Dublin | 1,630 | 2025-10-22 | 2026-10-08 |
| NCT06890884 ClinicalTrials.gov · also 2024-515526-89-00 |
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) Lymphoma, Large B-Cell, Diffuse Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | Recruiting | Dublin, Limerick, Waterford | 594 | 2025-04-11 | 2026-10-08 |
| NCT03924856 ClinicalTrials.gov |
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) Bladder Cancer Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Cork, Dublin, Waterford | 907 | 2019-06-13 | 2026-10-08 |
| NCT04009330 ClinicalTrials.gov |
Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome Acute Respiratory Distress Syndrome (ARDS) Updated ≤30d | Respiratory | Queen's University, Belfast Academic / other | Observational | (not given) | Dublin | 480 | 2019-11-22 | 2026-10-08 |
| NCT05899608 ClinicalTrials.gov |
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients Non-Small Cell Lung Cancer Updated ≤30d | Oncology | Summit Therapeutics Industry | Phase 3 | (not given) | Dublin, Galway | 1,600 | 2023-10-26 | 2026-10-08 |
| NCT05718817 ClinicalTrials.gov |
An Open-label Study of XEN1101 in Epilepsy Focal Epilepsy; Tonic-Clonic Seizures Updated ≤30d | Neurology | Xenon Pharmaceuticals Inc. Industry | Phase 3 | (not given) | Dublin | 880 | 2023-04-25 | 2026-10-08 |
| 2025-523390-42-00 EU CTIS |
A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD) Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD) Open in IrelandUpdated ≤30d | Neurology | Alnylam Pharmaceuticals Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-08-31 | 2026-10-08 |
| 2025-520466-22-00 EU CTIS |
Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01) Advanced Platinum-resistant Epithelial Ovarian Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | AstraZeneca AB Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-04-29 | 2026-10-08 |
| 2023-506924-94-00 EU CTIS |
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease Cardiovascular disease Updated ≤30d | Cardiovascular | Novo Nordisk A/S Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2023-02-28 | 2026-10-08 |
| 2023-504655-27-00 EU CTIS |
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma Primary Indeterminate Lesions or Small Choroidal Melanoma Updated ≤30d | Oncology | Aura Biosciences Inc. Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2024-12-23 | 2026-10-08 |
| 2023-504932-16-00 EU CTIS |
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) Muscle Invasive Bladder Cancer Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2019-06-04 | 2026-10-08 |
| 2023-503772-24-00 EU CTIS |
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) IgA Nephropathy Updated ≤30d | Kidney & urology | Vera Therapeutics Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-09-15 | 2026-10-08 |
| NCT06091865 ClinicalTrials.gov |
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma Diffuse Large B-cell Lymphoma (DLBCL) Updated ≤30d | Oncology | Regeneron Pharmaceuticals Industry | Phase 3 | Withdrawn | Dublin | 904 | 2023-12-13 | 2026-10-07 |
| NCT06072781 ClinicalTrials.gov |
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer Low Grade Serous Ovarian Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | Verastem, Inc. Industry | Phase 3 | Recruiting | Dublin | 270 | 2024-03-18 | 2026-10-07 |
| NCT04910685 ClinicalTrials.gov |
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Indolent Systemic Mastocytosis; Smoldering Systemic Mastocytosis Open in IrelandUpdated ≤30d | Other / unclassified | Blueprint Medicines Corporation Industry | Phase 2/3 | Recruiting | Cork | 534 | 2021-11-30 | 2026-10-07 |
| NCT05512364 ClinicalTrials.gov |
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | European Organisation for Research and Treatment of Cancer - EORTC Academic / other | Phase 3 | Recruiting | Dublin, Waterford | 220 | 2023-12-15 | 2026-10-07 |
| NCT05243797 ClinicalTrials.gov |
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Multiple Myeloma Open in IrelandUpdated ≤30d | Oncology | European Myeloma Network B.V. Academic / other | Phase 3 | Recruiting | Cork, Dublin, Galway, Limerick | 1,594 | 2022-09-08 | 2026-10-07 |
| NCT02555683 ClinicalTrials.gov |
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Asthma Updated ≤30d | Respiratory | Novartis Pharmaceuticals Industry | Phase 3 | (not given) | Dublin | 894 | 2015-12-11 | 2026-10-07 |
| NCT06598943 ClinicalTrials.gov |
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis; Ulcerative Colitis Chronic Updated ≤30d | Immunology, rheumatology & skin | Eli Lilly and Company Industry | Phase 2 | (not given) | Dublin | 143 | 2024-10-10 | 2026-10-07 |
| 2024-519270-40-00 EU CTIS |
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants with Major Depressive Disorder (EMBRACE) Major Depressive Disorder Open in IrelandUpdated ≤30d | Mental health | Cybin IRL Limited Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-10-30 | 2026-10-07 |
| 2024-513682-40-01 EU CTIS |
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression ≥1% Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer Open in IrelandUpdated ≤30d | Oncology | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-07-04 | 2026-10-07 |
| 2024-516030-35-00 EU CTIS |
A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone versus daratumumab, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)-DREAMM-10 Multiple myeloma Updated ≤30d | Oncology | Glaxosmithkline Research & Development Limited Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-04-30 | 2026-10-07 |
| 2023-503630-44-00 EU CTIS |
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (age 2 to <12 years) and infants (age 6 months to <2 years) with moderate-to-severe atopic dermatitis. The trial is randomized, double-blind, placebo-controlled, and parallel-group for children (age 2 to <12 years) and open label and single-group for infants (age 6 months to <2 years) Treatment of moderate-to-severe Atopic dermatitis Updated ≤30d | Immunology, rheumatology & skin | Leo Pharma A/S Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-11-20 | 2026-10-07 |
| 2022-501105-12-00 EU CTIS |
C5731001 - An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab
Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that
Expresses HER2 (IHC 1+ and Greater) Urothelial Carcinoma Updated ≤30d | Oncology | Seagen Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-07-15 | 2026-10-07 |
| 2023-506361-56-00 EU CTIS |
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15) Endometrial cancer Updated ≤30dWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-04-01 | 2026-10-07 |
| 2023-505766-28-00 EU CTIS |
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema Hereditary angioedema Updated ≤30d | Immunology, rheumatology & skin | Pharvaris Netherlands B.V. Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2022-10-10 | 2026-10-07 |
| NCT07322003 ClinicalTrials.gov |
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS Amyotrophic Lateral Sclerosis Open in IrelandUpdated ≤30d | Neurology | Prilenia Industry | Phase 3 | Recruiting | Dublin | 500 | 2026-02-01 | 2026-10-06 |
| NCT06793215 ClinicalTrials.gov |
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer Open in IrelandUpdated ≤30d | Oncology | Hoffmann-La Roche Industry | Phase 3 | Recruiting | Dublin | 600 | 2025-10-24 | 2026-10-06 |
| NCT07492680 ClinicalTrials.gov |
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Solid Tumors Open in IrelandUpdated ≤30d | Oncology | Bristol-Myers Squibb Industry | Phase 2 | Not yet recruiting, Recruiting | Cork, Dublin | 260 | 2026-07-27 | 2026-10-06 |
| NCT06136624 ClinicalTrials.gov · also 2023-504899-25-00 |
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Prostate Cancer Metastatic Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Dublin | 1,310 | 2023-12-31 | 2026-10-06 |
| NCT06353386 ClinicalTrials.gov · also 2023-506288-33-00 |
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Prostatic Neoplasms, Castration-Resistant Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 1/2 | Recruiting | Cork, Dublin | 220 | 2024-05-20 | 2026-10-06 |
| NCT07416604 ClinicalTrials.gov · also 2025-522435-33-00 |
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A Hemophilia A Open in IrelandUpdated ≤30dAlso in CTIS | Blood (non-cancer) | Hoffmann-La Roche Industry | Phase 3 | Recruiting | Dublin | 360 | 2026-04-27 | 2026-10-06 |
| NCT06635824 ClinicalTrials.gov · also 2024-512998-27-00 |
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC Updated ≤30dAlso in CTIS | Oncology | Genmab Industry | Phase 3 | (not given) | Cork, Dublin, Limerick, Waterford | 191 | 2024-11-25 | 2026-10-06 |
| NCT03878446 ClinicalTrials.gov |
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day Short Stature Children Born Small for Gestational Age (SGA) Updated ≤30dWomen's health | Women's health & maternal | Novo Nordisk A/S Industry | Phase 2 | (not given) | Dublin | 62 | 2019-07-04 | 2026-10-06 |
| NCT05043103 ClinicalTrials.gov |
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease Advanced Parkinson Disease Updated ≤30d | Neurology | Britannia Pharmaceuticals Ltd. Industry | Observational | (not given) | Dublin | 312 | 2021-07-06 | 2026-10-06 |
| NCT04901195 ClinicalTrials.gov |
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Updated ≤30d | Immunology, rheumatology & skin | UCB Biopharma SRL Industry | Phase 3 | (not given) | Dublin | 658 | 2021-05-27 | 2026-10-06 |
| 2025-524263-21-01 EU CTIS |
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER Resected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer Open in IrelandNewUpdated ≤30d | Oncology | F. Hoffmann-La Roche AG Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-09-02 | 2026-10-06 |
| 2025-524111-37-00 EU CTIS |
Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors advanced solid tumors Open in IrelandUpdated ≤30d | Oncology | Ottimo Pharma Limited Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-04-28 | 2026-10-06 |
| 2025-522512-16-00 EU CTIS |
Phase 1 trial of valemetostat and darolutamide in mCRPC Metastatic Castration Resistant Prostate Cancer (mCRPC) Open in IrelandUpdated ≤30d | Oncology | Daiichi Sankyo Inc. Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-04-23 | 2026-10-06 |
| 2025-522598-12-00 EU CTIS |
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion Untreated Metastatic Pancreatic Ductal Adenocarcinoma Open in IrelandUpdated ≤30d | Oncology | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2025-12-17 | 2026-10-06 |
| 2024-518365-10-00 EU CTIS |
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer Updated ≤30d | Oncology | F. Hoffmann-La Roche AG Industry | Phase 3 | Temporarily halted | Ireland (site detail on registry) | — | 2025-10-28 | 2026-10-06 |
| 2024-515092-36-00 EU CTIS |
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Updated ≤30d | Cardiovascular | Eidos Therapeutics Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-02-14 | 2026-10-06 |
| 2022-501939-16-00 EU CTIS |
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation. Updated ≤30d | Cardiovascular | Novo Nordisk A/S Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2023-05-09 | 2026-10-06 |
| 2022-501007-28-00 EU CTIS |
J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence Breast Neoplasms Updated ≤30dWomen's health | Oncology | Eli Lilly & Co. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2023-04-18 | 2026-10-06 |
| NCT07164313 ClinicalTrials.gov |
A Study of ZW251 in Participants With Advanced Solid Tumors Hepatocellular Carcinoma; Squamous Cell Non-Small Cell Lung Cancer; Germ Cell Tumor Open in IrelandUpdated ≤30d | Oncology | Zymeworks BC Inc. Industry | Phase 1 | Recruiting | Dublin | 140 | 2025-10-21 | 2026-10-05 |
| NCT06784193 ClinicalTrials.gov |
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Breast Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | Olema Pharmaceuticals, Inc. Industry | Phase 1 | Recruiting | Dublin | 180 | 2024-12-16 | 2026-10-05 |
| NCT06389877 ClinicalTrials.gov |
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) Alpha 1-Antitrypsin Deficiency Open in IrelandUpdated ≤30d | Other / unclassified | Beam Therapeutics Inc. Industry | Phase 1/2 | Recruiting | Dublin | 192 | 2024-06-19 | 2026-10-05 |
| NCT06959095 ClinicalTrials.gov |
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation Pulmonary Disease, Chronic Obstructive Open in IrelandUpdated ≤30d | Respiratory | GlaxoSmithKline Industry | Phase 3 | Recruiting | Cork, Drogheda, Dublin, Galway, Mullingar | 981 | 2025-06-20 | 2026-10-05 |
| NCT06982521 ClinicalTrials.gov |
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor; Breast Cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | Relay Therapeutics, Inc. Industry | Phase 3 | Recruiting | Dublin | 540 | 2025-08-26 | 2026-10-05 |
| NCT06659549 ClinicalTrials.gov |
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD Geographic Atrophy of the Macula Open in IrelandUpdated ≤30d | Cardiovascular | Galimedix Therapeutics Inc Industry | Phase 2 | Not yet recruiting, Recruiting | Kildare, Waterford | 110 | 2025-01-10 | 2026-10-05 |
| NCT07857070 ClinicalTrials.gov |
Newborn Brain Assessment - CergenX Wave Neonatal Encephalopathy; Neonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy); Neonatal Encephalopathy, Unspecified Open in IrelandNewUpdated ≤30d | Neonatal & paediatric | CergenX Limited Industry | Observational | (not given) | Cork | 165 | 2026-09 (est.) | 2026-10-05 |
| NCT03825835 ClinicalTrials.gov |
30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants Premature Infant; Respiratory Distress Syndrome in Premature Infant; Neurodevelopmental Outcome Updated ≤30d | Neurology | University of Alberta Academic / other | N/A (non-drug) | (not given) | Cork | 1,203 | 2022-06-27 | 2026-10-05 |
| NCT03997643 ClinicalTrials.gov |
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Head and Neck Cancer Updated ≤30d | Oncology | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other | Phase 2 | (not given) | Dublin, Galway, Rathgar, Wilton | 90 | 2019-09-06 | 2026-10-05 |
| NCT05360446 ClinicalTrials.gov |
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events Coronary Artery Disease Updated ≤30d | Cardiovascular | Novartis Pharmaceuticals Industry | Phase 3 | (not given) | Dublin, Galway | 610 | 2022-07-08 | 2026-10-05 |
| 2025-524202-15-00 EU CTIS |
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer Recurrent Platinum-Sensitive Ovarian Cancer Open in IrelandNewUpdated ≤30dWomen's health | Oncology | Genmab A/S Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-10-06 | 2026-10-05 |
| 2025-524641-27-00 EU CTIS |
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open in IrelandNewUpdated ≤30dWomen's health | Oncology | K-Group Beta Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-05 |
| 2024-513676-18-00 EU CTIS |
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE) Transthyretin Amyloidosis Open in IrelandUpdated ≤30d | Cardiovascular | Eidos Therapeutics Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-05 |
| 2024-519654-37-00 EU CTIS |
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (FORTIFI-HN01). Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Open in IrelandUpdated ≤30d | Oncology | Bicara Therapeutics Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-11-07 | 2026-10-05 |
| 2024-518998-33-00 EU CTIS |
A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies Ulcerative Colitis Updated ≤30d | Immunology, rheumatology & skin | AbbVie Deutschland GmbH & Co. KG Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-07-23 | 2026-10-05 |
| 2024-514917-36-00 EU CTIS |
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy)
for patients with high-risk neuroblastoma, and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy Patients with High Risk Neuroblastoma Open in IrelandUpdated ≤30d | Oncology | Institut Gustave Roussy Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-11-21 | 2026-10-05 |
| 2023-507263-19-00 EU CTIS |
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation Advanced Non-Small Cell Lung Cancer Updated ≤30d | Oncology | Mirati Therapeutics Inc. Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2020-12-23 | 2026-10-05 |
| 2023-504918-29-00 EU CTIS |
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer Hormone receptor positive breast cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-08-22 | 2026-10-05 |
| 2023-504323-25-01 EU CTIS |
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) breast cancer Open in IrelandUpdated ≤30dWomen's health | Oncology | Greenwich LifeSciences Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-03-19 | 2026-10-05 |
| 2022-502202-33-00 EU CTIS |
AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia Achondroplasia in Children and Adolescents Open in IrelandUpdated ≤30d | Neonatal & paediatric | Ascendis Pharma Growth Disorders A/S Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2023-07-06 | 2026-10-05 |
| NCT06788990 ClinicalTrials.gov · also 2024-519654-37-00 |
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Bicara Therapeutics Industry | Phase 2/3 | Recruiting | Cork, Dublin | 650 | 2025-01-28 | 2026-10-02 |
| NCT04142437 ClinicalTrials.gov |
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion Updated ≤30d | Oncology | Bayer Industry | Observational | Withdrawn | Many Locations | 150 | 2020-04-03 | 2026-10-02 |
| NCT06680817 ClinicalTrials.gov |
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) Neovascular Age-related Macular Degeneration; Diabetic Macular Edema Updated ≤30d | Cardiovascular | Hoffmann-La Roche Industry | Observational | (not given) | Dublin, Limerick, Waterford | 875 | 2025-02-05 | 2026-10-02 |
| NCT06953583 ClinicalTrials.gov |
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia Friedreich Ataxia Updated ≤30d | Neurology | Biogen Industry | Phase 3 | (not given) | Dublin | 255 | 2025-06-09 | 2026-10-02 |
| NCT04736706 ClinicalTrials.gov · also 2022-502122-41-00 |
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Carcinoma, Renal Cell Updated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin | 1,688 | 2021-04-14 | 2026-10-02 |
| 2026-526778-18-00 EU CTIS |
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease Anemia in subjects with sickle cell disease (SCD) Open in IrelandNewUpdated ≤30d | Blood (non-cancer) | Agios Pharmaceuticals Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-10-02 |
| 2025-522435-33-00 EU CTIS |
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A Hemophilia A Open in IrelandUpdated ≤30d | Blood (non-cancer) | F. Hoffmann-La Roche AG Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-06-17 | 2026-10-02 |
| 2024-519655-28-00 EU CTIS |
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply:
a. 1-3 lymph nodes involved AND any invasive tumour size.
b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm. Open in IrelandUpdated ≤30dWomen's health | Oncology | Unicancer Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-04-23 | 2026-10-02 |
| 2023-505850-16-00 EU CTIS |
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy. Multiple Myeloma Updated ≤30d | Oncology | Janssen - Cilag International Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-08-05 | 2026-10-02 |
| NCT07623161 ClinicalTrials.gov |
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Myelofibrosis; Anemia Open in IrelandUpdated ≤30d | Blood (non-cancer) | Takeda Industry | Phase 3 | Not yet recruiting | Cork, Dublin, Galway | 324 | 2026-09-10 | 2026-10-01 |
| NCT06535659 ClinicalTrials.gov |
VitaFlow LIBERTY Europe Aortic Valve Stenosis Open in IrelandUpdated ≤30d | Cardiovascular | Shanghai MicroPort CardioFlow Medtech Co., Ltd. Industry | Observational | Recruiting | Galway | 222 | 2025-05-06 | 2026-10-01 |
| NCT05636176 ClinicalTrials.gov · also 2022-501939-16-00 |
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation Heart Failure Updated ≤30dAlso in CTIS | Cardiovascular | Novo Nordisk A/S Industry | Phase 3 | (not given) | Cork, Dublin, Mahon, Cork | 4,874 | 2023-05-08 | 2026-10-01 |
| NCT00310180 ClinicalTrials.gov |
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7 Updated ≤30dWomen's health | Oncology | National Cancer Institute (NCI) Academic / other | Phase 3 | (not given) | Cork, Dublin, Galway, Letterkenny, Limerick, Mount Merrion, Sligo, Waterford | 10,273 | 2006-04-07 | 2026-10-01 |
| NCT02506153 ClinicalTrials.gov |
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Cutaneous Melanoma; Metastatic Mucosal Melanoma Updated ≤30d | Oncology | National Cancer Institute (NCI) Academic / other | Phase 3 | (not given) | Dublin, Galway, Waterford | 1,301 | 2015-11-10 | 2026-10-01 |
| NCT01804686 ClinicalTrials.gov |
A Long-term Extension Study of PCI-32765 (Ibrutinib) Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma Updated ≤30d | Oncology | Janssen Research & Development, LLC Industry | Phase 3 | (not given) | Dublin | 539 | 2013-09-09 | 2026-10-01 |
| NCT05946993 ClinicalTrials.gov |
Linking In With Advice and Supports for Men Impacted by Metastatic Cancer Survivorship; Prostate Cancer; Kidney Cancer; Urothelial Tract/Bladder Cancer, Nos Updated ≤30d | Oncology | University College Cork Academic / other | N/A (non-drug) | (not given) | Cork | 72 | 2023-05-08 | 2026-10-01 |
| NCT07852897 ClinicalTrials.gov |
Evaluation of Commercially Available Heel Pads for the Prevention of Pressure Ulcers: An Observational Study of Incidence and Usability in Adult Surgical Patients. Pressure Injury Prevention NewUpdated ≤30d | Musculoskeletal, pain & surgery | Trulife Industry | Observational | (not given) | Dublin | 35 | 2026-06-09 | 2026-10-01 |
| NCT01272037 ClinicalTrials.gov |
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma Updated ≤30dWomen's health | Oncology | National Cancer Institute (NCI) Academic / other | Phase 3 | (not given) | Cork, Dublin, Galway, Letterkenny, Limerick, Mount Merrion, Sligo, Waterford | 5,018 | 2011-02-28 | 2026-10-01 |
| NCT01169337 ClinicalTrials.gov |
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Light Chain Deposition Disease; Smoldering Multiple Myeloma Updated ≤30d | Oncology | National Cancer Institute (NCI) Academic / other | Phase 3 | (not given) | Dublin, Galway | 226 | 2011-01-24 | 2026-10-01 |
| 2023-508804-39-00 EU CTIS |
A Phase 3b Extension Study to Evaluate the Long-Term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease Ulcerative Colitis or Crohn’s Disease Open in IrelandUpdated ≤30d | Immunology, rheumatology & skin | Takeda Development Center Americas Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-10-15 | 2026-10-01 |
| 2023-510294-34-00 EU CTIS |
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI) small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL) Open in IrelandUpdated ≤30d | Oncology | University Of Cologne Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-06-12 | 2026-10-01 |
| 2024-516315-24-00 EU CTIS |
A phase III, randomized, double-masked, placebocontrolled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in pediatric subjects myopia Updated ≤30d | Eye & ear | Ocumension (Hong Kong) Ltd. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-05-27 | 2026-10-01 |
| 2024-510620-39-00 EU CTIS |
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy Advanced RCC with clear cell component Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-04-19 | 2026-10-01 |
| 2022-502503-30-00 EU CTIS |
Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia Acute lymphoblastic leukemia Open in IrelandUpdated ≤30d | Oncology | Princess Maxima Center For Pediatric Oncology Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2022-12-15 | 2026-10-01 |
| NCT07032662 ClinicalTrials.gov |
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic Inflammatory Demyelinating Polyneuropathy Open in IrelandUpdated ≤30d | Neurology | Immunovant Sciences GmbH Industry | Phase 2 | Not yet recruiting | Waterford | 162 | 2025-03-18 | 2026-09-30 |
| NCT07361497 ClinicalTrials.gov |
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) Non-small Cell Lung Cancer (NSCLC) Open in IrelandUpdated ≤30d | Oncology | Bristol-Myers Squibb Industry | Phase 3 | Not yet recruiting, Recruiting | Cork, Dublin | 850 | 2026-03-16 | 2026-09-30 |
| NCT05519085 ClinicalTrials.gov |
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Relapsed or Refractory Multiple Myeloma Updated ≤30d | Oncology | Celgene Industry | Phase 3 | Active, not recruiting, Withdrawn | Cork, Dublin, Galway, Limerick | 810 | 2022-09-20 | 2026-09-30 |
| NCT06764485 ClinicalTrials.gov |
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer Metastatic Castration-resistant Prostate Cancer Updated ≤30d | Oncology | Celgene Industry | Phase 3 | (not given) | Cork, Dublin | 960 | 2025-03-13 | 2026-09-30 |
| NCT03754790 ClinicalTrials.gov |
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX Hemophilia Updated ≤30d | Blood (non-cancer) | Genzyme, a Sanofi Company Industry | Phase 3 | (not given) | Crumlin, Dublin | 281 | 2019-01-09 | 2026-09-30 |
| NCT06940830 ClinicalTrials.gov · also 2024-517812-31-00 |
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa Hemophilia A Updated ≤30dAlso in CTIS | Blood (non-cancer) | Swedish Orphan Biovitrum Industry | Phase 4 | (not given) | Dublin | 252 | 2025-05-21 | 2026-09-30 |
| NCT04002297 ClinicalTrials.gov · also 2023-509908-15-00 |
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation Mantle Cell Lymphoma; Non-Hodgkin Lymphoma Updated ≤30dAlso in CTIS | Oncology | BeOne Medicines Industry | Phase 3 | (not given) | Cork, Dublin, Galway, Limerick, Waterford | 510 | 2019-08-20 | 2026-09-30 |
| NCT05611931 ClinicalTrials.gov |
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Endometrial Cancer Updated ≤30dWomen's health | Oncology | Karyopharm Therapeutics Inc Industry | Phase 3 | (not given) | Cork, Dublin, Galway, Waterford | 257 | 2023-04-18 | 2026-09-30 |
| NCT06077864 ClinicalTrials.gov |
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) Obesity Updated ≤30d | Cardiovascular | Boehringer Ingelheim Industry | Phase 3 | (not given) | Dublin, Galway | 5,531 | 2023-11-20 | 2026-09-30 |
| NCT05149755 ClinicalTrials.gov |
Evolut™ EXPAND TAVR II Pivotal Trial Moderate Aortic Valve Stenosis Updated ≤30d | Oncology | Medtronic Cardiovascular Industry | N/A (non-drug) | (not given) | Galway | 650 | 2022-04-27 | 2026-09-30 |
| 2026-527163-15-00 EU CTIS |
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC) Advanced Renal Cell Carcinoma Open in IrelandNewUpdated ≤30d | Oncology | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-09-30 |
| 2023-503699-25-00 EU CTIS |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Progressive Pulmonary Fibrosis Updated ≤30d | Respiratory | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-07-15 | 2026-09-30 |
| 2023-503697-21-01 EU CTIS |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Idiopathic pulmonary fibrosis Updated ≤30d | Respiratory | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-06-24 | 2026-09-30 |
| 2023-506256-25-00 EU CTIS |
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs Active Psoriatic Arthritis Updated ≤30d | Immunology, rheumatology & skin | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2021-10-20 | 2026-09-30 |
| 2023-504820-24-00 EU CTIS |
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) Neoadjuvant/Adjuvant treatment for participants with Resectable Stage II or IIIA-B (N2) NSCLC Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2018-03-21 | 2026-09-30 |
| NCT06881784 ClinicalTrials.gov |
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma) Open in IrelandUpdated ≤30d | Oncology | Revolution Medicines, Inc. Industry | Phase 3 | Recruiting | Cork, Dublin, Galway | 590 | 2025-05-06 | 2026-09-29 |
| NCT06237452 ClinicalTrials.gov |
VE303 for Prevention of Recurrent Clostridioides Difficile Infection Clostridium Difficile; Clostridium Difficile Infections; Clostridium Difficile Infection Recurrence; Clostridioides Difficile Infection Updated ≤30d | Infectious disease & vaccines | Vedanta Biosciences, Inc. Industry | Phase 3 | Withdrawn | Drogheda, Dublin | 852 | 2024-05-20 | 2026-09-29 |
| NCT07402915 ClinicalTrials.gov |
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Open in IrelandUpdated ≤30dWomen's health | Oncology | AstraZeneca Industry | Phase 1 | Recruiting | Dublin | 32 | 2026-01-26 | 2026-09-29 |
| NCT05038735 ClinicalTrials.gov · also 2023-509133-39-00 |
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. Breast Cancer Updated ≤30dWomen's healthAlso in CTIS | Oncology | Novartis Pharmaceuticals Industry | Phase 3 | (not given) | Dublin | 210 | 2021-12-17 | 2026-09-29 |
| NCT04796545 ClinicalTrials.gov |
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration AMD; Age-Related Macular Degeneration Updated ≤30d | Eye & ear | VisionCare, Inc. Industry | N/A (non-drug) | (not given) | Dublin | 68 | 2022-09-13 | 2026-09-29 |
| 2025-522792-29-00 EU CTIS |
An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%) Alpha-1 Antitrypsin Deficiency Open in IrelandUpdated ≤30d | Respiratory | Grifols Therapeutics LLC Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-05-05 | 2026-09-29 |
| 2022-501606-35-01 EU CTIS |
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peritoneal cancers Updated ≤30dWomen's health | Oncology | AbbVie Deutschland GmbH & Co. KG Industry | Phase 3/4 | Ended | Ireland (site detail on registry) | — | 2024-02-21 | 2026-09-29 |
| 2022-500758-41-00 EU CTIS |
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-201 IN AMYOTROPHIC LATERAL SCLEROSIS FOLLOWED BY AN OPEN-LABEL EXTENDED DOSING PERIOD Amyotrophic lateral sclerosis Updated ≤30d | Neurology | Quralis Corp. Academic / other | Phase 1 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2023-08-15 | 2026-09-29 |
| NCT07293754 ClinicalTrials.gov · also 2025-524010-28-00 |
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors Advanced Malignant Solid Tumor Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Repertoire Immune Medicines Industry | Phase 1/2 | Recruiting | Dublin | 150 | 2025-12-12 | 2026-09-28 |
| NCT06924970 ClinicalTrials.gov · also 2024-519746-70-01 |
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) Sickle Cell Disease Updated ≤30dAlso in CTIS | Blood (non-cancer) | Agios Pharmaceuticals, Inc. Industry | Phase 2 | (not given) | Dublin | 59 | 2025-05-01 | 2026-09-28 |
| NCT03481738 ClinicalTrials.gov |
Pyruvate Kinase Deficiency Global Longitudinal Registry Pyruvate Kinase Deficiency Updated ≤30d | Blood (non-cancer) | Agios Pharmaceuticals, Inc. Industry | Observational | (not given) | Dublin | 500 | 2018-04-23 | 2026-09-28 |
| NCT04793958 ClinicalTrials.gov |
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) Advanced Colorectal Cancer; Metastatic Colorectal Cancer Updated ≤30d | Oncology | Mirati Therapeutics Inc. Industry | Phase 3 | (not given) | Dublin | 461 | 2021-06-24 | 2026-09-28 |
| NCT03153475 ClinicalTrials.gov |
ATTUNE Revision System in the Revision Total Knee Arthroplasty Population Revision Total Knee Arthroplasty Updated ≤30d | Musculoskeletal, pain & surgery | DePuy Orthopaedics Industry | N/A (non-drug) | (not given) | Cork | 400 | 2017-05-30 | 2026-09-28 |
| NCT04033445 ClinicalTrials.gov |
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis Updated ≤30d | Immunology, rheumatology & skin | Janssen Research & Development, LLC Industry | Phase 2/3 | (not given) | Dublin, Galway | 1,064 | 2019-09-26 | 2026-09-28 |
| NCT04660344 ClinicalTrials.gov · also 2022-502705-15-00 |
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy Muscle-invasive Bladder Cancer Updated ≤30dAlso in CTIS | Oncology | Hoffmann-La Roche Industry | Phase 3 | (not given) | Cork, Dublin | 761 | 2021-05-03 | 2026-09-28 |
| NCT03653507 ClinicalTrials.gov |
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma Updated ≤30d | Oncology | Astellas Pharma Global Development, Inc. Industry | Phase 3 | (not given) | Dublin | 507 | 2018-11-28 | 2026-09-28 |
| NCT03833167 ClinicalTrials.gov |
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Carcinoma, Squamous Cell Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin | 450 | 2019-04-01 | 2026-09-28 |
| NCT03834493 ClinicalTrials.gov |
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) Prostatic Neoplasms Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin, Limerick | 1,244 | 2019-07-28 | 2026-09-28 |
| NCT02839850 ClinicalTrials.gov |
14022 ATTUNE Cementless RP Clinical Performance Evaluation Osteoarthritis Updated ≤30d | Immunology, rheumatology & skin | DePuy Orthopaedics Industry | N/A (non-drug) | (not given) | Cork | 540 | 2016-09-01 | 2026-09-28 |
| NCT04191096 ClinicalTrials.gov |
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Metastatic Hormone-Sensitive Prostate Cancer Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Cork, Dublin, Limerick, Waterford | 1,251 | 2020-02-12 | 2026-09-28 |
| 2023-508323-12-00 EU CTIS |
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy. Updated ≤30dWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-09-13 | 2026-09-28 |
| 2023-503837-23-00 EU CTIS |
An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 Mucopolysaccharidosis Type II [MPS II] Open in IrelandUpdated ≤30d | Neurology | Denali Therapeutics Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2023-12-12 | 2026-09-28 |
| NCT06868277 ClinicalTrials.gov · also 2024-517780-24-00 |
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer Carcinoma, Non-Small Cell Lung Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | AstraZeneca Industry | Phase 3 | Not yet recruiting, Recruiting | Cork, Dublin, Galway | 830 | 2025-04-10 | 2026-09-25 |
| NCT06548542 ClinicalTrials.gov · also 2024-513009-30-00 |
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease Crohn's Disease Open in IrelandUpdated ≤30dAlso in CTIS | Immunology, rheumatology & skin | AbbVie Industry | Phase 2 | Recruiting | Ballinasloe, Drogheda, Dublin, Letterkenny, Mullingar | 590 | 2024-09-04 | 2026-09-25 |
| NCT04823663 ClinicalTrials.gov |
BoStOn SCientific Rhythm MAnagemenT REgiStry Cardiac Disease Open in IrelandUpdated ≤30d | Cardiovascular | Boston Scientific Corporation Industry | Observational | Recruiting | Dublin | 12,500 | 2021-03-31 | 2026-09-25 |
| NCT04750798 ClinicalTrials.gov |
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias Arrhythmias, Cardiac Open in IrelandUpdated ≤30d | Cardiovascular | Biosense Webster, Inc. Industry | Observational | Recruiting | Dublin | 8,000 | 2021-02-22 | 2026-09-25 |
| NCT04862468 ClinicalTrials.gov |
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT Thrombosis, Deep Vein; Iliofemoral; Thrombosis Updated ≤30d | Cardiovascular | Mercator MedSystems, Inc. Industry | Phase 2 | Completed | Galway | 80 | 2021-10-29 | 2026-09-25 |
| NCT05912517 ClinicalTrials.gov · also 2022-502629-16-00 |
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Hemolytic Disease of the Fetus and Newborn Open in IrelandUpdated ≤30dWomen's healthAlso in CTIS | Women's health & maternal | Janssen Research & Development, LLC Industry | Phase 3 | Recruiting | Dublin | 120 | 2023-12-20 | 2026-09-25 |
| NCT06319820 ClinicalTrials.gov |
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer Non-Muscle Invasive Bladder Neoplasms Updated ≤30d | Oncology | Janssen Research & Development, LLC Industry | Phase 3 | Active, not recruiting | Cork, Dublin | 641 | 2024-04-18 | 2026-09-25 |
| NCT04923893 ClinicalTrials.gov · also 2023-505850-16-00 |
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy Multiple Myeloma Updated ≤30dAlso in CTIS | Oncology | Janssen Research & Development, LLC Industry | Phase 3 | (not given) | Dublin | 743 | 2021-08-19 | 2026-09-25 |
| NCT03599245 ClinicalTrials.gov |
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) Multiple Sclerosis Updated ≤30d | Neurology | Hoffmann-La Roche Industry | Phase 3 | (not given) | Dublin | 1,055 | 2018-07-12 | 2026-09-25 |
| NCT04242498 ClinicalTrials.gov |
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Updated ≤30d | Immunology, rheumatology & skin | UCB Biopharma SRL Industry | Phase 3 | (not given) | Dublin | 509 | 2020-03-02 | 2026-09-25 |
| NCT04175600 ClinicalTrials.gov |
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Hypertension, Pulmonary Updated ≤30d | Cardiovascular | Actelion Industry | Phase 3 | (not given) | Dublin | 138 | 2020-01-16 | 2026-09-25 |
| NCT03153449 ClinicalTrials.gov |
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population Primary Knee Arthroplasty Updated ≤30d | Musculoskeletal, pain & surgery | DePuy Orthopaedics Industry | N/A (non-drug) | (not given) | Cork | 400 | 2017-09-19 | 2026-09-25 |
| 2024-513445-37-00 EU CTIS |
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2 previously untreated RT, irrespective of risk factors and disease stage Open in IrelandUpdated ≤30d | Oncology | University Of Cologne Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-06-08 | 2026-09-25 |
| 2025-521188-11-00 EU CTIS |
EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease cardiovascular disease, hypertension, Type 2 diabetes Open in IrelandUpdated ≤30d | Cardiovascular | Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-10-15 | 2026-09-25 |
| 2024-517812-31-00 EU CTIS |
A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE) Haemophilia A Updated ≤30d | Blood (non-cancer) | Swedish Orphan Biovitrum AB (publ) Industry | Phase 4 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-05-21 | 2026-09-25 |
| NCT05784428 ClinicalTrials.gov |
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression Oligometastatic Disease; Oligoprogression; Toxicity Due to Radiotherapy; Quality of Life Open in IrelandUpdated ≤30d | Oncology | Robert Olson Academic / other | N/A (non-drug) | Recruiting | Cork, Dublin, Galway, Waterford | 598 | 2025-04-16 | 2026-09-24 |
| NCT06647290 ClinicalTrials.gov |
ENVELOP: Wound Care Following Pilonidal Sinus Surgery Pilonidal Sinus; Wound Healing Open in IrelandUpdated ≤30d | Infectious disease & vaccines | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Castlebar, Dublin, Kilkenny, Limerick, Tullamore, Waterford | 200 | 2024-10-01 | 2026-09-24 |
| NCT07575269 ClinicalTrials.gov |
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation Paroxysmal Atrial Fibrillation (PAF); Persistent Atrial Fibrillation Open in IrelandUpdated ≤30d | Cardiovascular | Boston Scientific Corporation Industry | N/A (non-drug) | Recruiting | Dublin | 571 | 2026-07-07 | 2026-09-24 |
| NCT06808217 ClinicalTrials.gov |
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation Atrial Fibrillation; Pulsed Field Ablation; FARAPULSE Updated ≤30d | Cardiovascular | Boston Scientific Corporation Industry | Observational | (not given) | Dublin | 550 | 2025-07-30 | 2026-09-24 |
| NCT05407324 ClinicalTrials.gov |
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Updated ≤30d | Neurology | Corcept Therapeutics Industry | Phase 2 | (not given) | Dublin | 279 | 2022-11-15 | 2026-09-24 |
| NCT04489771 ClinicalTrials.gov · also 2022-502123-21-00 |
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) Carcinoma, Renal Cell Updated ≤30dAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | (not given) | Cork, Dublin | 154 | 2020-09-13 | 2026-09-24 |
| NCT03614260 ClinicalTrials.gov |
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension Hypertension; Vascular Diseases; Cardiovascular Diseases Updated ≤30d | Cardiovascular | ReCor Medical, Inc. Industry | N/A (non-drug) | (not given) | Galway | 224 | 2018-12-14 | 2026-09-24 |
| 2024-512753-24-00 EU CTIS |
HOVON 173 AML: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy Acute Myeloid Leukemia (AML) Open in IrelandUpdated ≤30d | Oncology | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-08-05 | 2026-09-24 |
| 2023-509908-15-00 EU CTIS |
Full title of the clinical trial: A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation Mantle Cell Lymphoma Updated ≤30d | Oncology | BeOne Medicines AG Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2020-01-20 | 2026-09-24 |
| 2023-508204-38-00 EU CTIS |
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP301) Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Open in IrelandUpdated ≤30dWomen's health | Oncology | Verastem Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-07-02 | 2026-09-24 |
| 2022-500439-35-00 EU CTIS |
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 treatment-naive chronic lymphocytic leukemia Updated ≤30d | Oncology | University Of Cologne Academic / other | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-02-11 | 2026-09-24 |
| NCT07293351 ClinicalTrials.gov · also 2026-527163-15-00 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) Advanced Renal Cell Carcinoma (RCC) Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | Bristol-Myers Squibb Industry | Phase 1/2 | Not yet recruiting | Dublin | 474 | 2026-03-26 | 2026-09-23 |
| NCT05061550 ClinicalTrials.gov · also 2023-508852-21-00 |
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Non-small Cell Lung Cancer Open in IrelandUpdated ≤30dAlso in CTIS | Oncology | AstraZeneca Industry | Phase 2 | Recruiting | Dublin, Galway | 630 | 2022-04-14 | 2026-09-23 |
| NCT06561386 ClinicalTrials.gov |
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% Non-small Cell Lung Cancer Open in IrelandUpdated ≤30d | Oncology | Bristol-Myers Squibb Industry | Phase 3 | Recruiting, Withdrawn | Dublin | 1,000 | 2024-10-07 | 2026-09-23 |
| NCT03899155 ClinicalTrials.gov |
Pan Tumor Rollover Study Cancer Updated ≤30d | Oncology | Bristol-Myers Squibb Industry | Phase 2 | Withdrawn | Dublin, Limerick | 1,500 | 2019-08-09 | 2026-09-23 |
| 2022-502276-23-00 EU CTIS |
Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL JAK2V617F-positive high-risk Polycythemia Vera Open in IrelandUpdated ≤30d | Blood (non-cancer) | Italfarmaco S.p.A. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-04-25 | 2026-09-23 |
| NCT07218341 ClinicalTrials.gov |
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic Open in IrelandUpdated ≤30d | Oncology | Eli Lilly and Company Industry | Phase 4 | Not yet recruiting | Dublin | 150 | 2026-03-09 | 2026-09-22 |
| NCT07207811 ClinicalTrials.gov |
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis Transthyretin Amyloid Cardiomyopathy (ATTR CM) Open in IrelandUpdated ≤30d | Cardiovascular | Novo Nordisk A/S Industry | Phase 3 | Not yet recruiting | Ballinasloe, Dublin, Letterkenny | 1,280 | 2025-10-02 | 2026-09-22 |
| NCT03839771 ClinicalTrials.gov |
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 Updated ≤30d | Oncology | Stichting Hemato-Oncologie voor Volwassenen Nederland Academic / other | Phase 3 | (not given) | Cork, Dublin, Galway | 968 | 2019-03-01 | 2026-09-22 |
| NCT02821117 ClinicalTrials.gov |
FreeStyle Libre Glucose Monitoring System Paediatric Study Diabetes Mellitus Updated ≤30d | Metabolic & endocrine | Abbott Diabetes Care Industry | N/A (non-drug) | (not given) | Dublin | 76 | 2016-06-30 | 2026-09-22 |
| NCT06679881 ClinicalTrials.gov |
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Hereditary Angioedema (HAE) Updated ≤30d | Other / unclassified | Pharvaris Netherlands B.V. Industry | Phase 3 | (not given) | Dublin | 170 | 2025-02-01 | 2026-09-22 |
| NCT04810078 ClinicalTrials.gov |
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread Clear Cell Renal Cell Carcinoma Updated ≤30d | Oncology | Bristol-Myers Squibb Industry | Phase 3 | (not given) | Tallaght | 681 | 2021-05-21 | 2026-09-22 |
| 2025-521661-27-00 EU CTIS |
A Phase 2b/3 Adaptive, Randomized, Active controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy Primary Membranous Nephropathy Open in IrelandUpdated ≤30d | Kidney & urology | Vertex Pharmaceuticals Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-12-19 | 2026-09-22 |
| NCT05377047 ClinicalTrials.gov |
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer Breast Cancer Stage IV; Oligometastatic Disease Open in IrelandUpdated ≤30dWomen's health | Oncology | Vastra Gotaland Region Academic / other | Phase 3 | Recruiting | Cork, Dublin, Galway | 345 | 2022-09-19 | 2026-09-21 |
| NCT02832245 ClinicalTrials.gov |
Computerized Registry of Patients With Venous Thromboembolism (RIETE) Venous Thromboembolism Open in IrelandUpdated ≤30d | Cardiovascular | Manuel Monreal Academic / other | Observational | Recruiting | Dublin | 120,000 | 2001-03 | 2026-09-21 |
| NCT05523167 ClinicalTrials.gov |
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis; Polymyositis Updated ≤30d | Immunology, rheumatology & skin | argenx Industry | Phase 2/3 | (not given) | Dublin, Manorhamilton | 265 | 2022-10-12 | 2026-09-21 |
| 2024-519901-36-00 EU CTIS |
ETOP 27-23 ARCH – A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy. Patients with resected stage IIA-IIIB non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1% Open in IrelandUpdated ≤30d | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-12-17 | 2026-09-21 |
| 2024-512828-12-00 EU CTIS |
An open-label study to collect safety and effectiveness information on long-term treatment with vamorolone in boys with Duchenne Muscular Dystrophy who have completed prior studies with vamorolone (The GUARDIAN Study) Duchenne Muscular Dystrophy Updated ≤30d | Rare & genetic | Santhera Pharmaceuticals (Schweiz) AG Industry | Phase 4 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-12-05 | 2026-09-21 |
| 2023-507697-40-00 EU CTIS |
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-321) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Updated ≤30d | Oncology | Loxo Oncology Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-07-05 | 2026-09-21 |
| 2024-513168-24-00 EU CTIS |
A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity (SWIFT Study) HIV & Obesity Open in IrelandUpdated ≤30d | Metabolic & endocrine | University College Dublin Academic / other | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2022-06-01 | 2026-09-21 |
| 2023-505023-31-00 EU CTIS |
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022) Renal cell carcinoma Updated ≤30d | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2023-11-17 | 2026-09-21 |
| 2022-500699-76-00 EU CTIS |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) Active Systemic Lupus Erythematosus (SLE) Updated ≤30d | Immunology, rheumatology & skin | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2023-05-18 | 2026-09-21 |
| NCT05327686 ClinicalTrials.gov |
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma Open in Ireland | Oncology | NRG Oncology Academic / other | Phase 2 | Recruiting | Dublin | 240 | 2023-02-01 | 2026-09-18 |
| NCT07204275 ClinicalTrials.gov · also 2025-521661-27-00 |
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) Primary Membranous Nephropathy Open in IrelandAlso in CTIS | Kidney & urology | Vertex Pharmaceuticals Incorporated Industry | Phase 2/3 | Recruiting | Cork, Dublin, Galway | 176 | 2025-09-30 | 2026-09-18 |
| NCT06077760 ClinicalTrials.gov · also 2023-504923-20-00 |
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) Non-small Cell Lung Cancer Also in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin | 868 | 2023-12-06 | 2026-09-18 |
| 2024-510730-40-00 EU CTIS |
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab (ABT-981) in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa | Immunology, rheumatology & skin | AbbVie Deutschland GmbH & Co. KG Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-12-12 | 2026-09-18 |
| 2022-502825-17-00 EU CTIS |
A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1 Alone in Patients with Resectable Stage III and IV Melanoma Melanoma | Oncology | Regeneron Pharmaceuticals Inc. Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2024-10-07 | 2026-09-18 |
| 2023-507698-16-00 EU CTIS |
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma (BRUIN CLL-322) | Oncology | Loxo Oncology Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-10-14 | 2026-09-18 |
| 2022-500237-92-00 EU CTIS |
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND] Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) | Oncology | Incyte Corp. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-04-23 | 2026-09-18 |
| 2023-506921-12-00 EU CTIS |
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756) ER+/HER2- Breast Cancer Women's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2018-12-27 | 2026-09-18 |
| NCT02914535 ClinicalTrials.gov |
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Ulcerative Colitis | Immunology, rheumatology & skin | Alfasigma S.p.A. Industry | Phase 3 | (not given) | Dublin | 1,173 | 2017-02-23 | 2026-09-17 |
| NCT07332091 ClinicalTrials.gov · also 2025-523793-16-00 |
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis Open in IrelandAlso in CTIS | Other / unclassified | CSL Behring Industry | Phase 2 | Not yet recruiting | Cork, Dublin | 84 | 2026-01-22 | 2026-09-16 |
| 2024-517500-11-00 EU CTIS |
A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy with or without bevacizumab in Patients with Advanced Solid Tumours Colorectal Cancer, Advanced Solid Gastrointestinal Tumors, Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma Open in Ireland | Oncology | Bold Therapeutics Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-07-15 | 2026-09-16 |
| NCT05340582 ClinicalTrials.gov |
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants Patent Ductus Arteriosus After Premature Birth | Neonatal & paediatric | Mount Sinai Hospital, Canada Academic / other | Phase 2 | Active, not recruiting | Dublin | 310 | 2022-12-12 | 2026-09-15 |
| NCT07628608 ClinicalTrials.gov |
Safety and User Experience of BP-CBB Safety and Tolerability in Healthy Volunteers | Other / unclassified | Bactolife A/S Industry | N/A (non-drug) | (not given) | Cork | 60 | 2026-06-16 | 2026-09-15 |
| NCT06608563 ClinicalTrials.gov |
The Effect of an Adhesive System on the Retention and Caries Prevention for Fissure Sealants in Permanent Molars Dental Caries; Fissure Sealant | Other / unclassified | University of Dublin, Trinity College Academic / other | N/A (non-drug) | (not given) | Dublin | 100 | 2024-06-05 | 2026-09-15 |
| 2024-515162-13-00 EU CTIS |
BRISOTE: A Multicentre, Randomised, Double-blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist Eosinophilic Asthma | Respiratory | AstraZeneca AB Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2025-04-29 | 2026-09-15 |
| 2024-512701-11-00 EU CTIS |
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase.
Name: SKYPS Systemic Juvenile Idiopathic Arthritis (sJIA) Open in Ireland | Immunology, rheumatology & skin | Sanofi-Aventis Recherche & Developpement Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2018-08-29 | 2026-09-15 |
| 2024-511653-22-00 EU CTIS |
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA Cutaneous Squamous Cell Carcinoma (CSCC) | Oncology | Regeneron Pharmaceuticals Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2020-02-12 | 2026-09-15 |
| NCT05722938 ClinicalTrials.gov |
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) Community-acquired Pneumonia Open in Ireland | Respiratory | Biotest Industry | Phase 3 | Not yet recruiting, Recruiting | Dublin, Galway | 590 | 2023-09-09 | 2026-09-14 |
| NCT07115004 ClinicalTrials.gov |
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) Von Willebrand Disease (VWD) Open in Ireland | Other / unclassified | Vega Therapeutics, Inc Industry | Phase 3 | Recruiting | Dublin | 60 | 2025-10-15 | 2026-09-14 |
| NCT04191135 ClinicalTrials.gov |
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) Triple Negative Breast Neoplasms Women's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | (not given) | Cork, Dublin | 462 | 2019-12-19 | 2026-09-14 |
| NCT06500455 ClinicalTrials.gov |
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Digestive System Carcinoma; Metastatic Lung Non-Small Cell Carcinoma Women's health | Oncology | NRG Oncology Academic / other | Phase 3 | (not given) | Cork, Dublin, Galway | 274 | 2024-12-12 | 2026-09-14 |
| 2025-521293-34-00 EU CTIS |
A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa Moderate-to-severe hidradenitis suppurativa | Immunology, rheumatology & skin | Almirall S.A. Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-12-09 | 2026-09-14 |
| 2025-520665-47-00 EU CTIS |
A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants with Advanced Rod Cone Dystrophy End-stage rod-cone dystrophy Open in Ireland | Rare & genetic | Sparingvision Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-10-08 | 2026-09-14 |
| 2022-501943-34-00 EU CTIS |
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Open in Ireland | Digestive & liver | Takeda Development Center Americas Inc. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2023-06-27 | 2026-09-14 |
| 2022-500587-35-01 EU CTIS |
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Stroke Open in Ireland | Neurology | University Of Nottingham Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2023-07-06 | 2026-09-14 |
| NCT04663750 ClinicalTrials.gov |
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). Eye Diseases; Macular Degeneration, Wet; Sub-Macular Hemorrhage Open in Ireland | Eye & ear | King's College Hospital NHS Trust Academic / other | Phase 3 | Recruiting | Waterford | 210 | 2021-04-16 | 2026-09-11 |
| 2023-503188-40-00 EU CTIS |
An Open-label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Who Achieved Clinical Response Following Open–label Vedolizumab Intravenous Therapy Active Ulcerative Colitis or Crohn’s Disease Open in Ireland | Immunology, rheumatology & skin | Takeda Development Center Americas Inc. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2025-01-06 | 2026-09-11 |
| 2023-507536-21-00 EU CTIS |
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors Advanced Solid Tumors Open in Ireland | Oncology | Medicenna Therapeutics Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-10-04 | 2026-09-11 |
| NCT05665595 ClinicalTrials.gov |
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) Melanoma | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin | 1,594 | 2023-01-19 | 2026-09-10 |
| NCT05507216 ClinicalTrials.gov |
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 Ulcerative Colitis | Immunology, rheumatology & skin | Abivax S.A. Industry | Phase 3 | (not given) | Abbotstown, Dublin, Galway, Mullingar | 636 | 2023-01-25 | 2026-09-10 |
| 2023-507961-24-00 EU CTIS |
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy High-Risk HER2-Positive Breast Cancer Women's health | Oncology | Daiichi Sankyo Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-04-19 | 2026-09-10 |
| NCT05582993 ClinicalTrials.gov · also 2023-509877-22-00 |
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) Von Willebrand Disease (VWD) Open in IrelandAlso in CTIS | Neonatal & paediatric | Takeda Industry | Phase 3 | Recruiting | Dublin | 24 | 2024-11-06 | 2026-09-09 |
| NCT07507500 ClinicalTrials.gov |
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months Myocardial Infarction (MI) Open in Ireland | Cardiovascular | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Academic / other | Phase 4 | Not yet recruiting | Dublin | 8,100 | 2026-09-02 | 2026-09-09 |
| NCT06253871 ClinicalTrials.gov |
A Phase 1/1b Study of IAM1363 in HER2 Cancers HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer; HER2 + Breast Cancer Open in IrelandWomen's health | Oncology | Iambic Therapeutics, Inc Industry | Phase 1 | Recruiting | Cork, Dublin | 383 | 2024-03-25 | 2026-09-09 |
| NCT02998710 ClinicalTrials.gov |
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA) Homocystinuria Due to CBS Deficiency | Other / unclassified | Travere Therapeutics, Inc. Industry | Observational | (not given) | Dublin | 110 | 2017-01 | 2026-09-09 |
| NCT04602468 ClinicalTrials.gov |
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Cystic Fibrosis; Cystic Fibrosis Liver Disease; Cystic Fibrosis in Children; Adherence, Medication | Respiratory | Royal College of Surgeons, Ireland Academic / other | Phase 4 | (not given) | Dublin, Limerick, Tallaght | 206 | 2020-09-03 | 2026-09-09 |
| NCT05322473 ClinicalTrials.gov |
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa | Infectious disease & vaccines | MoonLake Immunotherapeutics AG Industry | Phase 2 | (not given) | Dublin | 234 | 2022-04-25 | 2026-09-09 |
| NCT05685238 ClinicalTrials.gov |
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A Haemophilia A; Haemophilia A With Inhibitors | Blood (non-cancer) | Novo Nordisk A/S Industry | Phase 3 | (not given) | Dublin | 451 | 2023-02-13 | 2026-09-09 |
| 2023-510292-65-00 EU CTIS |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chronic Graft-Versus Host Disease (AXemplify 357) chronic graft-versus-host disease Open in Ireland | Immunology, rheumatology & skin | Incyte Corp. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-02-25 | 2026-09-09 |
| 2024-510800-35-00 EU CTIS |
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM) Relapsed or Refractory Multiple Myeloma (RRMM) | Oncology | Celgene Corp. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-06-17 | 2026-09-09 |
| 2023-509859-13-00 EU CTIS |
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib And Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM): Successor-1 Relapsed or Refractory Multiple Myeloma (RRMM) | Oncology | Celgene Corp. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-11-09 | 2026-09-09 |
| NCT07807111 ClinicalTrials.gov · also 2025-520665-47-00 |
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy Retinitis Pigmentosa (RP); Rod Cone Dystrophy Open in IrelandNewAlso in CTIS | Eye & ear | SparingVision Industry | Phase 1/2 | Recruiting | Dublin | 27 | 2025-10-08 | 2026-09-08 |
| NCT02842086 ClinicalTrials.gov |
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection Pre-Exposure Prophylaxis of HIV-1 Infection Women's health | Infectious disease & vaccines | Gilead Sciences Industry | Phase 3 | (not given) | Dublin | 5,399 | 2016-09-02 | 2026-09-08 |
| NCT02129699 ClinicalTrials.gov |
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy Lung Cancer Non-small Cell Stage IV | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 3 | (not given) | Cork, Dublin, Galway, Limerick, Waterford | 595 | 2015-01-06 | 2026-09-08 |
| 2025-523857-32-00 EU CTIS |
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy Spinal Muscular Atrophy Open in IrelandNew | Neurology | Biogen Idec Research Limited Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-09-07 |
| 2025-524230-25-00 EU CTIS |
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) Open in IrelandNew | Oncology | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic / other | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-09-07 |
| 2023-506987-15-00 EU CTIS |
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) Metastatic Castration-Resistant Prostate Cancer | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2016-11-17 | 2026-09-07 |
| NCT04680052 ClinicalTrials.gov · also 2023-504684-16-00 |
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. Follicular Lymphoma; Marginal Zone Lymphoma Also in CTIS | Oncology | Incyte Corporation Industry | Phase 3 | (not given) | Dublin, Galway | 654 | 2021-04-15 | 2026-09-04 |
| 2025-523686-15-00 EU CTIS |
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Advanced or Metastatic Solid Tumors Open in Ireland | Oncology | Olema Pharmaceuticals Inc. Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-04-08 | 2026-09-04 |
| 2024-519827-16-00 EU CTIS |
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients Open in Ireland | Oncology | European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-09-30 | 2026-09-04 |
| 2024-511377-30-00 EU CTIS |
A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled and Open-label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population with Symptomatic Obstructive Hypertrophic Cardiomyopathy SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Open in Ireland | Cardiovascular | Cytokinetics Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-01-23 | 2026-09-04 |
| 2023-506027-29-00 EU CTIS |
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive Open in Ireland | Oncology | Institut Gustave Roussy Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2014-10-01 | 2026-09-04 |
| 2023-508482-32-00 EU CTIS |
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections. Neutropenias Open in Ireland | Infectious disease & vaccines | X4 Pharmaceuticals Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-07-22 | 2026-09-04 |
| 2023-504816-14-00 EU CTIS |
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095) Endometrial cancer Women's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-03-08 | 2026-09-04 |
| NCT04203576 ClinicalTrials.gov |
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF) Heart Failure | Cardiovascular | Foundry Innovation & Research 1, Limited (FIRE1) Industry | N/A (non-drug) | (not given) | Galway | 50 | 2019-11-22 | 2026-09-03 |
| NCT05673187 ClinicalTrials.gov |
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status NSCLC Stage IV; KRAS P.G12C | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 2 | (not given) | Dublin, Limerick, Waterford | 68 | 2023-06-12 | 2026-09-03 |
| NCT04246177 ClinicalTrials.gov |
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) Carcinoma, Hepatocellular | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin | 480 | 2020-05-22 | 2026-09-03 |
| 2022-502705-15-00 EU CTIS |
A Phase III, Double-blind, Multicenter, Randomized study of Atezolizumab (anti-PD‑L1 antibody) versus Placebo as Adjuvant therapy in Patients with High-Risk Muscle-Invasive Bladder Cancer who are CTDNA positive following cystectomy High-risk muscle-invasive bladder cancer | Oncology | F. Hoffmann-La Roche AG Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2021-03-08 | 2026-09-03 |
| 2022-502425-18-00 EU CTIS |
PEACE 6 Vulnerable : A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents. Adenocarcinoma of the prostate Open in Ireland | Oncology | Unicancer Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2022-04-19 | 2026-09-03 |
| NCT06652438 ClinicalTrials.gov · also 2024-512733-32-00 |
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML Acute Myeloid Leukemia, Adult Open in IrelandAlso in CTIS | Oncology | Stichting Hemato-Oncologie voor Volwassenen Nederland Academic / other | Phase 3 | Recruiting | Cork, Dublin, Galway, Waterford | 448 | 2025-05-05 | 2026-09-02 |
| NCT01746225 ClinicalTrials.gov |
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer Metastatic Breastcancer Women's health | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 2 | (not given) | Cork, Dublin, Galway, Limerick, Waterford | 258 | 2013-04 | 2026-09-02 |
| NCT06468228 ClinicalTrials.gov · also 2024-510730-40-00 |
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Also in CTIS | Immunology, rheumatology & skin | AbbVie Industry | Phase 3 | (not given) | Cork, Drogheda, Dublin | 1,400 | 2024-06-27 | 2026-09-02 |
| 2025-524397-42-00 EU CTIS |
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma Participants with relapsed HRNB and participants
with HRNB refractory to treatment
The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent. Open in Ireland | Neurology | Renaissance Pharma Limited Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-09-10 | 2026-09-02 |
| 2024-517422-25-00 EU CTIS |
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge Metastatic Castration-resistant Prostate Cancer (mCRPC) | Oncology | Celgene Corp. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-05-22 | 2026-09-02 |
| 2023-508341-40-00 EU CTIS |
COACH: A Phase 2, Open-Label, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia Children with Achondroplasia | Neonatal & paediatric | Ascendis Pharma Growth Disorders A/S Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-07-26 | 2026-09-02 |
| NCT07798674 ClinicalTrials.gov |
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias Hereditary Spastic Paraplegia; Spastic Ataxia Open in IrelandNew | Neurology | Heidelberg University Academic / other | Observational | Recruiting | Dublin | 4,000 | 2024-07-16 | 2026-09-01 |
| NCT06590467 ClinicalTrials.gov |
Abbott Structural Heart Device Registry Heart Diseases; ASD - Atrial Septal Defect; VSD - Muscular Ventricular Septal Defect; PFO - Patent Foramen Ovale Open in Ireland | Cardiovascular | Abbott Medical Devices Industry | Observational | Recruiting | Crumlin | 2,500 | 2024-08-21 | 2026-09-01 |
| NCT07023835 ClinicalTrials.gov |
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS) Open in Ireland | Neurology | Zydus Therapeutics Inc. Industry | Phase 2 | Not yet recruiting | Dublin | 240 | 2025-09-17 | 2026-09-01 |
| NCT06016946 ClinicalTrials.gov |
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study Friedreich Ataxia Open in Ireland | Neurology | Friedreich's Ataxia Research Alliance Academic / other | Observational | Recruiting | Dublin | 3,000 | 2023-06-28 | 2026-09-01 |
| NCT04977986 ClinicalTrials.gov |
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome Fragile X Syndrome; Fragile X Syndrome (FXS) | Neonatal & paediatric | Harmony Biosciences Management, Inc. Industry | Phase 3 | (not given) | Dublin | 257 | 2021-09-13 | 2026-09-01 |
| 2025-523497-16-00 EU CTIS |
TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency Lung and/or Liver Disease Associated with Alpha-1 Antitrypsin Deficiency (AATD) Open in Ireland | Respiratory | Tessera Therapeutics Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-09-01 |
| NCT05822583 ClinicalTrials.gov |
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial COVID-19 | Respiratory | University of Minnesota Academic / other | Phase 4 | (not given) | Dublin | 285 | 2023-07-06 | 2026-08-31 |
| NCT05669755 ClinicalTrials.gov |
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels Cardiovascular Disease | Cardiovascular | Novo Nordisk A/S Industry | Phase 3 | (not given) | Dublin, Galway | 7,101 | 2023-03-01 | 2026-08-31 |
| 2025-524825-42-00 EU CTIS |
C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer Open in IrelandNew | Oncology | Pfizer Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-08-31 |
| 2025-522774-36-00 EU CTIS |
A Phase 1 Study of NDI-219216 in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair Advanced solid tumors Open in Ireland | Oncology | Nimbus Wadjet Inc. Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-10-24 | 2026-08-31 |
| 2024-516728-32-00 EU CTIS |
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis Indolent Systemic Mastocytosis and SSM Open in Ireland | Oncology | Blueprint Medicines Corp. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2021-10-29 | 2026-08-31 |
| 2025-521563-13-01 EU CTIS |
Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression Paediatric myopia Open in Ireland | Eye & ear | Laboratoires Thea Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-06-30 | 2026-08-29 |
| NCT06285318 ClinicalTrials.gov |
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials Relapsed/Refractory Multiple Myeloma (RRMM) | Oncology | Janssen-Cilag Ltd. Industry | Observational | Completed | Cork, Dublin, Galway | 900 | 2023-12-18 | 2026-08-28 |
| NCT06302348 ClinicalTrials.gov · also 2024-514435-20-00 |
A Study of Sepiapterin in Participants With Phenylketonuria (PKU) Phenylketonuria Open in IrelandAlso in CTIS | Other / unclassified | PTC Therapeutics Industry | Phase 3 | Recruiting | Dublin | 56 | 2024-03-04 | 2026-08-28 |
| NCT05714085 ClinicalTrials.gov · also 2022-501238-52-00 |
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) Heart Failure; Left Ventricular Systolic Dysfunction Open in IrelandAlso in CTIS | Cardiovascular | Merck Sharp & Dohme LLC Industry | Phase 2/3 | Recruiting | Dublin | 342 | 2023-05-31 | 2026-08-28 |
| NCT07789483 ClinicalTrials.gov |
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Open in IrelandNew | Cardiovascular | Alexion Pharmaceuticals, Inc. Industry | Phase 3 | (not given) | Dublin | 1,180 | 2027-11-23 (est.) | 2026-08-28 |
| NCT07734532 ClinicalTrials.gov |
Infant Formula Study With Pre- And Postbiotics Formula Milk; Infants New | Neonatal & paediatric | Nutricia UK Ltd Industry | N/A (non-drug) | (not given) | Cork | 30 | 2021-06-17 | 2026-08-28 |
| NCT06132958 ClinicalTrials.gov · also 2023-504816-14-00 |
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Endometrial Cancer Women's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Cork, Dublin | 710 | 2023-12-06 | 2026-08-28 |
| NCT06459180 ClinicalTrials.gov · also 2023-508323-12-00 |
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Cervical Cancer Women's healthAlso in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Cork, Dublin | 686 | 2024-07-24 | 2026-08-28 |
| 2024-517499-39-00 EU CTIS |
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45) Duchenne Muscular Dystrophy Open in Ireland | Rare & genetic | Entrada Therapeutics Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-07-16 | 2026-08-28 |
| 2024-513087-26-00 EU CTIS |
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer
(HARMONi-3) Metastatic Non-small Cell Lung Cancer | Oncology | Summit Therapeutics Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-09-10 | 2026-08-28 |
| 2023-506526-37-00 EU CTIS |
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT INHIBITORS Paroxysmal Nocturnal Hemoglobinuria (PNH) | Blood (non-cancer) | F. Hoffmann-La Roche AG Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2021-03-17 | 2026-08-28 |
| 2023-509429-37-00 EU CTIS |
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY Advanced or Metastatic Non-Small Cell Lung Cancer | Oncology | AstraZeneca AB Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-10-03 | 2026-08-28 |
| NCT05409976 ClinicalTrials.gov |
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study Venous Thromboses; Venous Disease; Venous Leg Ulcer; Venous Stasis | Cardiovascular | W.L.Gore & Associates Industry | N/A (non-drug) | (not given) | Galway | 136 | 2022-10-25 | 2026-08-27 |
| 2025-524010-28-00 EU CTIS |
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors Advanced Solid Tumor Open in Ireland | Oncology | Repertoire Immune Medicines Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-03-20 | 2026-08-27 |
| 2025-521278-32-00 EU CTIS |
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Idiopathic Pulmonary Fibrosis (IPF) | Respiratory | Mediar Therapeutics Inc. Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-12-04 | 2026-08-27 |
| 2024-516846-20-00 EU CTIS |
Randomised Placebo-Controlled Trial of Early Targeted Treatment of Patent Ductus Arteriosus with Paracetamol in Extremely Low Birth Weight Infants (ETAPA) Patent Ductus Arteriosus Open in Ireland | Neonatal & paediatric | University College Dublin Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2021-09-26 | 2026-08-27 |
| 2023-506081-31-00 EU CTIS |
A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in mechanically ventilated critically ill patients following traumatic injury Traumatic Injury Open in Ireland | Other / unclassified | University College Dublin Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2022-03-29 | 2026-08-27 |
| 2023-504923-20-00 EU CTIS |
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002) Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-04-04 | 2026-08-27 |
| 2023-507881-19-00 EU CTIS |
Vaccination to prevent Mpox Infection (MPOX-VAX Study) Mpox infection | Infectious disease & vaccines | University College Dublin Academic / other | Phase 4 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-06-29 | 2026-08-27 |
| NCT03133546 ClinicalTrials.gov |
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M Non Small Cell Lung Cancer Metastatic | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 2 | (not given) | Dublin, Limerick | 155 | 2017-05-31 | 2026-08-26 |
| NCT04544293 ClinicalTrials.gov |
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Autoimmune Pulmonary Alveolar Proteinosis | Respiratory | Savara Inc. Industry | Phase 3 | (not given) | Dublin | 164 | 2021-05-19 | 2026-08-26 |
| NCT04025879 ClinicalTrials.gov |
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung | Oncology | Bristol-Myers Squibb Industry | Phase 3 | (not given) | Dublin | 461 | 2019-11-05 | 2026-08-26 |
| NCT01562028 ClinicalTrials.gov |
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) Lung Cancer | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 2 | (not given) | Dublin, Galway, Limerick, Tallaght | 109 | 2012-06 | 2026-08-26 |
| NCT01652469 ClinicalTrials.gov |
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Carcinoma, Non-Small-Cell Lung | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 3 | (not given) | Dublin | 81 | 2012-08 | 2026-08-26 |
| NCT03615326 ClinicalTrials.gov |
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin | 738 | 2018-10-05 | 2026-08-26 |
| 2023-508922-83-00 EU CTIS |
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non Small Cell Lung Cancer with KRAS G12C Mutation Advanced Non-Small Cell Lung Cancer Open in Ireland | Oncology | Mirati Therapeutics Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2021-03-17 | 2026-08-26 |
| 2024-516530-36-00 EU CTIS |
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum. low-grade serous carcinoma of the ovary or peritoneum Women's health | Oncology | Cancer Trials Ireland Academic / other | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-01-08 | 2026-08-26 |
| NCT06789913 ClinicalTrials.gov · also 2024-518895-30-00 |
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations; Vascular Malformations; PIK3CA Mutation Open in IrelandAlso in CTIS | Cardiovascular | Relay Therapeutics, Inc. Industry | Phase 2 | Recruiting | Dublin | 277 | 2025-06-13 | 2026-08-25 |
| NCT06821542 ClinicalTrials.gov |
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy Chronic Graft-versus-host-disease | Respiratory | Incyte Corporation Industry | Phase 3 | (not given) | Dublin | 9 | 2025-06-04 | 2026-08-25 |
| NCT01521923 ClinicalTrials.gov |
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis Rheumatoid Arthritis | Immunology, rheumatology & skin | UCB Pharma Industry | Phase 3 | (not given) | Cork, Dublin, Limerick | 359 | 2012-01 | 2026-08-25 |
| NCT01519791 ClinicalTrials.gov |
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis Rheumatoid Arthritis | Immunology, rheumatology & skin | UCB Pharma SA Industry | Phase 3 | (not given) | Cork, Dublin, Limerick | 880 | 2012-01 | 2026-08-25 |
| 2024-515526-89-00 EU CTIS |
A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus Polatuzumab Vedotin plus R-CHP in Treatment-naive Participants with GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL). Diffuse Large B-Cell Lymphoma (DLBCL) Open in Ireland | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-05-16 | 2026-08-25 |
| 2023-510128-66-00 EU CTIS |
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC) Open in Ireland | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-09-02 | 2026-08-25 |
| 2023-503765-37-00 EU CTIS |
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B Hemophilia B | Blood (non-cancer) | CSL Behring LLC Academic / other | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-09-30 | 2026-08-25 |
| 2025-525036-34-00 EU CTIS |
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations Solid Tumours Open in IrelandNew | Oncology | Terremoto Biosciences Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-09-18 | 2026-08-24 |
| NCT04133909 ClinicalTrials.gov |
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Pulmonary Disease, Chronic Obstructive | Respiratory | GlaxoSmithKline Industry | Phase 3 | (not given) | Drogheda, Dublin, Galway, Limerick | 806 | 2019-10-30 | 2026-08-21 |
| NCT06365853 ClinicalTrials.gov |
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive Women's health | Oncology | AbbVie Industry | Phase 2 | (not given) | Dublin | 108 | 2024-07-29 | 2026-08-21 |
| NCT05458297 ClinicalTrials.gov · also 2022-501374-19-00 |
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma; Richter Transformation Lymphoma Also in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | (not given) | Dublin | 189 | 2022-07-21 | 2026-08-21 |
| NCT02362503 ClinicalTrials.gov |
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients HIV Infections | Infectious disease & vaccines | ViiV Healthcare Industry | Phase 3 | (not given) | Dublin | 371 | 2015-02-23 | 2026-08-21 |
| NCT06263946 ClinicalTrials.gov |
Essilor® Stellest® Lenses Multicentre European Study (SLOMES) Myopia | Other / unclassified | Essilor International Industry | N/A (non-drug) | (not given) | Dublin | 150 | 2024-03-22 | 2026-08-21 |
| 2025-520565-51-00 EU CTIS |
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer. small cell lung cancer Open in Ireland | Oncology | Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-06-23 | 2026-08-21 |
| 2024-516772-15-00 EU CTIS |
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Open in Ireland | Oncology | AbbVie Deutschland GmbH & Co. KG Industry | Phase 1 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-08-29 | 2026-08-21 |
| NCT04008030 ClinicalTrials.gov |
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) Metastatic Colorectal Cancer | Oncology | Bristol-Myers Squibb Industry | Phase 3 | (not given) | Dublin, Limerick | 839 | 2019-08-05 | 2026-08-20 |
| NCT05889182 ClinicalTrials.gov |
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Hidradenitis Suppurativa | Immunology, rheumatology & skin | AbbVie Industry | Phase 3 | (not given) | Cork, Dublin, Galway, Waterford | 1,328 | 2023-06-21 | 2026-08-20 |
| NCT05724602 ClinicalTrials.gov |
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Locally Advanced Head and Neck Squamous Cell Carcinoma | Oncology | European Organisation for Research and Treatment of Cancer - EORTC Academic / other | Phase 2 | (not given) | Galway, Rathgar | 13 | 2023-11-15 | 2026-08-20 |
| NCT05501873 ClinicalTrials.gov |
Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System Atrial Fibrillation | Cardiovascular | Boston Scientific Corporation Industry | Observational | (not given) | Dublin | 1,173 | 2023-03-24 | 2026-08-19 |
| NCT06864312 ClinicalTrials.gov |
Rebound Pain Following Regional Anaesthesia for Ankle Fracture Surgery Ankle Fracture (Bimalleolar Equivalent, Bimalleolar, or Trimalleolar); Ankle Fracture - Lateral Malleolus; Ankle Fracture - Medial Malleolus; Rebound Pain | Musculoskeletal, pain & surgery | University College Cork Academic / other | Phase 4 | (not given) | Cork | 120 | 2023-10-16 | 2026-08-19 |
| NCT06855329 ClinicalTrials.gov |
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis Progressive Pulmonary Fibrosis; Interstitial Lung Disease Open in Ireland | Respiratory | University of Massachusetts, Worcester Academic / other | Observational | Recruiting | Dublin | 500 | 2025-05-01 | 2026-08-18 |
| NCT05690724 ClinicalTrials.gov |
Exploratory Trial in Healthy Adults With Mild Cognitive Impairment,16-week Intervention With Mitocholine™ Mild Cognitive Impairment | Neurology | Mitocholine Ltd Industry | N/A (non-drug) | (not given) | Cork | 100 | 2023-01-09 | 2026-08-18 |
| NCT05147220 ClinicalTrials.gov |
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) Relapsing Multiple Sclerosis | Neurology | Novartis Pharmaceuticals Industry | Phase 3 | (not given) | Dublin | 1,000 | 2021-12-16 | 2026-08-18 |
| NCT07770035 ClinicalTrials.gov |
School-aged Outcomes Post Hypoxic Ischaemic Encephalopathy Hypoxic-Ischemic Encephalopathy New | Other / unclassified | University College Cork Academic / other | Observational | (not given) | Cork | 196 | 2024-03-09 | 2026-08-18 |
| 2024-518296-56-00 EU CTIS |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease Crohn’s Disease | Immunology, rheumatology & skin | Merck Sharp & Dohme LLC Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2025-09-29 | 2026-08-18 |
| 2024-515698-85-00 EU CTIS |
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) Locally Advanced or Metastatic Non-small Cell Lung Cancer Open in Ireland | Oncology | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-06-12 | 2026-08-18 |
| 2023-506842-22-00 EU CTIS |
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer Women's health | Oncology | AbbVie Deutschland GmbH & Co. KG Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-05-19 | 2026-08-18 |
| 2023-505989-29-00 EU CTIS |
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab vs Durvalumab Alone in Subjects with Extensive Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi 305) Extensive stage small cell lung cancer (ES-SCLC) | Oncology | Amgen Inc. Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2024-11-21 | 2026-08-18 |
| NCT07769021 ClinicalTrials.gov |
Tracheostomy Practice in Adult Intensive Care Units Tracheostomy Patients; Tracheostomy Decannulation; Intensive Care (ICU) Open in IrelandNew | Other / unclassified | Royal College of Surgeons, Ireland Academic / other | Observational | (not given) | Dublin, Galway | 2,500 | 2026-11-02 (est.) | 2026-08-17 |
| NCT05929807 ClinicalTrials.gov |
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia Achondroplasia | Neonatal & paediatric | Ascendis Pharma Growth Disorders A/S Industry | Phase 2/3 | (not given) | Dublin | 140 | 2023-06-21 | 2026-08-17 |
| NCT04895696 ClinicalTrials.gov · also 2023-504320-25-00 |
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) Systemic Lupus Erythematosus Also in CTIS | Immunology, rheumatology & skin | Beeline Medicines Corporation Industry | Phase 2 | (not given) | Dublin, Galway, Manorhamilton | 248 | 2021-10-11 | 2026-08-17 |
| NCT05047185 ClinicalTrials.gov |
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II | Other / unclassified | Pharvaris Netherlands B.V. Industry | Phase 2 | (not given) | Dublin | 34 | 2022-04-19 | 2026-08-17 |
| 2025-521514-26-00 EU CTIS |
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22) Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 Open in IrelandWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-01-26 | 2026-08-17 |
| 2023-507353-15-00 EU CTIS |
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON) progressive pulmonary fibrosis (PPF), idiopathic pulmonary fibrosis (IPF) | Respiratory | Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2024-09-10 | 2026-08-17 |
| NCT07441408 ClinicalTrials.gov |
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis Pulmonary Fibrosis Open in Ireland | Respiratory | Bristol-Myers Squibb Industry | Phase 3 | (not given) | Drogheda, Dublin, Tallaght | 2,380 | 2026-12-16 (est.) | 2026-08-14 |
| NCT06850636 ClinicalTrials.gov |
Higher vs Lower Lumber Epidural Catheter Insertion During Labour: A Randomised Trial to Compare Efficacy. Labour Analgesia, Epidural Anaesthesia Women's health | Musculoskeletal, pain & surgery | The Rotunda Hospital Academic / other | N/A (non-drug) | (not given) | Dublin | 164 | 2025-02-25 | 2026-08-14 |
| NCT03742895 ClinicalTrials.gov |
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) Advanced Solid Neoplasms | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | (not given) | Cork, Dublin | 329 | 2018-12-12 | 2026-08-14 |
| NCT03105102 ClinicalTrials.gov |
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease Crohn's Disease | Immunology, rheumatology & skin | AbbVie Industry | Phase 3 | (not given) | Beaumont, Elm Park, Galway | 1,336 | 2018-04-09 | 2026-08-14 |
| 2025-523431-19-00 EU CTIS |
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF) Idiopathic Pulmonary Fibrosis (IPF) Open in Ireland | Respiratory | Avalyn Pharma Inc. Industry | Phase 2 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-05-20 | 2026-08-14 |
| 2024-516248-24-00 EU CTIS |
A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema Hereditary Angioedema Open in Ireland | Rare & genetic | Pharvaris Netherlands B.V. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-03-28 | 2026-08-14 |
| 2024-516582-36-00 EU CTIS |
Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to curative-intent treatment – SHAMROCK study Early stage HER2-positive breast cancer Open in IrelandWomen's health | Oncology | Cancer Trials Ireland Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-05-01 | 2026-08-14 |
| 2022-502123-21-00 EU CTIS |
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma Advanced Renal Cell Carcinoma | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2020-12-08 | 2026-08-14 |
| NCT01784068 ClinicalTrials.gov |
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients Chronic Myelogenous Leukemia | Oncology | Novartis Pharmaceuticals Industry | Phase 2 | (not given) | Dublin, Galway | 215 | 2013-03-19 | 2026-08-13 |
| 2025-524285-18-00 EU CTIS |
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion Open in Ireland | Oncology | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-08-25 | 2026-08-13 |
| 2023-506962-30-00 EU CTIS |
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis Non-alcoholic steatohepatitis (NASH) | Mental health | Novo Nordisk A/S Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-03-29 | 2026-08-13 |
| 2023-504684-16-00 EU CTIS |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma follicular lymphoma (FL) and marginal zone lymphoma (MZL) | Oncology | Incyte Corp. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-06-05 | 2026-08-13 |
| NCT04307576 ClinicalTrials.gov |
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Leukemia, Acute Lymphoblastic Open in Ireland | Oncology | Mats Heyman Academic / other | Phase 3 | Recruiting | Dublin | 6,430 | 2020-07-13 | 2026-08-12 |
| NCT07546500 ClinicalTrials.gov |
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression Ovarian Cancer Open in IrelandWomen's health | Oncology | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Industry | Phase 3 | Not yet recruiting | Cork, Dublin | 420 | 2026-04-17 | 2026-08-12 |
| NCT07761130 ClinicalTrials.gov |
A Feasibility Study of the Improving Health and Lifestyle Programme After Stroke (iHeLP) Stroke New | Neurology | University of Limerick Academic / other | N/A (non-drug) | (not given) | Dublin, Limerick | 19 | 2026-02-09 | 2026-08-12 |
| NCT06983782 ClinicalTrials.gov |
A Feasibility Randomised Controlled Trial of an Online Exercise Programme for Adults With Cerebral Palsy Cerebral Palsy; Exercise; Adults; Fitness | Other / unclassified | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | (not given) | Dublin | 47 | 2025-07-25 | 2026-08-12 |
| NCT07759908 ClinicalTrials.gov |
Effects of a Synbiotic Intervention on Perimenopausal/Menopausal Symptoms Menopause; Perimenopause; Perimenopausal Women NewWomen's health | Women's health & maternal | University College Cork Academic / other | N/A (non-drug) | (not given) | Cork | 49 | 2025-06-06 | 2026-08-12 |
| NCT04204252 ClinicalTrials.gov |
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" Alpha 1-Antitrypsin Deficiency | Other / unclassified | Kamada, Ltd. Industry | Phase 3 | (not given) | Dublin | 98 | 2019-11-25 | 2026-08-12 |
| NCT05658497 ClinicalTrials.gov |
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Multiple Sclerosis Open in IrelandWomen's health | Women's health & maternal | Biogen Industry | Observational | Recruiting | Dublin | 908 | 2023-10-27 | 2026-08-11 |
| NCT07555483 ClinicalTrials.gov · also 2025-522792-29-00 |
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) Alpha 1 Antitrypsin Deficiency Open in IrelandAlso in CTIS | Respiratory | Grifols Therapeutics LLC Industry | Phase 3 | Not yet recruiting | Dublin | 40 | 2026-05-05 | 2026-08-11 |
| NCT04739761 ClinicalTrials.gov |
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer Breast Cancer Women's health | Oncology | AstraZeneca Industry | Phase 3 | (not given) | Cork, Dublin | 506 | 2021-06-22 | 2026-08-11 |
| NCT04685135 ClinicalTrials.gov |
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer | Oncology | Mirati Therapeutics Inc. Industry | Phase 3 | (not given) | Dublin, Galway, Limerick, Tallaght | 453 | 2021-02-23 | 2026-08-11 |
| NCT01437787 ClinicalTrials.gov |
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Hematopoietic Neoplasm | Oncology | Bristol-Myers Squibb Industry | Phase 3 | (not given) | Dublin, Galway | 289 | 2011-12-31 | 2026-08-11 |
| NCT05524883 ClinicalTrials.gov |
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Duchenne Muscular Dystrophy (DMD) | Rare & genetic | Dyne Therapeutics Industry | Phase 1/2 | (not given) | Dublin | 86 | 2022-08-12 | 2026-08-11 |
| NCT03656536 ClinicalTrials.gov |
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma | Oncology | Incyte Corporation Industry | Phase 3 | (not given) | Dublin | 167 | 2019-06-03 | 2026-08-11 |
| 2024-514082-19-00 EU CTIS |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of
CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis (DAZALS) Amyotrophic Lateral Sclerosis | Neurology | Corcept Therapeutics Inc. Industry | Phase 2 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-11-04 | 2026-08-11 |
| 2024-515198-91-00 EU CTIS |
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD) Dominantly Inherited Alzheimer Disease (DIAD) | Neurology | Washington University School Of Medicine Academic / other | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2022-12-20 | 2026-08-11 |
| NCT05952557 ClinicalTrials.gov |
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Breast Cancer, Early Breast Cancer Women's health | Oncology | AstraZeneca Industry | Phase 3 | (not given) | Cork, Dublin, Galway, Waterford | 5,511 | 2023-10-05 | 2026-08-10 |
| NCT05711940 ClinicalTrials.gov |
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Treatment Resistant Depression | Mental health | COMPASS Pathways Industry | Phase 3 | (not given) | Dublin, Galway | 572 | 2023-02-14 | 2026-08-10 |
| NCT06183931 ClinicalTrials.gov |
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM Transthyretin Amyloid Cardiomyopathy | Cardiovascular | Alexion Pharmaceuticals, Inc. Industry | Phase 3 | (not given) | Dublin | 1,181 | 2024-01-11 | 2026-08-10 |
| 2025-523576-23-00 EU CTIS |
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy Unresectable Stage III non-small cell lung cancer without progression Open in Ireland | Oncology | Bristol-Myers Squibb Services Unlimited Company Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-06-12 | 2026-08-10 |
| 2024-518154-16-00 EU CTIS |
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS(MUT) NSCLC non-small cell lung cancer Open in Ireland | Oncology | Revolution Medicines Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-08-27 | 2026-08-10 |
| 2024-517423-40-00 EU CTIS |
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate Prostate01) Metastatic Castration-Resistant Prostate Cancer Open in Ireland | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-06-23 | 2026-08-10 |
| 2024-512925-95-00 EU CTIS |
C4391024 - An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study of PF-07220060 Plus Letrozole Compared to CDK4/6 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor (HR)-Positive, HER2-Negative Advanced/Metastatic Breast Cancer who Have not Received any Prior Systemic Anticancer Treatment for Advanced/Metastatic Disease (FourLight-3) Advanced/Metastatic Breast Cancer Women's health | Oncology | Pfizer Inc. Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2025-05-16 | 2026-08-10 |
| 2024-511754-41-00 EU CTIS |
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial) idiopathic pulmonary fibrosis | Respiratory | Endeavor Biomedicines Inc. Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2025-05-29 | 2026-08-10 |
| 2023-504320-25-00 EU CTIS |
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus. Active Systemic Lupus Erythematosus | Immunology, rheumatology & skin | Beeline Medicines Corp. Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2021-11-25 | 2026-08-10 |
| 2025-522056-10-01 EU CTIS |
A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6) von Willebrand Disease Open in Ireland | Blood (non-cancer) | Vega Therapeutics Inc. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-03-19 | 2026-08-07 |
| 2024-516009-22-00 EU CTIS |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) myelodysplastic neoplasms/syndromes (MDS) Open in Ireland | Oncology | Takeda Development Center Americas Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-04-30 | 2026-08-07 |
| 2023-510357-42-00 EU CTIS |
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE) hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EBC). Women's health | Oncology | Novartis Pharma AG Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2019-05-22 | 2026-08-07 |
| 2023-509049-11-00 EU CTIS |
Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy:
OVHIPEC-2 FIGO stage III ovarian cancer who are eligible for primary cytoreductive surgery resulting in non-residual disease, or residual disease up to 2.5 mm Women's health | Oncology | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic / other | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2020-01-01 | 2026-08-07 |
| NCT05232916 ClinicalTrials.gov |
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects Breast Cancer Open in IrelandWomen's health | Oncology | Greenwich LifeSciences, Inc. Industry | Phase 3 | Recruiting | Dublin | 2,250 | 2022-12-16 | 2026-08-06 |
| NCT07024706 ClinicalTrials.gov |
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) Open in Ireland | Oncology | AstraZeneca Industry | Phase 2 | Recruiting | Dublin | 80 | 2026-06-04 | 2026-08-06 |
| NCT07746609 ClinicalTrials.gov |
The Design and Evaluation of a Digital Physical Activity Intervention for Individuals With Severe Mental Illness in an Irish Mental Health Residential Setting Severe Mental Illness; Health Professionals New | Other / unclassified | Munster Technological University Academic / other | N/A (non-drug) | (not given) | Cork | 18 | 2024-02-01 | 2026-08-06 |
| 2025-523530-30-00 EU CTIS |
Single-centre clinical trial investigating the safety and tolerability of increasing multiple doses of nebulised SS0331 in healthy participants Treatment and post exposure prevention of respiratory tract infection, Biologic countermeasure Open in Ireland | Respiratory | Softox Defense Solutions AS Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-05-11 | 2026-08-06 |
| 2023-504807-94-00 EU CTIS |
A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Breast Cancer; Advanced solid tumors including but not limited to gynecologic Cancer; Head and Neck Squamous Cell Carcinoma Open in IrelandWomen's health | Oncology | Scorpion Therapeutics Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2023-12-26 | 2026-08-06 |
| NCT06330064 ClinicalTrials.gov · also 2023-509632-26-00 |
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) Recurrent or Metastatic Solid Tumors Open in IrelandWomen's healthAlso in CTIS | Oncology | Daiichi Sankyo Industry | Phase 1/2 | Not yet recruiting, Recruiting | Cork, Dublin, Galway | 680 | 2024-04-10 | 2026-08-05 |
| 2025-524040-35-00 EU CTIS |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma Severe uncontrolled asthma Open in Ireland | Respiratory | Generate Biomedicines Inc. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-06-25 | 2026-08-05 |
| NCT06563895 ClinicalTrials.gov |
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies Open in Ireland | Cardiovascular | Eidos Therapeutics, a BridgeBio company Industry | Phase 3 | Recruiting | Dublin | 587 | 2025-05-12 | 2026-08-04 |
| NCT06880744 ClinicalTrials.gov · also 2024-518998-33-00 |
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab Ulcerative Colitis Also in CTIS | Immunology, rheumatology & skin | AbbVie Industry | Phase 3 | (not given) | Ballinasloe, Drogheda, Dublin, Mullingar | 573 | 2025-06-17 | 2026-08-04 |
| NCT07227402 ClinicalTrials.gov |
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Renal Cell Carcinoma Open in Ireland | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Recruiting | Cork, Dublin | 904 | 2025-11-26 | 2026-08-03 |
| NCT06100289 ClinicalTrials.gov · also 2023-503188-40-00 |
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Ulcerative Colitis; Crohn's Disease Also in CTIS | Immunology, rheumatology & skin | Takeda Industry | Phase 3 | Active, not recruiting | Dublin | 70 | 2025-01-22 | 2026-08-03 |
| NCT03253263 ClinicalTrials.gov |
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants Bronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage; Retinopathy of Prematurity (ROP) | Respiratory | OHB Neonatology Ltd. Industry | Phase 2 | (not given) | Cork | 295 | 2019-05-09 | 2026-08-03 |
| 2023-510319-20-00 EU CTIS |
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) Gastroesophageal Adenocarcinoma (GEA) | Oncology | Jazz Pharmaceuticals Ireland Limited Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2021-10-21 | 2026-08-03 |
| 2024-514180-25-00 EU CTIS |
C4251008 - An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer unresectable or metastatic HER2+ colorectal cancer Open in Ireland | Oncology | Seagen Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2022-11-21 | 2026-08-03 |
| 2022-501374-19-00 EU CTIS |
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK‑2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (waveLINE-006). Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome) | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2022-09-16 | 2026-08-03 |
| NCT07106632 ClinicalTrials.gov · also 2024-519655-28-00 |
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests Early Breast Cancer; Premenopausal Breast Cancer; HR+/HER2- Breast Cancer Open in IrelandWomen's healthAlso in CTIS | Oncology | UNICANCER Academic / other | Phase 3 | Not yet recruiting | Cork, Dublin, Limerick, Tullamore, Waterford | 3,380 | 2026-06-26 | 2026-07-31 |
| NCT06374875 ClinicalTrials.gov |
Fibrosis Lessens After Metabolic Surgery Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Non-Alcoholic Fatty Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH); Liver Fibrosis Open in Ireland | Mental health | The Cleveland Clinic Academic / other | Phase 4 | Not yet recruiting | Dublin | 120 | 2024-07-11 | 2026-07-31 |
| NCT05876754 ClinicalTrials.gov |
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma Cholangiocarcinoma | Oncology | Servier Affaires Médicales Industry | Phase 3 | (not given) | Cork, Dublin | 299 | 2023-05-03 | 2026-07-31 |
| NCT03765918 ClinicalTrials.gov |
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Head and Neck Neoplasms | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin | 714 | 2018-12-17 | 2026-07-31 |
| 2023-508773-82-00 EU CTIS |
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC Stage IIB-IIIB (N2) resectable non small cell lung cancer Open in Ireland | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-05-06 | 2026-07-31 |
| NCT05329350 ClinicalTrials.gov |
Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases Muscular Ventricular Septal Defect Open in Ireland | Cardiovascular | Occlutech International AB Industry | Observational | Not yet recruiting | Dublin | 50 | 2022-03-03 | 2026-07-30 |
| NCT02632409 ClinicalTrials.gov |
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Various Advanced Cancer | Oncology | Bristol-Myers Squibb Industry | Phase 3 | (not given) | Dublin, Wilton | 709 | 2016-03-22 | 2026-07-30 |
| NCT02439775 ClinicalTrials.gov |
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System Hypertension; Vascular Diseases; Cardiovascular Diseases | Cardiovascular | Medtronic Vascular Industry | N/A (non-drug) | (not given) | Galway | 337 | 2015-07-22 | 2026-07-30 |
| 2025-521546-23-00 EU CTIS |
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis Secondary progressive multiple sclerosis Open in Ireland | Neurology | Novartis Pharma AG Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-04-21 | 2026-07-30 |
| 2023-504993-40-00 EU CTIS |
A Phase 3b, multi-center, randomized, parallel-group, open-label, non-inferiority study evaluating the efficacy, safety, and tolerability of oral dolutegravir/lamivudine once-daily as a first-line regimen compared to oral bictegravir/emtricitabine/tenofovir alafenamide once daily for virologic suppression and maintenance in antiretroviral therapy naive adults living with HIV Human immunodeficiency virus (HIV) | Infectious disease & vaccines | Viiv Healthcare UK Limited Industry | Phase 3 | Ended | Ireland (site detail on registry) | — | 2024-02-14 | 2026-07-30 |
| 2022-502937-24-00 EU CTIS |
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Immunology, rheumatology & skin | Abbvie Deutschland GmbH & Co. KG Industry | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2019-01-02 | 2026-07-30 |
| NCT07106762 ClinicalTrials.gov |
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Urothelial Cancer Open in Ireland | Oncology | Bristol-Myers Squibb Industry | Phase 2/3 | Not yet recruiting, Recruiting | Cork, Dublin | 470 | 2025-09-30 | 2026-07-29 |
| NCT03425643 ClinicalTrials.gov · also 2023-504820-24-00 |
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Non-small Cell Lung Cancer Also in CTIS | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | (not given) | Dublin, Limerick, Wilton | 797 | 2018-04-24 | 2026-07-29 |
| 2024-519188-17-00 EU CTIS |
A Phase 1/1b Study of IAM1363 in HER2 Cancers Relapsed/refractory malignancy with documented diagnosis of human epidermal growth factor receptor 2 (HER2) alterations Open in Ireland | Oncology | Iambic Therapeutics Inc. Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-10-07 | 2026-07-29 |
| 2024-517780-24-00 EU CTIS |
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04) Lung Cancer Open in Ireland | Oncology | AstraZeneca AB Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-09-18 | 2026-07-29 |
| NCT07731555 ClinicalTrials.gov |
Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological Analyses Glioblastoma Open in IrelandNew | Oncology | Patrick Morris Academic / other | N/A (non-drug) | Recruiting | Beaumont | 100 | 2022-03-01 | 2026-07-28 |
| NCT04644575 ClinicalTrials.gov |
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A Hemophilia A | Blood (non-cancer) | Bioverativ, a Sanofi company Industry | Phase 3 | (not given) | Dublin | 261 | 2021-02-23 | 2026-07-28 |
| NCT05186740 ClinicalTrials.gov |
ProVee Urethral Expander System IDE Study (ProVIDE) BPH With Symptomatic Lower Urinary Tract Symptoms | Kidney & urology | ProVerum Medical Industry | N/A (non-drug) | (not given) | Dublin | 221 | 2022-06-09 | 2026-07-28 |
| NCT04432584 ClinicalTrials.gov · also 2023-506526-37-00 |
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors Paroxysmal Nocturnal Hemoglobinuria Also in CTIS | Other / unclassified | Hoffmann-La Roche Industry | Phase 3 | (not given) | Dublin | 190 | 2020-09-30 | 2026-07-28 |
| 2023-509256-34-00 EU CTIS |
A Phase 1/2 Dose-Exploration and Dose-Expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease Open in Ireland | Respiratory | Beam Therapeutics Inc. Academic / other | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-09-28 | 2026-07-28 |
| 2023-504231-41-01 EU CTIS |
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Locally advanced or metastatic urothelial cancer | Oncology | Bicycletx Limited Industry | Phase 2 | Ended | Ireland (site detail on registry) | — | 2024-10-02 | 2026-07-28 |
| 2023-506150-21-00 EU CTIS |
A Phase II, Double-Blind, Randomised, Placebo-Controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-Free Diet Celiac Disease Open in Ireland | Digestive & liver | Dr. Falk Pharma GmbH Industry | Phase 2 | Authorised, recruiting | Ireland (site detail on registry) | — | 2024-05-29 | 2026-07-28 |
| NCT06494878 ClinicalTrials.gov |
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Venous Thromboembolism; Postpartum Period; Aspirin; Low Molecular Weight Heparin Open in IrelandWomen's health | Women's health & maternal | University of Calgary Academic / other | Phase 3 | Not yet recruiting | Dublin | 8,805 | 2026-06-04 | 2026-07-27 |
| NCT01760005 ClinicalTrials.gov |
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 Alzheimers Disease; Dementia; Alzheimers Disease, Familial | Neurology | Washington University School of Medicine Academic / other | Phase 2/3 | (not given) | Dublin | 490 | 2012-12 | 2026-07-27 |
| NCT03025308 ClinicalTrials.gov |
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis Rheumatoid Arthritis | Immunology, rheumatology & skin | Alfasigma S.p.A. Industry | Phase 3 | (not given) | Dublin | 2,731 | 2017-02-28 | 2026-07-27 |
| NCT05269394 ClinicalTrials.gov |
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Alzheimers Disease; Dementia; Alzheimers Disease, Familial | Neurology | Washington University School of Medicine Academic / other | Phase 2/3 | (not given) | Dublin | 197 | 2021-12-22 | 2026-07-27 |
| NCT04012944 ClinicalTrials.gov |
SIRONA 2 Trial Heart Failure NYHA Class III Heart Failure NYHA Class III | Cardiovascular | Endotronix, Inc. Industry | N/A (non-drug) | (not given) | Dublin | 81 | 2019-06-26 | 2026-07-27 |
| NCT07417254 ClinicalTrials.gov |
Novel Personalised Nutrition Intervention With Tailored Behavioural Support Behavior Change; Dietary Behaviour; Personalised Nutrition; Sustainable Healthy Diet | Other / unclassified | University College Dublin Academic / other | N/A (non-drug) | (not given) | Dublin | 66 | 2025-10-20 | 2026-07-27 |
| 2024-520218-23-00 EU CTIS |
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension. Pulmonary Arterial Hypertension Open in Ireland | Cardiovascular | Inhibikase Therapeutics Inc. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-05-20 | 2026-07-27 |
| NCT06512454 ClinicalTrials.gov |
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems Alpha1-Antitrypsin Deficiency Open in Ireland | Digestive & liver | Takeda Industry | Observational | Recruiting | Dublin | 500 | 2024-09-25 | 2026-07-24 |
| NCT04089059 ClinicalTrials.gov |
PROACTIVE-HF IDE Trial Heart Failure NYHA Class III Heart Failure NYHA Class III | Cardiovascular | Endotronix, Inc. Industry | N/A (non-drug) | (not given) | Galway | 738 | 2020-01-10 | 2026-07-24 |
| NCT06040086 ClinicalTrials.gov |
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | AstraZeneca Industry | Phase 3 | (not given) | Cork, Dublin, Galway, Moneymore | 1,454 | 2023-09-22 | 2026-07-24 |
| 2025-522580-15-00 EU CTIS |
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis (ALS) Open in Ireland | Neurology | Zydus Therapeutics Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-07-23 | 2026-07-24 |
| NCT07721766 ClinicalTrials.gov |
Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training Healthy Volunteers; Muscle Hypertrophy; Glycolysis; Moderately Trainend Open in IrelandNew | Musculoskeletal, pain & surgery | Technical University of Munich Academic / other | N/A (non-drug) | Recruiting | Limerick | 120 | 2026-05-04 | 2026-07-23 |
| NCT03523858 ClinicalTrials.gov |
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis Progressive Multiple Sclerosis (PMS) | Neurology | Hoffmann-La Roche Industry | Phase 3 | (not given) | Cork, Dublin | 927 | 2018-05-28 | 2026-07-23 |
| 2024-514841-12-00 EU CTIS |
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2-early breast cancer. Women's health | Oncology | ABCSG GmbH, Alliance Foundation Trials LLC Academic / other | Phase 3 | Ongoing, recruitment ended | Ireland (site detail on registry) | — | 2015-10-27 | 2026-07-23 |
| NCT05815745 ClinicalTrials.gov |
"Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment" (PROTECT-HF) Bradycardia; Pacing; Right Ventricular Pacing; His Bundle Pacing Open in Ireland | Cardiovascular | Imperial College London Academic / other | N/A (non-drug) | Recruiting | Dublin | 2,600 | 2023-06-05 | 2026-07-22 |
| NCT07057817 ClinicalTrials.gov |
The ACHILLS Trial; Application of Cerament in Heel Infection for Lower Limb Salvage Osteomyelitis; Diabetes; Calcanectomy Open in Ireland | Metabolic & endocrine | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Galway | 30 | 2026-01-01 | 2026-07-22 |
| NCT05253651 ClinicalTrials.gov · also 2024-514180-25-00 |
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer Colorectal Neoplasms Open in IrelandAlso in CTIS | Oncology | Seagen, a wholly owned subsidiary of Pfizer Industry | Phase 3 | Recruiting | Cork, Dublin, Waterford | 400 | 2022-10-24 | 2026-07-22 |
| 2024-520418-22-00 EU CTIS |
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation. Chronic Obstructive Pulmonary Disease Open in Ireland | Respiratory | Glaxosmithkline Research & Development Limited Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-01-20 | 2026-07-22 |
| NCT07218809 ClinicalTrials.gov |
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer Epithelial Ovarian Cancer Open in IrelandWomen's health | Oncology | AstraZeneca Industry | Phase 3 | Not yet recruiting | Cork, Dublin, Waterford | 1,100 | 2025-12-29 | 2026-07-21 |
| NCT06025253 ClinicalTrials.gov |
PINTA - Prophylactic Incisional Negative Pressure Therapy for Major Amputations Wound Surgical; Wound Infection; Cosmesis Open in Ireland | Infectious disease & vaccines | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin, Galway, Limerick, Waterford | 728 | 2024-03-01 | 2026-07-21 |
| NCT05098132 ClinicalTrials.gov · also 2025-522632-14-00 |
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers Advanced Solid Tumor; Non Small Cell Lung Cancer; Untreated Advanced NSCLC; 1st Line NSCLC Open in IrelandAlso in CTIS | Oncology | Synthekine Industry | Phase 1/2 | Recruiting | Dublin, Galway | 364 | 2022-01-25 | 2026-07-21 |
| 2024-519331-42-00 EU CTIS |
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29) pMMR endometrial carcinoma Open in IrelandWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-08-22 | 2026-07-21 |
| 2025-524463-20-00 EU CTIS |
The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks. Asthma Open in Ireland | Respiratory | Glaxosmithkline Research & Development Limited Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-07-31 | 2026-07-20 |
| 2024-518858-17-00 EU CTIS |
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Open in Ireland | Oncology | AstraZeneca AB Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-05-22 | 2026-07-20 |
| 2025-523558-14-00 EU CTIS |
A Phase 1 Study of AIR-001 in Adults with AATD. Alpha-1 Antitrypsin Deficiency Open in Ireland | Respiratory | Airna Corp. Industry | Phase 1 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-07-27 | 2026-07-20 |
| 2023-508015-23-00 EU CTIS |
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse 022/ENGOT ov84/GOG-3103) Ovarian cancer recurrent Open in IrelandWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2025-04-11 | 2026-07-20 |
| 2024-519875-24-00 EU CTIS |
A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors (CAREFNDR) Carcinoid syndrome Open in Ireland | Oncology | Crinetics Pharmaceuticals Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2025-09-26 | 2026-07-20 |
| 2022-501352-28-00 EU CTIS |
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP) Severe community-acquired pneumonia (sCAP) Open in Ireland | Respiratory | Biotest GmbH & Co. KGaA Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2023-06-07 | 2026-07-20 |
| 2025-523590-42-00 EU CTIS |
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors. Locally Advanced or Metastatic Solid Tumors Open in Ireland | Oncology | Crescent Biopharma Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-06-11 | 2026-07-15 |
| NCT06906926 ClinicalTrials.gov |
Harmony TPV EMEA PMS Severe Pulmonary Valve Regurgitation Open in Ireland | Respiratory | Medtronic Cardiovascular Industry | N/A (non-drug) | Recruiting | Dublin | 80 | 2025-07-30 | 2026-07-14 |
| 2025-522145-21-00 EU CTIS |
Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2) Metastatic hormone sensitive prostate cancer Open in Ireland | Oncology | University College London Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-04-13 | 2026-07-14 |
| 2025-523275-27-00 EU CTIS |
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP). Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) Open in Ireland | Metabolic & endocrine | Disc Medicine Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-05-26 | 2026-07-14 |
| 2024-516110-38-00 EU CTIS |
PHITT: Paediatric Hepatic International Tumour Trial Hepatoblastoma and Hepatocellular Carcinoma Open in Ireland | Oncology | The University Of Birmingham Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2018-03-06 | 2026-07-14 |
| NCT07523620 ClinicalTrials.gov |
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration Atrial Fibrillation (AF); Paroxysmal AF; Persistent Atrial Fibrillation Open in Ireland | Cardiovascular | Abbott Medical Devices Industry | N/A (non-drug) | Recruiting | Dublin | 240 | 2026-03-31 | 2026-07-13 |
| 2025-522632-14-00 EU CTIS |
A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications Non-small cell lung cancer (NSCLC) Open in Ireland | Oncology | Synthekine Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-05-11 | 2026-07-13 |
| 2023-504962-52-00 EU CTIS |
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery Triple negative breast cancer. Open in IrelandWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-07-10 | 2026-07-13 |
| 2022-502629-16-00 EU CTIS |
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN). Hemolytic Disease of the Fetus and Newborn (HDFN) Open in IrelandWomen's health | Women's health & maternal | Janssen - Cilag International Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-07-10 | 2026-07-13 |
| 2025-523083-21-00 EU CTIS |
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Open in IrelandWomen's health | Oncology | Relay Therapeutics Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-12-08 | 2026-07-10 |
| 2023-507889-89-00 EU CTIS |
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia Respiratory tract infection Open in Ireland | Respiratory | Universitair Medisch Centrum Utrecht Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2016-02-19 | 2026-07-10 |
| NCT04685616 ClinicalTrials.gov |
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma Hodgkin Lymphoma Open in Ireland | Oncology | University College, London Academic / other | Phase 3 | Recruiting | Dublin, Galway | 1,042 | 2022-04-14 | 2026-07-08 |
| NCT06140524 ClinicalTrials.gov · also 2023-505242-25-00 |
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS); Smoldering Multiple Myeloma (SMM) Open in IrelandAlso in CTIS | Oncology | Regeneron Pharmaceuticals Industry | Phase 2 | Recruiting | Cork, Dublin, Galway | 116 | 2024-09-16 | 2026-07-08 |
| 2024-515147-32-02 EU CTIS |
POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychological support for cocaine use disorder Cocaine addiction Open in Ireland | Mental health | Trinity College Dublin Academic / other | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-09-28 | 2026-07-08 |
| 2023-508398-10-00 EU CTIS |
Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (DISRITUX) ANCA-associated vasculitis Open in Ireland | Immunology, rheumatology & skin | Region Oestergoetland Academic / other | Phase 4 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-12-12 | 2026-07-08 |
| NCT05768139 ClinicalTrials.gov · also 2023-504807-94-00 |
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Breast Cancer; Solid Tumors, Adult Open in IrelandWomen's healthAlso in CTIS | Oncology | Eli Lilly and Company Industry | Phase 1/2 | Recruiting | Dublin | 880 | 2023-04-17 | 2026-07-07 |
| NCT07552168 ClinicalTrials.gov |
INSPIRE: INnovative SABR for Prostate Cancer All IREland Prostate Adenocarcinoma Open in Ireland | Oncology | Cancer Trials Ireland Academic / other | Phase 2 | Not yet recruiting, Recruiting | Cork, Dublin, Waterford | 136 | 2026-04-23 | 2026-07-06 |
| 2024-517189-40-00 EU CTIS |
A Phase 1 Study of TORL-1-23 in Advanced Cancer Advanced Cancer Open in Ireland | Oncology | Torl Biotherapeutics LLC Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-07-20 | 2026-07-06 |
| 2024-513754-29-00 EU CTIS |
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age (VX21-121-105) Cystic Fibrosis Open in Ireland | Respiratory | Vertex Pharmaceuticals Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2023-03-06 | 2026-07-06 |
| 2023-509877-22-00 EU CTIS |
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Vonicog Alfa (rVWF) in Children Diagnosed With Severe von Willebrand disease. severe von Willebrand Disease Open in Ireland | Neonatal & paediatric | Takeda Development Center Americas Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-10-30 | 2026-07-03 |
| 2025-523544-12-00 EU CTIS |
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions Myelodysplastic neoplasms/syndromes (MDS) Open in Ireland | Oncology | Takeda Development Center Americas Inc. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-06-02 | 2026-07-02 |
| 2025-523533-25-00 EU CTIS |
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia Cancer-associated Cachexia Open in Ireland | Oncology | CatalYm GmbH Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-03-26 | 2026-07-01 |
| 2024-510579-40-00 EU CTIS |
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Rhabdoyosarcoma Open in Ireland | Oncology | The University Of Birmingham Academic / other | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2020-10-07 | 2026-07-01 |
| 2024-513009-30-00 EU CTIS |
A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn’s Disease Moderate to Severe Crohn’s Disease Open in Ireland | Immunology, rheumatology & skin | AbbVie Deutschland GmbH & Co. KG Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-11-21 | 2026-06-29 |
| NCT07672392 ClinicalTrials.gov |
The Effect of a Post-operative Exercise Programme Versus Standard Care on Physical Fitness of Patients With Breast Cancer Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Reconstruction Surgery Breast Cancer; Exercise Open in IrelandWomen's health | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Beaumont | 78 | 2024-08-01 | 2026-06-26 |
| 2023-508047-40-00 EU CTIS |
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102) Ovarian cancer Open in IrelandWomen's health | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-04-30 | 2026-06-25 |
| 2024-512412-22-00 EU CTIS |
A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli Hemolytic Uremic Syndrome Open in Ireland | Infectious disease & vaccines | Chemo Research S.L., Inmunova S.A. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2025-06-24 | 2026-06-24 |
| 2022-501238-52-00 EU CTIS |
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR) Heart failure due to systemic left ventricular systolic dysfunction Open in Ireland | Cardiovascular | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2023-03-23 | 2026-06-24 |
| 2024-513077-48-00 EU CTIS |
A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma Open in Ireland | Oncology | Neurotrials LLC Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-12-19 | 2026-06-23 |
| 2024-514435-20-00 EU CTIS |
A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin (EPIPHENY) Phenylketonuria Open in Ireland | Neurology | PTC Therapeutics Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-12-23 | 2026-06-18 |
| 2025-522767-15-00 EU CTIS |
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study Acute Myeloid Leukemia Open in Ireland | Oncology | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-01-27 | 2026-06-17 |
| 2025-521627-78-00 EU CTIS |
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) Neoplasms, Lung Open in Ireland | Oncology | Glaxosmithkline Research & Development Limited Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-01-28 | 2026-06-15 |
| NCT05950945 ClinicalTrials.gov |
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer Breast Cancer Open in IrelandWomen's health | Oncology | Daiichi Sankyo Industry | Phase 3 | Recruiting, Withdrawn | Cork, Dublin, Galway | 250 | 2023-12-30 | 2026-06-12 |
| 2023-505242-25-00 EU CTIS |
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA High-Risk Monoclonal Gammopathy of Undetermined Significance;
Non-High-Risk Smoldering Multiple Myeloma Open in Ireland | Oncology | Regeneron Pharmaceuticals Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-11-05 | 2026-06-12 |
| 2023-503895-25-00 EU CTIS |
Preventing caRdiovascular collapsE with VasoprEssors duriNg Tracheal IntubatiON: The PREVENTION Randomized Controlled Trial criticall illness Open in Ireland | Cardiovascular | Universita Degli Studi Di Torino Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-08-01 | 2026-06-12 |
| NCT07142304 ClinicalTrials.gov |
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study Chemotherapy Induced Peripheral Neuropathy (CIPN) Open in Ireland | Neurology | Luminate Medical, Inc. Industry | N/A (non-drug) | Recruiting | Dublin | 142 | 2025-10-03 | 2026-06-10 |
| 2025-523400-72-00 EU CTIS |
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis Cystic fibrosis Open in Ireland | Respiratory | Vertex Pharmaceuticals Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-06-10 |
| 2024-512222-28-00 EU CTIS |
SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellular, papillary, myxopapillary, clear-cell and tanycytic or anaplastic ependymoma. Open in Ireland | Eye & ear | Centre Leon Berard Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2015-06-02 | 2026-06-10 |
| NCT07636395 ClinicalTrials.gov |
Eating Behaviour Before, During, and After Obesity Medication Obesity Type 2 Diabetes Mellitus; Obesity & Overweight Open in Ireland | Metabolic & endocrine | University College Dublin Academic / other | Observational | Recruiting | Dublin | 30 | 2026-05-25 (est.) | 2026-06-09 |
| 2025-522255-25-00 EU CTIS |
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms Open in IrelandWomen's health | Oncology | Eli Lilly & Co. Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-05-18 | 2026-06-09 |
| 2023-506817-23-01 EU CTIS |
EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) Metastatic hormone naïve prostate cancer (mHNPC) Open in Ireland | Oncology | European Organisation For Research And Treatment Of Cancer Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-05-23 | 2026-06-08 |
| 2023-510384-36-00 EU CTIS |
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation – MajesTEC-4 Newly Diagnosed Multiple Myeloma Open in Ireland | Oncology | European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2022-09-13 | 2026-06-05 |
| 2024-518007-22-00 EU CTIS |
A Phase III Randomised, Open Label Trial of an Intradermal or Subcutaneous booster dose of MVA-BN Vaccine to Investigate MPXV Immunogenicity and Safety for Protection Against Mpox in an Intradermally or Subcutaneously Primary Vaccinated Population – an adaptive protocol and a Non-Randomised Trial of a Subcutaneous Booster Dose for Subcutaneously Primary Vaccinated Prevention of monkeypox (mpox) infection Open in Ireland | Infectious disease & vaccines | The Public Health Agency Of Sweden Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-12-05 | 2026-06-04 |
| 2023-509632-26-00 EU CTIS |
A Phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I DXd) in subjects with recurrent or metastatic solid tumors Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma) Open in IrelandWomen's health | Oncology | Daiichi Sankyo Inc. Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-02-11 | 2026-06-04 |
| 2025-523088-39-00 EU CTIS |
A Phase 1 Study for ZW251 in Participants with Solid Tumors. Advanced Solid Tumors Open in Ireland | Oncology | Zymeworks Bc Inc. Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-01-28 | 2026-06-03 |
| 2024-517729-20-00 EU CTIS |
Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Melanoma Open in Ireland | Oncology | Regeneron Pharmaceuticals Inc. Industry | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2026-06-02 |
| NCT07616258 ClinicalTrials.gov |
Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Primary Breast Cancer Breast Cancer Open in IrelandWomen's health | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Beaumont | 560 | 2025-10-02 | 2026-06-01 |
| NCT07616245 ClinicalTrials.gov |
MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy Oesphageal Cancer Open in Ireland | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Beaumont | 160 | 2025-10-02 | 2026-06-01 |
| NCT07230535 ClinicalTrials.gov |
Evaluation of Wellbeing and Patient Reported Outcomes After Open vs Robotic Mastectomy With DIEP Reconstruction Breast Cancer, Breast Neoplasms; Breast Reconstruction; DIEP Flap Breast Reconstruction; Robotic Surgery Open in IrelandWomen's health | Oncology | Beaumont Hospital Academic / other | N/A (non-drug) | Recruiting | Beaumont | 250 | 2025-12-01 | 2026-06-01 |
| 2023-507482-26-00 EU CTIS |
PEACE 8: Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer and oligometastases on functional imaging. Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography). Open in Ireland | Oncology | Unicancer Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-10-04 | 2026-05-29 |
| NCT07609134 ClinicalTrials.gov |
The Development of the Walsh Asthma Self-management Programme and Feasibility of Implementation in Adults With Asthma in Primary Care Asthma; Self-management; Asthma Control Open in Ireland | Respiratory | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 40 | 2026-05 (est.) | 2026-05-27 |
| NCT07095660 ClinicalTrials.gov |
RECANA OUS - Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-IRL) Venous Obstruction Open in Ireland | Cardiovascular | Intervene, Inc. Industry | N/A (non-drug) | Recruiting | Galway | 20 | 2025-07-02 | 2026-05-27 |
| NCT06227910 ClinicalTrials.gov · also 2023-509391-42-00 |
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease Crohn's Disease Open in IrelandAlso in CTIS | Immunology, rheumatology & skin | Takeda Industry | Phase 3 | Not yet recruiting | Dublin | 396 | 2025-01-02 | 2026-05-27 |
| NCT07586930 ClinicalTrials.gov |
CP: Intestinal Permeability Intestinal Permability Open in Ireland | Digestive & liver | Rousselot BVBA Industry | N/A (non-drug) | Recruiting | Cork | 92 | 2026-03-25 | 2026-05-27 |
| NCT07160868 ClinicalTrials.gov |
Obstructive Sleep Apnoea and Difficult Asthma (OSADA) Asthma (Diagnosis); OSA - Obstructive Sleep Apnea; CPAP Treatment Open in Ireland | Respiratory | St. James's Hospital, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 80 | 2025-09-01 | 2026-05-26 |
| NCT07181590 ClinicalTrials.gov |
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF Paroxysmal AF; Atrial Arrhythmia; Atrial Fibrillation; Persistent Atrial Fibrillation Open in Ireland | Cardiovascular | Abbott Medical Devices Industry | N/A (non-drug) | Recruiting | Dublin | 300 | 2025-12-11 | 2026-05-26 |
| NCT07605936 ClinicalTrials.gov |
Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study Frailty at Older Adults; Prostate Cancer Open in Ireland | Oncology | University of Limerick Academic / other | Observational | Recruiting | Limerick | 80 | 2026-04-23 | 2026-05-26 |
| 2022-501157-36-00 EU CTIS |
Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients Critically ill patients who are dependent on high level medical care including mechanical ventilation, vasopressors and sedative/analgesic medication Open in Ireland | Other / unclassified | Monash University Academic / other | Phase 4 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-02-07 | 2026-05-25 |
| NCT03151629 ClinicalTrials.gov |
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Prostate Cancer Open in Ireland | Oncology | Prostate Cancer Clinical Trials Consortium Academic / other | Observational | Recruiting | Dublin, Sligo | 5,000 | 2017-07-21 | 2026-05-22 |
| NCT07600229 ClinicalTrials.gov |
Barefoot Walking VS Standardised Conservative Care for Plantar Fasciopathy Plantar Fasciopathy; Plantar Fasciitis; Plantar Fasciitis, Chronic; Heel Pain Open in Ireland | Musculoskeletal, pain & surgery | Elisabetta Brigo Academic / other | N/A (non-drug) | Recruiting | Carlow | 74 | 2026-05-07 | 2026-05-22 |
| 2023-506288-33-00 EU CTIS |
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (OMAHA-01A) Metastatic castration resistant prostate cancer (mCRPC) Open in Ireland | Oncology | Merck Sharp & Dohme LLC Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-03-03 | 2026-05-22 |
| 2022-502408-57-00 EU CTIS |
PEACE-6 Poor Responders: A randomized phase III trial evaluating the efficacy and safety of 177Lu-PSMA-617 in addition to Standard of Care (SoC) versus SoC alone in de novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC. Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level) Open in Ireland | Oncology | Unicancer Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2024-09-04 | 2026-05-22 |
| 2023-504198-19-00 EU CTIS |
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Open in Ireland | Digestive & liver | Takeda Development Center Americas Inc. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2024-04-18 | 2026-05-21 |
| 2024-512733-32-00 EU CTIS |
HOVON 177: Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy Acute Myeloid Leukemia (AML) Open in Ireland | Oncology | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-03-31 | 2026-05-20 |
| NCT04165109 ClinicalTrials.gov |
Trial-Ready Cohort-Down Syndrome (TRC-DS) Down Syndrome; Alzheimer Disease; Dementia Open in Ireland | Neurology | University of Southern California Academic / other | Observational | Recruiting | Dublin | 550 | 2021-06-07 | 2026-05-18 |
| NCT04421820 ClinicalTrials.gov |
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma Open in Ireland | Oncology | Bold Therapeutics, Inc. Industry | Phase 1/2 | Recruiting | Dublin | 220 | 2020-08-28 | 2026-05-18 |
| NCT06749327 ClinicalTrials.gov |
Dissecting the Roles of High-quality Diets and Ultra Processed Foods on Cardiometabolic Health Cardiometabolic Risk Factors Open in Ireland | Cardiovascular | Queen's University, Belfast Academic / other | N/A (non-drug) | (not given) | Dublin | 330 | 2026-10-01 (est.) | 2026-05-18 |
| NCT07592234 ClinicalTrials.gov |
Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events Serious Adverse Events; Patient Safety; Pharmacovigilance; Oncology Open in Ireland | Oncology | St Vincent's University Hospital, Ireland Academic / other | Observational | Recruiting | Dublin | 100 | 2026-02-01 | 2026-05-18 |
| NCT07559643 ClinicalTrials.gov |
The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial. Bariatric Surgery; Anti-Xa Activity; VTE (Venous Thromboembolism); Obesity & Overweight Open in Ireland | Cardiovascular | University College Dublin Academic / other | N/A (non-drug) | (not given) | Dublin | 180 | 2026-08-01 (est.) | 2026-05-18 |
| NCT07244341 ClinicalTrials.gov · also 2025-522512-16-00 |
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) Metastatic Castration-resistant Prostate Cancer Open in IrelandAlso in CTIS | Oncology | Daiichi Sankyo Industry | Phase 1 | Recruiting | Dublin | 60 | 2025-12-03 | 2026-05-15 |
| NCT07196020 ClinicalTrials.gov |
Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study Venous Thromboembolism; Cancer Open in Ireland | Oncology | University of Dublin, Trinity College Academic / other | Observational | Recruiting | Cork, Dublin | 380 | 2025-10-01 | 2026-05-15 |
| NCT06284317 ClinicalTrials.gov |
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. Non Small Cell Lung Cancer Open in Ireland | Oncology | ETOP IBCSG Partners Foundation Academic / other | Phase 3 | Recruiting | Dublin | 290 | 2025-01-15 | 2026-05-14 |
| 2025-524002-16-00 EU CTIS |
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Open in Ireland | Neurology | Ferrer Internacional S.A., Prilenia Therapeutics B.V. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2026-05-12 | 2026-05-14 |
| NCT05677971 ClinicalTrials.gov · also 2022-501943-34-00 |
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Alpha1-Antitrypsin Deficiency Open in IrelandAlso in CTIS | Digestive & liver | Takeda Industry | Phase 3 | Recruiting | Dublin | 160 | 2023-03-06 | 2026-05-13 |
| NCT06857539 ClinicalTrials.gov |
Assessing Intellectual and Motor Outcomes in High-risk Infants Cerebral Palsy; Cerebral Palsy (CP); Cerebral Palsy Children; High-risk Infants Open in Ireland | Neurology | University College Cork Academic / other | Observational | Not yet recruiting, Recruiting | Cork, Dublin | 600 | 2025-03-21 | 2026-05-13 |
| NCT07585149 ClinicalTrials.gov |
Generating Intervals of Reference FFor Early Life Brain Biomarkers. Reference Intervals; Biomarker in Early Diagnosis; Neonatal Open in Ireland | Neonatal & paediatric | University College Cork Academic / other | Observational | Recruiting | Cork | 150 | 2026-04-13 | 2026-05-13 |
| NCT07524517 ClinicalTrials.gov |
NeoSHARK: Anatomical Versus Round Facemasks for Breathing Support in Preterm and Term Newborn Infants Neonatal Intensive Care Open in Ireland | Neonatal & paediatric | University College Dublin Academic / other | N/A (non-drug) | Recruiting | Dublin | 50 | 2026-05 (est.) | 2026-05-12 |
| NCT07577609 ClinicalTrials.gov |
AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION) Coronary Artery Disease (CAD); Computed Tomography Angiography; Biomarkers; AI (Artificial Intelligence) Open in Ireland | Cardiovascular | University of Galway Academic / other | Observational | Recruiting | Galway | 10,000 | 2022-12-21 | 2026-05-11 |
| NCT07572370 ClinicalTrials.gov |
Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Breast Cancer Breast Cancer Open in IrelandWomen's health | Oncology | Royal College of Surgeons, Ireland Academic / other | Observational | Recruiting | Dublin | 560 | 2025-12-11 | 2026-05-07 |
| NCT06898450 ClinicalTrials.gov |
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. Advanced Solid Tumors Cancer; MSI-H Cancer Open in Ireland | Oncology | Nimbus Wadjet, Inc. Industry | Phase 1/2 | Recruiting | Dublin | 134 | 2025-03-31 | 2026-05-06 |
| NCT04043494 ClinicalTrials.gov |
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma Lymphoblastic Lymphoma, Childhood Open in Ireland | Oncology | University Hospital Muenster Academic / other | Phase 3 | Not yet recruiting | Dublin | 683 | 2019-08-23 | 2026-05-06 |
| NCT07182773 ClinicalTrials.gov |
Pre-infusion Aerobic Cycling Exercise for CardioRespiratory Fitness in Cancer Patients Cancer Open in Ireland | Oncology | University of Dublin, Trinity College Academic / other | N/A (non-drug) | Recruiting | Dublin | 80 | 2025-09-24 | 2026-05-04 |
| NCT06544499 ClinicalTrials.gov · also 2024-515451-38-00 |
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia Primary Immune Thrombocytopenia (ITP) Open in IrelandAlso in CTIS | Cardiovascular | argenx Industry | Phase 3 | Recruiting | Dublin | 69 | 2024-10-18 | 2026-05-01 |
| NCT07561957 ClinicalTrials.gov |
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines Chronic Kidney Disease; Proteinuria; Blood Pressure Control; Congenital Anomalies of the Kidneys and Urinary Tract Open in Ireland | Oncology | St. James's Hospital, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 80 | 2026-01-14 | 2026-05-01 |
| NCT07558668 ClinicalTrials.gov |
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis Moderate to Severe Atopic Dermatitis Open in Ireland | Immunology, rheumatology & skin | Sitryx Therapeutics Ltd Industry | Phase 1 | Recruiting | Dublin | 149 | 2025-02-26 | 2026-04-30 |
| NCT07208175 ClinicalTrials.gov |
Effectiveness of Ultrasound-Guided Versus Traditional IV Insertion by Oncology Nurses in Adult Population Recieving Systemic Anti-cancer Therapy Cancer Open in Ireland | Oncology | University of Galway Academic / other | N/A (non-drug) | Recruiting | Galway | 98 | 2025-10-20 | 2026-04-29 |
| NCT04174755 ClinicalTrials.gov |
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV Obesity; HIV-1-infection Open in Ireland | Metabolic & endocrine | University College Dublin Academic / other | N/A (non-drug) | Recruiting | Dublin | 80 | 2022-06-22 | 2026-04-29 |
| NCT07489521 ClinicalTrials.gov |
Arthrosamid vs. Steroid for the Management of Knee Osteoarthritis Osteo Arthritis Knee; Osteoarthritis; Intraarticular Injection Open in Ireland | Immunology, rheumatology & skin | Cappagh National Orthopaedic Hospital Academic / other | Phase 4 | Recruiting | Dublin | 200 | 2026-01-29 | 2026-04-28 |
| NCT04916613 ClinicalTrials.gov · also 2022-502425-18-00 |
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) Prostate Cancer Metastatic Open in IrelandAlso in CTIS | Oncology | UNICANCER Academic / other | Phase 3 | Recruiting | Dublin, Limerick | 300 | 2022-04-19 | 2026-04-28 |
| 2022-501709-11-00 EU CTIS |
A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy
ALIDHE Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leukemia (AML) Open in Ireland | Oncology | Servier Affaires Medicales Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2023-06-06 | 2026-04-27 |
| NCT06679101 ClinicalTrials.gov |
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) Multiple Myeloma; Newly Diagnosed Multiple Myeloma Open in Ireland | Oncology | GlaxoSmithKline Industry | Phase 3 | Recruiting | Dublin, Galway, Waterford | 520 | 2024-12-16 | 2026-04-22 |
| 2024-515451-38-00 EU CTIS |
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia Primary Immune thrombocytopenia (ITP) Open in Ireland | Cardiovascular | Argenx Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-02-27 | 2026-04-21 |
| 2023-509780-25-00 EU CTIS |
Does the Use of Higher Versus Lower Oxygen Concentration Improve Neurodevelopmental Outcomes at 24 Months (plus or minus 6 months) in Very Low Birthweight Infants: The HiLo-Trial Prematurity Open in Ireland | Neurology | University College Cork Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-10-09 | 2026-04-20 |
| 2024-519917-72-00 EU CTIS |
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy) Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) Open in Ireland | Cardiovascular | Alnylam Pharmaceuticals Inc. Industry | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2025-10-29 | 2026-04-17 |
| NCT06620653 ClinicalTrials.gov |
Heart Failure Virtual Ward Research Study Heart Failure Open in Ireland | Cardiovascular | National University of Ireland, Galway, Ireland Academic / other | N/A (non-drug) | Recruiting | Ballinasloe | 346 | 2024-10-18 | 2026-04-15 |
| NCT07453823 ClinicalTrials.gov |
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight Gastrointestinal Microbiome (Focus); Gastrointestinal Symptoms Open in Ireland | Digestive & liver | Chr Hansen - part of Novonesis Industry | N/A (non-drug) | Recruiting | Cork | 90 | 2026-03-18 | 2026-04-15 |
| NCT06454656 ClinicalTrials.gov |
A Motor Learning Intervention to Target Walking Performance in Ambulant Children With Cerebral Palsy Cerebral Palsy; Walking, Difficulty; Spastic Diplegia; Hemiplegic Cerebral Palsy Open in Ireland | Neonatal & paediatric | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Balrath | 14 | 2024-08-12 | 2026-04-14 |
| 2024-517131-52-00 EU CTIS |
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open in Ireland | Oncology | BeOne Medicines AG Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-11-03 | 2026-04-14 |
| NCT07524595 ClinicalTrials.gov |
Self-Expanding Hydra Transcatheter Heart Valve (THV) Series Versus Balloon-Expandable Devices for Valve-In-Valve Transcatheter Aortic Valve Implantation (TAVI) for Patients With Failed Surgical Aortic Bioprosthesis. AORTIC VALVE DISEASES; Valve-in-valve Procedures; Surgical Valve Replacement; Valve Disease, Aortic Open in Ireland | Cardiovascular | National University of Ireland, Galway, Ireland Academic / other | N/A (non-drug) | (not given) | Galway | 111 | 2026-04 (est.) | 2026-04-13 |
| 2023-508818-42-00 EU CTIS |
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study] Generalized Epidermolysis Bullosa Simplex (EBS) Open in Ireland | Immunology, rheumatology & skin | Twi Biotechnology Inc. Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-05-21 | 2026-04-10 |
| NCT06079398 ClinicalTrials.gov |
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia Achondroplasia Open in Ireland | Neonatal & paediatric | Ascendis Pharma A/S Industry | Phase 2 | Recruiting | Dublin | 72 | 2024-01-23 | 2026-04-08 |
| 2025-521040-37-00 EU CTIS |
Diagnostic HER2DX-guided trEatment For patIeNts wIth early-sTage HER2-positIVE breast cancer HER2-positive early breast cancer Open in IrelandWomen's health | Oncology | Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-11-26 | 2026-04-08 |
| NCT04294927 ClinicalTrials.gov |
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention BRCA1 Gene Mutation; BRCA2 Gene Mutation; RAD51C Gene Mutation; RAD51D Gene Mutation Open in IrelandWomen's health | Oncology | University Medical Center Nijmegen Academic / other | N/A (non-drug) | Recruiting | Cork | 3,000 | 2020-03-01 | 2026-04-06 |
| NCT07512505 ClinicalTrials.gov |
Remote Vital Sign Monitoring in Palliative Care Patients Using a Wearable ECG Monitor Cancer; Malignancies Multiple; Terminal Care; Hospice Open in Ireland | Oncology | Our Lady's Hospice and Care Services Academic / other | Observational | Recruiting | Dublin | 120 | 2025-11-06 | 2026-04-06 |
| NCT07393880 ClinicalTrials.gov |
Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus Tinnitus, Subjective; Tinnitus; Chronic Tinnitus Open in Ireland | Eye & ear | University of Dublin, Trinity College Academic / other | N/A (non-drug) | Recruiting | Dublin | 100 | 2026-01-30 | 2026-04-03 |
| NCT07426809 ClinicalTrials.gov |
Margin Optimisation Using Z-axis Assessment With Real-time Tomosynthesis (MOZART Study). Breast Cancer Open in IrelandWomen's health | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Beaumont | 314 | 2025-12-18 | 2026-04-03 |
| 2025-523877-40-00 EU CTIS |
TREAT-EC (Tirzepatide in the treatment of endometrial cancer) - a clinical trial Endometrial adenocarcinoma Open in IrelandWomen's health | Oncology | University College Dublin Academic / other | Phase 2 | Authorised, recruiting | Ireland (site detail on registry) | — | 2026-10-15 | 2026-04-02 |
| NCT07505329 ClinicalTrials.gov |
An Intervention Study in Healthy Infants Aged 0-6 Months With Probiotics Lacticaseibacillus Rhamnosus LRa05 (LRa05) and Bifidobacterium Animalis Subsp. Lactis BLa80 (BLa80) vs. Placebo, for Promoting Gut Microbiome Development. Less Than 3 Months Old; Healthy Infants Open in Ireland | Infectious disease & vaccines | University College Cork Academic / other | N/A (non-drug) | (not given) | Cork | 300 | 2026-04 (est.) | 2026-04-01 |
| NCT07231783 ClinicalTrials.gov |
The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults Healthy Aging; Muscle Function Open in Ireland | Musculoskeletal, pain & surgery | Amazentis SA Industry | N/A (non-drug) | Recruiting | Cork | 120 | 2025-12-10 | 2026-03-31 |
| NCT07503717 ClinicalTrials.gov |
SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance Breast Cancer; HER2-Positive Metastatic Breast Cancer Open in IrelandWomen's health | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Beaumont | 69 | 2025-06-01 | 2026-03-31 |
| NCT07503704 ClinicalTrials.gov |
A Prospective Study of the Genomic Landscape of Central Nervous System Disease Secondary to Breast Cancer Utilising Cell-free DNA Derived From Cerebrospinal Fluid (CSF) Breast Cancer Open in IrelandWomen's health | Oncology | Royal College of Surgeons, Ireland Academic / other | Observational | Recruiting | Dublin | 69 | 2024-10-01 | 2026-03-31 |
| NCT04109079 ClinicalTrials.gov |
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy Breast Cancer; Sentinel Lymph Node; Neoplasm, Breast Open in IrelandWomen's health | Oncology | University Hospitals of Derby and Burton NHS Foundation Trust Academic / other | N/A (non-drug) | Recruiting | Dublin, Galway | 1,900 | 2021-02-26 | 2026-03-30 |
| NCT07360847 ClinicalTrials.gov |
Profiling Patients With Rotator Cuff Related Shoulder Pain: What Factors Influence Outcomes With Non-operative Care in a Secondary Care Specialist Shoulder Clinic? Rotator Cuff Related Shoulder Pain; RCRSP Open in Ireland | Musculoskeletal, pain & surgery | University of Limerick Academic / other | Observational | Recruiting | Limerick | 150 | 2026-01-05 | 2026-03-27 |
| NCT06932562 ClinicalTrials.gov · also 2024-519827-16-00 |
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant Multiple Myeloma Open in IrelandAlso in CTIS | Oncology | European Myeloma Network B.V. Academic / other | Phase 3 | Recruiting | Cork, Dublin, Limerick | 1,000 | 2025-12-23 | 2026-03-25 |
| NCT06093672 ClinicalTrials.gov · also 2022-502276-23-00 |
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Polycythemia Vera Open in IrelandAlso in CTIS | Other / unclassified | Italfarmaco Industry | Phase 3 | Recruiting, Withdrawn | Cork, Dublin | 220 | 2024-03-26 | 2026-03-25 |
| NCT07477938 ClinicalTrials.gov |
A Single-Arm Interventional Trial of Pepper- Robot Delivered Cancer Education for Adults With Intellectual Disability Cancer Awareness and Prevention Education; Breast Cancer Awareness; Intellectual Disabilities (F70-F79) Open in IrelandWomen's health | Oncology | National University of Ireland, Galway, Ireland Academic / other | N/A (non-drug) | (not given) | Galway | 25 | 2026-05-01 (est.) | 2026-03-17 |
| NCT05669950 ClinicalTrials.gov |
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia Open in Ireland | Metabolic & endocrine | H. Lundbeck A/S Industry | Phase 1/2 | Recruiting | Dublin | 42 | 2022-12-19 | 2026-03-09 |
| 2024-516440-25-00 EU CTIS |
A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. KRAS G12D-mutant solid tumors. Open in Ireland | Oncology | Eli Lilly & Co. Industry | Phase 1 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2025-02-06 | 2026-03-09 |
| NCT07455422 ClinicalTrials.gov |
A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer Barrett Esophagus; Barrett Esophagus Adenocarcinoma; Adenocarcinoma - GEJ; Gastroenterology Open in Ireland | Oncology | University Hospital, Antwerp Academic / other | N/A (non-drug) | (not given) | Dublin | 266 | 2026-06-01 (est.) | 2026-03-06 |
| NCT01633489 ClinicalTrials.gov |
Lysosomal Acid Lipase (LAL) Deficiency Registry Lysosomal Acid Lipase Deficiency; Cholesterol Ester Storage Disease; Wolman Disease; Acid Cholesteryl Ester Hydrolase Deficiency, Type 2 Open in Ireland | Cardiovascular | Alexion Pharmaceuticals, Inc. Industry | Observational | Recruiting | Dublin | 300 | 2013-05-30 | 2026-03-06 |
| NCT07453498 ClinicalTrials.gov |
Evaluating the Efficacy of the Psoas Sheath Block for Post Operative Analgesia Following Hip Arthroplasty Total Hip Arthroplasty (THA) Open in Ireland | Musculoskeletal, pain & surgery | University College Hospital Galway Academic / other | N/A (non-drug) | Recruiting | Galway | 130 | 2025-11-18 | 2026-03-06 |
| NCT05866757 ClinicalTrials.gov |
Discontinuation Study Multiple Myeloma; Cancer; Hematologic Cancer Open in Ireland | Oncology | University College Cork Academic / other | N/A (non-drug) | Recruiting | Cork | 70 | 2023-08-28 | 2026-03-04 |
| NCT06709651 ClinicalTrials.gov |
Microbiome Immunotherapy Neoadjuvant Assessment Triple Negative Breast Cancer Open in IrelandWomen's health | Oncology | University College Cork Academic / other | Observational | Recruiting | Cork | 30 | 2024-10-02 | 2026-03-04 |
| NCT06546631 ClinicalTrials.gov |
Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients Glioma Open in Ireland | Oncology | University College Cork Academic / other | Observational | Recruiting | Cork | 55 | 2024-08-22 | 2026-03-04 |
| NCT07443579 ClinicalTrials.gov |
Optimal Mammography View Sequencing in Women With a History of Breast Cancer Undergoing Surveillance Mammography Breast Cancer; Breast Cancer Recurrence; Post Treatment Surveillance Open in IrelandWomen's health | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Beaumont | 400 | 2026-02-24 | 2026-03-02 |
| NCT07434804 ClinicalTrials.gov |
Exploring the Feasibility of Using Virtual Reality as an Educational Tool in Chronic Pain Rehabilitation Pain; Chronic Pain; Chronic Pain (Back / Neck); Adults Open in Ireland | Neurology | University College Dublin Academic / other | N/A (non-drug) | (not given) | Dublin | 50 | 2026-02-20 (est.) | 2026-02-27 |
| 2023-504661-23-00 EU CTIS |
HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies Antiphospholipid antibodies, APS Open in IrelandWomen's health | Women's health & maternal | Rigshospitalet Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2023-06-27 | 2026-02-26 |
| NCT06523374 ClinicalTrials.gov |
A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer Barrett's Esophagus; Esophageal Adenocarcinoma Open in Ireland | Oncology | University Hospital, Antwerp Academic / other | N/A (non-drug) | Recruiting | Dublin | 50 | 2025-08-13 | 2026-02-24 |
| NCT07426848 ClinicalTrials.gov |
OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients Primary Brain Tumour; Glioblastoma; Brain Neoplasms Open in Ireland | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 96 | 2025-12-18 | 2026-02-23 |
| NCT07426835 ClinicalTrials.gov |
The PHARO Trial: The Incidence of Para-conduit Hernia With Closure of Hiatus Versus the Standard Approach in Robotic Oesophagectomy - A Randomised Controlled Pilot Trial Oesphageal Cancer; Para-conduit Hernia Open in Ireland | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 40 | 2025-12-19 | 2026-02-23 |
| NCT07426861 ClinicalTrials.gov |
Pre-Operative Nurse-Led Education With Direct Physiotherapy Referral to Reduce Post-Prostatectomy Incontinence Prostate Cancer; Urinary Incontinence; Postoperative Complications; Radical Prostatectomy Open in Ireland | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Beaumont | 80 | 2025-12-20 | 2026-02-23 |
| 2024-516805-22-00 EU CTIS |
A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive Disorder (EXTEND) Major Depressive Disorder Open in Ireland | Mental health | Cybin IRL Limited Industry | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2026-06-30 | 2026-02-23 |
| NCT07425002 ClinicalTrials.gov |
Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM) Breast Cancer Open in IrelandWomen's health | Oncology | Cancer Trials Ireland Academic / other | N/A (non-drug) | Not yet recruiting, Recruiting | Cork, Dublin, Galway | 1,600 | 2025-11-11 | 2026-02-20 |
| NCT07420023 ClinicalTrials.gov |
The Satiety Control Optimization by Nutritional Enhancement Study Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease Open in Ireland | Cardiovascular | University College Cork Academic / other | N/A (non-drug) | Recruiting | Cork | 24 | 2025-08-18 | 2026-02-19 |
| NCT07417228 ClinicalTrials.gov |
The Impact of Concurrent Training on Women Experiencing Symptoms of Menopause Menopause Symptoms Open in IrelandWomen's health | Women's health & maternal | University College Dublin Academic / other | N/A (non-drug) | Recruiting | Dublin | 90 | 2025-12-12 | 2026-02-18 |
| NCT06764693 ClinicalTrials.gov |
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis Psoriatic Arthritis Open in Ireland | Immunology, rheumatology & skin | AbbVie Industry | Observational | Recruiting | Cork, Dublin, Elm Park, Tralee | 1,200 | 2025-01-31 | 2026-02-17 |
| 2023-504899-25-00 EU CTIS |
MK-5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003) Metastatic castration resistant prostate cancer Open in Ireland | Oncology | Merck Sharp & Dohme LLC Industry | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-04-04 | 2026-02-16 |
| NCT07376746 ClinicalTrials.gov |
Improving ADHD Symptoms and Quality of Life Through Diet ADHD Open in Ireland | Mental health | University College Cork Academic / other | N/A (non-drug) | (not given) | Cork | 200 | 2026-02 (est.) | 2026-02-12 |
| NCT07407530 ClinicalTrials.gov |
Comparison of 'Sip Til Send' Regimens Prior to Elective Caesarean Delivery Using Bedside Gastric Ultrasound Gastric Emptying; Caesarean Delivery; Pregnancy Open in IrelandWomen's health | Women's health & maternal | The Rotunda Hospital Academic / other | N/A (non-drug) | Not yet recruiting, Recruiting | Dublin | 190 | 2025-08-01 | 2026-02-12 |
| NCT07401550 ClinicalTrials.gov |
Assessment and Prediction of Cardiovascular Health and Disease Risk Using Wearable Biometrics. Cardiovascular Diseases (CVD); Cardiovascular Disease Prevention; Cardiovascular Disease Risk Factor; Coronary Artery Disease (CAD) Open in Ireland | Cardiovascular | University College Dublin Academic / other | Observational | Recruiting | Dublin | 100 | 2025-12-09 | 2026-02-10 |
| NCT07386483 ClinicalTrials.gov |
Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome Psychosis Open in Ireland | Mental health | University College Dublin Academic / other | N/A (non-drug) | (not given) | Dublin | 40 | 2026-02-01 (est.) | 2026-02-09 |
| NCT07397975 ClinicalTrials.gov |
Speech-based Assessment of Relapse Risk in People With Psychosis Psychotic Disorder Open in Ireland | Mental health | Philipp Homan Academic / other | Observational | Not yet recruiting | Greystones | 360 | 2026-01-29 | 2026-02-09 |
| NCT06939231 ClinicalTrials.gov |
Supporting University Students Transition Towards Sustainable and Healthy Dietary Behaviours: A Living Lab Approach. Dietary Behaviours; Sustainable Healthy Diet; Personalised Nutrition Open in Ireland | Other / unclassified | University College Dublin Academic / other | N/A (non-drug) | Recruiting | Dublin | 520 | 2024-02-26 | 2026-02-09 |
| 2024-518819-19-00 EU CTIS |
Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases triple negative breast cancer Open in IrelandWomen's health | Oncology | Medical University Of Vienna Academic / other | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2023-05-23 | 2026-01-23 |
| NCT07351526 ClinicalTrials.gov |
Inpatient Post-Acute Rehabilitation For Patients in the Midwest: a Prospective Cohort Study of Clinical Characteristics and Process Outcomes Rehabilitation; Frailty; Complex Patients in Rehabilitation Phase Open in Ireland | Other / unclassified | University of Limerick Academic / other | Observational | Recruiting | Limerick | 100 | 2025-02-22 | 2026-01-20 |
| NCT04319627 ClinicalTrials.gov |
Statins for Venous Event Reduction in Patients With Venous Thromboembolism Venous Thromboembolism; Blood Clot; Post Thrombotic Syndrome Open in Ireland | Cardiovascular | Ottawa Hospital Research Institute Academic / other | Phase 3 | Not yet recruiting | Dublin | 2,700 | 2021-02-10 | 2026-01-15 |
| NCT06383949 ClinicalTrials.gov |
Real World Data Collection on the Synergy Disc Cervical Degenerative Disc Disease Open in IrelandWomen's health | Other / unclassified | Synergy Spine Solutions Industry | Observational | Recruiting | Dublin | 50 | 2024-08-06 | 2026-01-09 |
| NCT07310914 ClinicalTrials.gov |
Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis Multiple Sclerosis Open in Ireland | Neurology | Danish Multiple Sclerosis Hospitals Academic / other | Phase 2 | (not given) | Dublin | 94 | 2026-02-01 (est.) | 2025-12-30 |
| NCT07303439 ClinicalTrials.gov |
Randomised Trial of Dual Device Treatment Involving Drug-coated Balloon Angioplasty and Drug-eluting Stent Implantation Compared to Single Device Treatments in Patients With Diabetes Mellitus Diabetes Mellitus; Coronary Arterial Disease (CAD); de Novo Coronary Lesions; De Novo Stenosis Open in Ireland | Cardiovascular | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 120 | 2025-08-06 | 2025-12-24 |
| NCT06690775 ClinicalTrials.gov |
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer; Endometrioid Ovarian Cancer Open in IrelandWomen's health | Oncology | TORL Biotherapeutics, LLC Industry | Phase 2 | Recruiting | Dublin | 230 | 2024-11-20 | 2025-12-23 |
| NCT01840293 ClinicalTrials.gov |
Breast Cancer Proteomics and Molecular Heterogeneity Primary Breast Cancer; Recurrent/Metastatic Breast Cancer Open in IrelandWomen's health | Oncology | Cancer Trials Ireland Academic / other | Observational | Active, not recruiting, Completed, Recruiting | Cork, Dublin, Limerick, Waterford | 1,780 | 2013-02 | 2025-12-19 |
| NCT07292636 ClinicalTrials.gov |
The Effectiveness of the Twin Block and Carriere Motion Appliances in Post-pubertal Patients and an Evaluation of the Impact of Class II Malocclusion and Its Correction on Oral Health-related Quality of Life CLASS II DIVISION 1 MALOCCLUSION; Class II Malocclusion; Growth; Overjet Open in Ireland | Musculoskeletal, pain & surgery | Aslam Alkadhimi Academic / other | N/A (non-drug) | (not given) | Dublin | 88 | 2026-03 (est.) | 2025-12-18 |
| NCT07267845 ClinicalTrials.gov |
The Effect of α-GPC on Cognitive Function and Sports Performance Healthy Participants Open in Ireland | Neurology | Nanjing Nutrabuilding Bio-tech Co., Ltd. Academic / other | N/A (non-drug) | Recruiting | Cork | 80 | 2025-10-21 | 2025-12-09 |
| NCT07268482 ClinicalTrials.gov |
Assessing Sensor-Guided Compression Therapy for Venous Leg Ulcers Healing Outcomes Venous Leg Ulcer (VLU) Open in Ireland | Other / unclassified | Feeltect Limited Industry | N/A (non-drug) | (not given) | Galway | 40 | 2026-01-15 (est.) | 2025-12-05 |
| NCT06237803 ClinicalTrials.gov |
European Myeloma Network (EMN) Sample Project Multiple Myeloma; Smoldering Multiple Myeloma; Plasma Cell Leukemia; Extramedullary Myeloma Open in Ireland | Oncology | European Myeloma Network B.V. Academic / other | Observational | Recruiting | Galway | 6,000 | 2022-12-21 | 2025-12-03 |
| NCT07237334 ClinicalTrials.gov |
A Prospective Cohort Study of Clinical and Process Outcomes of Older Adults That Transition Through the Geriatric Emergency Medicine Unit(GEM-U) Frailty Open in Ireland | Other / unclassified | University of Limerick Academic / other | Observational | Recruiting | Limerick | 150 | 2025-02-10 | 2025-11-19 |
| NCT07209930 ClinicalTrials.gov |
Inter- and Intraindividual Variability of the Acute Glucose Response to Exercise in Healthy Adults and People Living With Type 1 Diabetes: A Cross-over Replicate Trial Exercise; Healthy Participants; Glucose Variability; Type 1 Diabetes (T1D) Open in Ireland | Metabolic & endocrine | University College Dublin Academic / other | N/A (non-drug) | Recruiting | Dublin | 24 | 2025-01-28 | 2025-10-07 |
| NCT06399614 ClinicalTrials.gov |
Occupational Therapy-led Services for Adults Presenting Acutely With a Hand Condition Hand Injuries Open in Ireland | Other / unclassified | University of Limerick Academic / other | Observational | Not yet recruiting, Recruiting | Dublin, Galway, Limerick, Tipperary | 150 | 2024-01-11 | 2025-10-01 |
| NCT05745714 ClinicalTrials.gov |
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Acute Lymphoblastic Leukemia, in Relapse; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Open in Ireland | Oncology | Princess Maxima Center for Pediatric Oncology Academic / other | Phase 1/2 | Not yet recruiting | Dublin | 26 | 2025-10-01 (est.) | 2025-09-16 |
| NCT05751044 ClinicalTrials.gov |
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Open in Ireland | Oncology | Princess Maxima Center for Pediatric Oncology Academic / other | Phase 1/2 | Not yet recruiting | Dublin | 26 | 2025-10-01 (est.) | 2025-09-16 |
| NCT02979119 ClinicalTrials.gov |
The European Paediatric Network for Haemophilia Management ( PedNet Registry) Factor VIII Deficiency; Factor IX Deficiency Open in Ireland | Blood (non-cancer) | PedNet Haemophilia Research Foundation Academic / other | Observational | Recruiting | Dublin | 4,000 | 2014-06 | 2025-09-16 |
| NCT05658640 ClinicalTrials.gov |
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies Acute Lymphoblastic Leukemia, in Relapse; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Open in Ireland | Oncology | Princess Maxima Center for Pediatric Oncology Academic / other | Phase 1/2 | Not yet recruiting | Dublin | 26 | 2023-11-14 | 2025-09-16 |
| NCT06906250 ClinicalTrials.gov |
European Venous Registry Deep Venous Disease of the Lower Limbs Open in Ireland | Other / unclassified | IRCCS San Raffaele Academic / other | Observational | Recruiting | Galway | 100 | 2025-07-05 | 2025-09-08 |
| NCT07085819 ClinicalTrials.gov |
Sleep Promoting Properties of a Botanical Extract in a Population Complaining From Non-Restorative Sleep (NRS) Non Restorative Sleep; Sleep Disorder (Disorder) Open in Ireland | Other / unclassified | Kerry Group P.L.C Industry | N/A (non-drug) | Recruiting | Cork | 160 | 2025-07-15 | 2025-08-26 |
| NCT07075016 ClinicalTrials.gov |
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy Acute Myeloid Leukemia Open in Ireland | Oncology | Stichting Hemato-Oncologie voor Volwassenen Nederland Academic / other | Phase 3 | Not yet recruiting | Cork, Dublin, Galway | 227 | 2025-08-05 | 2025-08-19 |
| NCT06714279 ClinicalTrials.gov |
Laparoscopic-Assisted Transversus Abdominus Plane Block Versus Intraperitoneal Irrigation of Local Anesthetic for Patients Undergoing Laparoscopic Cholecystectomy Laparoscopic Cholecystectomy; TAP Block; Local Anesthetic Open in Ireland | Musculoskeletal, pain & surgery | Royal College of Surgeons, Ireland Academic / other | Phase 1 | Recruiting | Dublin | 144 | 2025-03-12 | 2025-08-14 |
| NCT07100691 ClinicalTrials.gov |
Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery Pulmonary Aspiration During Anaesthetic Induction; Gastric Emptying Time; Preoperative Risk Assessment; Obesity (Disorder) Open in Ireland | Respiratory | Mater Misericordiae University Hospital Academic / other | Phase 4 | (not given) | Dublin | 80 | 2025-08 (est.) | 2025-08-06 |
| NCT07099027 ClinicalTrials.gov |
The Lung Health Check Pilot Non-Small Cell Lung Cancer Open in Ireland | Oncology | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 2,183 | 2025-05-19 | 2025-08-01 |
| NCT06024824 ClinicalTrials.gov |
Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) Pancreatic Adenocarcinoma Open in Ireland | Oncology | Cancer Trials Ireland Academic / other | Phase 1/2 | Recruiting | Dublin | 49 | 2024-01-30 | 2025-07-20 |
| NCT04588311 ClinicalTrials.gov |
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients Trauma; Traumatic Injury; Traumatic Brain Injury; Wounds and Injuries Open in Ireland | Neurology | Australian and New Zealand Intensive Care Research Centre Academic / other | Phase 3 | Recruiting | Beaumont, Cork, Dublin | 2,500 | 2020-11-09 | 2025-07-16 |
| NCT06149546 ClinicalTrials.gov |
Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial) Pancreatic Cancer Open in Ireland | Oncology | Cancer Trials Ireland Academic / other | N/A (non-drug) | Recruiting | Dublin | 70 | 2024-05-01 | 2025-07-08 |
| NCT07046052 ClinicalTrials.gov |
PENG Block: Continuous Infusion vs. Programmed Intermittent Bolus in Neck of Femur Fracture Hip Fracture; Analgesia Post Fracture Open in Ireland | Musculoskeletal, pain & surgery | University College Cork Academic / other | N/A (non-drug) | Recruiting | Cork | 150 | 2024-03-28 | 2025-07-01 |
| NCT06587321 ClinicalTrials.gov |
Remote Assessment of Signs and Symptoms in Palliative Care Palliative Care; Vital Signs; Remote Monitoring Open in Ireland | Other / unclassified | Our Lady's Hospice and Care Services Academic / other | Observational | Recruiting | Dublin | 30 | 2024-04-01 | 2025-06-27 |
| NCT05871996 ClinicalTrials.gov |
Palliative Care and Oncology Survey on Terminology Cancer Open in Ireland | Oncology | Our Lady's Hospice and Care Services Academic / other | Observational | Recruiting | Dublin | 1,532 | 2023-10-03 | 2025-06-27 |
| 2022-500031-37-00 EU CTIS |
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma stage IA/IIA Hodgkin lymphoma Open in Ireland | Oncology | University College London Academic / other | Phase 3 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2024-04-08 | 2025-06-23 |
| NCT07009964 ClinicalTrials.gov |
An Exploratory Feasibility Study Well-Being; Lifestyle, Healthy; Young Adult; Behavior and Behavior Mechanisms Open in Ireland | Other / unclassified | University College Dublin Academic / other | N/A (non-drug) | (not given) | Dublin | 12 | 2025-11-01 (est.) | 2025-06-19 |
| NCT07027241 ClinicalTrials.gov |
Frailty Intervention in Postoperative Hip Fracture Inpatients Hip Fractures (ICD-10 72.01-72.2); Frailty at Older Adults; Strength Training; Resistance Training Open in Ireland | Musculoskeletal, pain & surgery | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | (not given) | Waterford | 50 | 2025-08-01 (est.) | 2025-06-18 |
| 2024-518177-33-00 EU CTIS |
A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss Cancer Anorexia Open in Ireland | Oncology | Artelo Biosciences Limited Industry | Phase 2 | Ongoing, recruiting | Ireland (site detail on registry) | — | 2021-10-01 | 2025-05-12 |
| 2025-520725-20-00 EU CTIS |
Selective decontamination of the digestive tract in preventing surgical site infections in elective colorectal surgery: a randomised controlled trial (SELDDEC Trial) Surgical site infection Open in Ireland | Infectious disease & vaccines | University Hospital Limerick Academic / other | Phase 2 | Authorised, recruitment pending | Ireland (site detail on registry) | — | — | 2025-05-07 |
| 2022-500966-82-00 EU CTIS |
NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The NEEDS Trial) Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus Open in Ireland | Oncology | Karolinska University Hospital Academic / other | Phase 3 | Authorised, recruiting | Ireland (site detail on registry) | — | 2020-03-11 | 2025-05-07 |
| NCT04375904 ClinicalTrials.gov |
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung) NSCLC/Oligometastatic Cancer (Single Lung Lesion) Open in Ireland | Oncology | Cancer Trials Ireland Academic / other | Phase 2 | Recruiting | Dublin | 68 | 2020-12-22 | 2025-05-02 |
| NCT06078813 ClinicalTrials.gov |
Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases Solid Tumor Spine Metastases Open in Ireland | Oncology | Cancer Trials Ireland Academic / other | Phase 1/2 | Recruiting | Cork, Dublin | 126 | 2023-11-21 | 2025-04-30 |
| NCT06940453 ClinicalTrials.gov |
CONDUIT™ Anterior Lumbar Interbody Fusion (ALIF) Cage System in Lumbar Degenerative Disease Lumbar Degenerative Disease Open in Ireland | Other / unclassified | University College Dublin Academic / other | Observational | Recruiting | Dublin | 35 | 2024-06-28 | 2025-04-23 |
| NCT04016649 ClinicalTrials.gov |
The Mechanical Characterisation of Human Saphenous and Popliteal Vein Peripheral Vascular Diseases Open in Ireland | Cardiovascular | University Hospital of Limerick Academic / other | Observational | Recruiting | Limerick | 50 | 2019-01-21 | 2025-04-17 |
| NCT05802706 ClinicalTrials.gov |
The Biomechanical Study of Diseased Human Carotid, Femoral and Abdominal Aortic Tissue Vascular Diseases Open in Ireland | Cardiovascular | University Hospital of Limerick Academic / other | Observational | Recruiting | Limerick | 300 | 2016-01-01 | 2025-04-17 |
| NCT05014581 ClinicalTrials.gov |
Preventing Cardiovascular Collapse With Vasopressors During Tracheal Intubation Critical Illness; Respiratory Failure Open in Ireland | Cardiovascular | University of Turin, Italy Academic / other | Phase 3 | Not yet recruiting | Galway | 420 | 2024-08-01 | 2025-03-28 |
| NCT06898801 ClinicalTrials.gov |
An Educational Intervention to Improve the Success of Intubation in Newborns Using a Video Laryngoscope by Reducing the Time the Procedure Takes. Respiratory Distress Syndrome, Newborn; Endotracheal Intubation; Neonatal Intubation Performance; Prematurity Open in Ireland | Respiratory | University College Dublin Academic / other | N/A (non-drug) | (not given) | Dublin | 140 | 2025-03 (est.) | 2025-03-27 |
| NCT03818503 ClinicalTrials.gov |
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe Cancer Open in Ireland | Oncology | European Organisation for Research and Treatment of Cancer - EORTC Academic / other | Observational | Recruiting | Dublin, Galway | 2,000 | 2019-06-24 | 2025-03-21 |
| NCT05942924 ClinicalTrials.gov |
The NEU-STIM Trial Infant, Premature, Diseases; Birth, Preterm Open in Ireland | Neonatal & paediatric | Leiden University Medical Center Academic / other | N/A (non-drug) | Recruiting | Dublin, Galway | 3,280 | 2024-03-11 | 2025-03-10 |
| NCT04460352 ClinicalTrials.gov |
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer Esophageal Squamous Cell Carcinoma Open in Ireland | Oncology | Karolinska University Hospital Academic / other | Phase 3 | Recruiting | Dublin | 1,020 | 2020-11-27 | 2025-03-06 |
| NCT06820008 ClinicalTrials.gov |
Measurement and Impact of Physical Impairment in Amyotrophic Lateral Sclerosis: Use of Digital Technologies - A Precision ALS Project Amyotrophic Lateral Sclerosis; Motor Neurone Disease Open in Ireland | Neurology | University of Dublin, Trinity College Academic / other | Observational | Recruiting | Dublin | 60 | 2024-11-21 | 2025-02-11 |
| NCT06816862 ClinicalTrials.gov |
SYMPHONY™ OCT System for Instabilities of the Upper Thoracic and Cervical Spine Cervical Instabilities Spine; Spine; Instability Open in IrelandWomen's health | Musculoskeletal, pain & surgery | University College Dublin Academic / other | Observational | Recruiting | Dublin | 35 | 2024-12-01 | 2025-02-10 |
| NCT06818539 ClinicalTrials.gov |
Burnout and Resilience in Hospital-based Nursing and Medical Personnel and Trainees Stress; Burnout Open in Ireland | Other / unclassified | University of Limerick Academic / other | Observational | (not given) | Limerick | 650 | 2025-02-01 (est.) | 2025-02-10 |
| NCT04174157 ClinicalTrials.gov |
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) Spinal Muscular Atrophy (SMA) Open in Ireland | Neurology | Novartis Pharmaceuticals Industry | Observational | Recruiting | Dublin | 700 | 2018-09-25 | 2025-01-31 |
| NCT05759299 ClinicalTrials.gov |
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia Airway Complication of Anesthesia Open in Ireland | Musculoskeletal, pain & surgery | University of Turin, Italy Academic / other | Observational | Not yet recruiting | Galway | 10,500 | 2024-01-15 | 2025-01-20 |
| NCT06781658 ClinicalTrials.gov |
Rehab in Mild Stable DCM: Feasibility RCT Comparing Structured Rehabilitation to Clinical Surveillance Degenerative Cervical Myelopathy Open in IrelandWomen's health | Other / unclassified | Royal College of Surgeons, Ireland Academic / other | N/A (non-drug) | (not given) | Dublin | 24 | 2025-01-13 (est.) | 2025-01-17 |
| NCT05793554 ClinicalTrials.gov |
CLASSICA: Validating AI in Classifying Cancer in Real-Time Surgery Rectum Neoplasm; Rectum Polyp; Rectal Cancer Open in Ireland | Oncology | Mater Misericordiae University Hospital Academic / other | Observational | Recruiting | Dublin | 600 | 2023-03-31 | 2025-01-17 |
| NCT00825929 ClinicalTrials.gov |
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. HIV Infections Open in IrelandWomen's health | Women's health & maternal | Radboud University Medical Center Academic / other | Observational | Recruiting | Dublin | 176 | 2009-02 | 2025-01-13 |
| NCT06723899 ClinicalTrials.gov |
Testing the Effectiveness of a Work Rehabilitation Intervention for Women with Breast Cancer Breast Cancer Open in IrelandWomen's health | Oncology | University of Dublin, Trinity College Academic / other | N/A (non-drug) | Recruiting | Galway, Waterford | 248 | 2024-11-13 | 2024-12-17 |
| NCT03827187 ClinicalTrials.gov |
Awareness Detection and Communication in Disorders of Consciousness Disorder of Consciousness; Paralysis; Motor Neuron Disease; Stroke Open in Ireland | Neurology | University of Ulster Academic / other | N/A (non-drug) | Not yet recruiting | Dublin | 30 | 2022-02-08 | 2024-12-13 |
| NCT06535633 ClinicalTrials.gov |
Community-based Exercise for Older Adults With Chronic Musculoskeletal Pain Chronic Musculoskeletal Pain Open in Ireland | Musculoskeletal, pain & surgery | University of Limerick Academic / other | N/A (non-drug) | Recruiting | Limerick | 72 | 2024-09-01 | 2024-12-12 |
| NCT06729671 ClinicalTrials.gov |
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction Psychosis Open in Ireland | Mental health | University College Cork Academic / other | N/A (non-drug) | Recruiting | Cork | 70 | 2024-05-16 | 2024-12-11 |
| NCT06709209 ClinicalTrials.gov |
AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis Ulcerative Colitis (UC) Open in Ireland | Immunology, rheumatology & skin | University College Cork Academic / other | Observational | Recruiting | Cork | 300 | 2024-11-04 | 2024-12-03 |
| NCT03860883 ClinicalTrials.gov |
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Cutaneous Melanoma, Stage II Open in Ireland | Oncology | Melanoma and Skin Cancer Trials Limited Academic / other | N/A (non-drug) | Recruiting | Cork, Dublin | 2,998 | 2019-12-17 | 2024-11-27 |
| NCT06708819 ClinicalTrials.gov |
AUGUR-AI - Indocyanine Green Fluorescence Angiography Representer Colorectal Surgery; Colorectal Resection; Anastomosis, Surgical; Fluorescence Guided Surgery Open in Ireland | Musculoskeletal, pain & surgery | Mater Misericordiae University Hospital Academic / other | Observational | (not given) | Dublin | 300 | 2025-01 (est.) | 2024-11-27 |
| NCT06702228 ClinicalTrials.gov |
Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland Connective Tissue Diseases; Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Familial Idiopathic Pulmonary Fibrosis Open in Ireland | Respiratory | Royal College of Surgeons, Ireland Academic / other | Observational | Recruiting | Dublin | 300 | 2021-09-28 | 2024-11-22 |
| NCT06398496 ClinicalTrials.gov |
The Effects of Exercise on Gut Bacteria, Mood and Cognition in Depression Depressive Disorder, Major Open in Ireland | Mental health | University College Cork Academic / other | N/A (non-drug) | Recruiting | Cork | 40 | 2024-02-14 | 2024-11-08 |
| NCT06678594 ClinicalTrials.gov |
Implementation of a Standardized Algorithm for Coronary Calcification With Plaque Modification Myocardial Ischaemia; Severely Calcified Coronary Stenoses; Coronary Calcification Open in Ireland | Cardiovascular | Royal College of Surgeons, Ireland Academic / other | Observational | Recruiting | Dublin | 500 | 2024-09-24 | 2024-11-07 |
| 2024-517606-29-00 EU CTIS |
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY
(TenCRAOS):
A Prospective, randomised-controlled, double-dummy, double-blind phase 3 multi-centre trial of
TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation) Central retinal artery occlusion Open in Ireland | Eye & ear | Oslo University Hospital HF Academic / other | Phase 3 | Authorised, recruitment pending | Ireland (site detail on registry) | — | 2020-10-30 | 2024-11-05 |
| NCT06557551 ClinicalTrials.gov |
Prophylactic Surfactant by Thin Endotracheal Catheter for Preterm Infants At Birth: the ProTeCt Trial Infant, Newborn, Diseases; Prematurity; Prematurity; Extreme; Respiratory Distress Syndrome in Premature Infant Open in Ireland | Respiratory | University College Dublin Academic / other | N/A (non-drug) | Recruiting | Dublin | 164 | 2024-08-19 | 2024-10-15 |
| NCT02328131 ClinicalTrials.gov |
European Registry on the Management of Helicobacter Pylori Infection H. Pylori Infection Open in Ireland | Infectious disease & vaccines | Javier P. Gisbert Academic / other | Observational | Recruiting | Dublin | 10,000 | 2013-06 | 2024-10-02 |
| NCT05613023 ClinicalTrials.gov |
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Prostate Cancer Open in Ireland | Oncology | Institute of Cancer Research, United Kingdom Academic / other | Phase 3 | Recruiting | Cork, Dublin, Limerick | 1,128 | 2022-09-09 | 2024-09-19 |
| NCT06602687 ClinicalTrials.gov |
PICSI Impact on Euploidy in Assisted Reproduction Infertility Open in IrelandWomen's health | Women's health & maternal | Merrion Fertility Clinic Academic / other | N/A (non-drug) | Recruiting | Dublin | 142 | 2024-01-01 | 2024-09-19 |
| NCT02735707 ClinicalTrials.gov · also 2023-507889-89-00 |
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Community-acquired Pneumonia, Influenza, COVID-19 Open in IrelandAlso in CTIS | Respiratory | UMC Utrecht Academic / other | Phase 3 | Active, not recruiting, Recruiting | Cork, Dublin, Galway, Waterford | 20,000 | 2016-04-11 | 2024-07-12 |
| NCT06460090 ClinicalTrials.gov |
Evaluating a Targeted Selective Speech, Language, and Communication Intervention at Scale - Protocol for the 'Happy Talk' Cluster Randomised Controlled Trial. Developmental Language Disorder and Language Impairment; Deprivation Open in Ireland | Other / unclassified | University College Cork Academic / other | N/A (non-drug) | (not given) | Dublin, Galway, Wexford, Wicklow | 840 | 2024-06 (est.) | 2024-06-14 |
| NCT04625907 ClinicalTrials.gov |
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma Rhabdomyosarcoma Open in Ireland | Oncology | University of Birmingham Academic / other | Phase 1/2 | Not yet recruiting | Crumlin | 1,672 | 2020-09-17 | 2024-05-23 |
| NCT04912648 ClinicalTrials.gov |
FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study Hyperandrogenism; Metabolic Disease; Sex Hormones Adverse Reaction Open in IrelandWomen's health | Metabolic & endocrine | Royal College of Surgeons, Ireland Academic / other | Observational | Recruiting | Dublin | 500 | 2021-04-01 | 2024-05-02 |
| NCT02265770 ClinicalTrials.gov |
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Childhood Ependymoma Open in Ireland | Neonatal & paediatric | Centre Leon Berard Academic / other | Phase 2/3 | Recruiting | Dublin | 536 | 2015-06-02 | 2024-04-26 |
| NCT02771548 ClinicalTrials.gov |
Biomechanical Analysis of Dynamic Tasks and Muscular Strength Following Anterior Cruciate Ligament Reconstruction Rupture of Anterior Cruciate Ligament Open in Ireland | Musculoskeletal, pain & surgery | Dr Neil Welch ASCC Academic / other | Observational | Recruiting | Dublin | 1,000 | 2014-01 | 2024-04-22 |
| NCT04793919 ClinicalTrials.gov |
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia Open in Ireland | Oncology | Associazione Italiana Ematologia Oncologia Pediatrica Academic / other | Phase 2 | Not yet recruiting | Dublin | 89 | 2019-10-09 | 2024-04-15 |
| NCT06297005 ClinicalTrials.gov |
The Impact of E-cigarettes During Pregnancy on Childhood Health Outcomes Study Vaping; Pregnancy Related; Pediatric Respiratory Diseases Open in IrelandWomen's health | Women's health & maternal | University College Dublin Academic / other | Observational | Recruiting | Dublin | 1,200 | 2023-10-09 | 2024-04-12 |
| NCT06275204 ClinicalTrials.gov |
H. Pylori Screen-and-treat Study in a Population of Young Adults Gastric Cancer; H Pylori Infection; H Pylori Eradication; H-pylori Open in Ireland | Oncology | University of Latvia Academic / other | Observational | Recruiting | Dublin | 6,800 | 2024-03-04 (est.) | 2024-03-05 |
| NCT01574053 ClinicalTrials.gov |
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Huntington's Disease Open in Ireland | Neurology | CHDI Foundation, Inc. Academic / other | Observational | Recruiting | Dublin | 35,000 | 2012-07 | 2024-02-28 |
| NCT06030349 ClinicalTrials.gov |
Clinical Outcomes From Treatment and Evaluation of Obstructive Sleep Apnoea in Children With Down Syndrome Obstructive Sleep Apnea; Down Syndrome; Quality of Life; Behavior Open in Ireland | Neonatal & paediatric | Children's Health Ireland Academic / other | Observational | Recruiting | Dublin | 200 | 2022-11-28 | 2024-02-12 |
| NCT06115629 ClinicalTrials.gov |
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial Esophageal Cancer; Gastric Cancer Open in Ireland | Oncology | University of Dublin, Trinity College Academic / other | Phase 3 | (not given) | Cork, Dublin, Galway | 952 | 2023-11 (est.) | 2023-11-03 |
| NCT04923191 ClinicalTrials.gov |
The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent Coronary Artery Disease Open in Ireland | Cardiovascular | National University of Ireland, Galway, Ireland Academic / other | N/A (non-drug) | Recruiting | Galway | 2,540 | 2021-11-12 | 2023-10-30 |
| NCT06095648 ClinicalTrials.gov |
Study Comparing Platelet Transfusion Volumes in Premature Babies Thrombocytopenia; Transfusion Open in Ireland | Cardiovascular | University College Dublin Academic / other | N/A (non-drug) | (not given) | Dublin | 370 | 2023-10-28 (est.) | 2023-10-23 |
| NCT05907837 ClinicalTrials.gov |
Early Detection & Intervention of Cerebral Palsy in Ireland Cerebral Palsy; Neurodevelopmental Disorders Open in Ireland | Neurology | University College Cork Academic / other | Observational | Not yet recruiting, Recruiting | Cork, Dublin, Limerick | 1,500 | 2023-07-01 | 2023-10-02 |
| NCT05663008 ClinicalTrials.gov |
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis ALS (Amyotrophic Lateral Sclerosis); Postpoliomyelitis Syndrome; Spinal Muscular Atrophy Open in Ireland | Neurology | University of Dublin, Trinity College Academic / other | Observational | Recruiting | Dublin | 400 | 2015-10-01 | 2022-12-23 |
| NCT04432025 ClinicalTrials.gov |
Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus Obesity; Type 2 Diabetes Open in Ireland | Metabolic & endocrine | Imperial College London Academic / other | N/A (non-drug) | Recruiting | Dublin | 150 | 2021-04-01 | 2022-08-08 |
| NCT05074732 ClinicalTrials.gov |
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study. Schizophrenia; Forensic Psychiatry; Outcome Measure; Violence Open in Ireland | Cardiovascular | Health Service Executive, Ireland Academic / other | Observational | Recruiting | Dublin | 350 | 2019-12-01 | 2021-10-12 |
Free weekly Ireland update
What's new in Irish clinical trials, every Monday
New trials opening at Irish sites, status changes, and sponsor and site activity across every therapy area, with registry links.
- US and EU registries combined, filtered to Republic of Ireland sites
- Watchlists by therapy area, sponsor or site
- Prices in euro, invoiced from an Irish company
Your ticks help us prioritise what to build. They don't commit you to anything, and no payment is taken.
Methodology
- ClinicalTrials.gov API v2: location search
Irelandfor records that are recruiting, not yet recruiting, or updated in the last 90 days. Only records with a site whose country is exactly "Ireland" are kept. 10 matches with no Republic of Ireland site were dropped (for example, Northern Ireland sites, which registries list under the United Kingdom). - EU CTIS: member-state filter for Ireland (485 trials in all). Kept if Ireland's own country status is authorised or recruiting, or the record was updated in the last 90 days.
- Open in Ireland uses the status of the Irish sites (US registry) or Ireland's country status (CTIS), not the trial's overall status.
- Duplicates: many trials are registered in both systems. 89 US records cite an EU trial number that also appears here, and these are tagged "Also in CTIS". Matching is only possible where the sponsor recorded the EU number, so a few more duplicates may remain. The unique count is an estimate.
- Therapy areas are assigned by keyword rules on conditions, MeSH terms and titles, falling back to CTIS's own therapeutic area. The women's-health flag means female-only eligibility or a women's-health condition keyword. Both are approximate.
- Data pulled 21 Oct 2026, 10:06 UTC, regenerated automatically. Fields are shown as the registries record them.
Sources
- ClinicalTrials.gov API v2, U.S. National Library of Medicine
- EU Clinical Trials Information System (CTIS), European Medicines Agency
Disclaimer
Business research data, not medical advice. TrialsForHer summarises public registry records for professional and research use. It isn't medical advice, doesn't recommend or endorse any trial or treatment, and isn't a way to enrol in a study. Registry entries can be incomplete or out of date, so always check the official record. If you're a patient or carer, talk to your clinician or contact the study team listed on the registry. Not affiliated with any organisation named on this page.